Peptide-mediated delivery of gold nanoparticles and proteins into lysosomes of mammalian cells by Dekiwadia, C
  
Peptide-mediated delivery of gold 
nanoparticles and proteins into 
lysosomes of mammalian cells  
 
 
 
A thesis submitted in fulfilment of the requirements for  
the degree of Doctor of Philosophy  
 
Chaitali D. Dekiwadia  
M.Sc, Biotechnology  
 
School of Applied Science 
Science, Engineering and Technology Portfolio 
RMIT University 
March 2010 
 
 II 
Declaration 
 
 
 
I certify that except where due acknowledgement has been made, the work 
described in this thesis is that of the author alone; the work has not been 
submitted previously, in whole or in part, to qualify for any other academic award; 
the content of the thesis is the result of work which has been carried out since the 
official commencement date of the approved research program; and, any editorial 
work, paid or unpaid, carried out by a third party is acknowledged.  
 
 
Signed: ………………………………………  (Chaitali D. Dekiwadia) 
 
Date: ……………………………………… 
 III 
Acknowledgements 
I wish to proceed by thanking my supervisors who have supported me over the 
duration of this research project.  I begin by extending my gratitude to my 
supervisor Dr. John Fecondo for his invaluable guidance, patience and tireless 
support throughout the project. 
I would also like to thank Prof. Ann Lawrie who I have always admired throughout 
my study at RMIT.  To be lucky enough to have been supervised by Ann alone 
was an honour.  I would like to thank Ann for her kindness, support and her 
understanding at times that were difficult for me during the duration of this 
project. 
I would like to take this opportunity to thank everyone who helped me to complete 
this research project. In spite of the difficulties entailed by the scope and duration 
of this project, there was always somebody to help me out when needed. My 
special thanks School of Applied sciences for providing me financial assistance 
during my PhD candidature 
I would like to give a special vote of thanks to Sapna for her constant help with 
different techniques in the lab.  
I would also like to thank my friends especially Sameera, Rebecca, Markus, 
Sethu, Harshit, Parsa, Shalika, Gouda, Liz, Hash, Emily, Luke for all the laughs 
and their moral support during the stressful times of my study.  
 
 IV 
I heartily thank my boyfriend Indrajeet for his unconditional love and support 
during my good and bad times.  
 
I would like to acknowledge my family, for their love and support and numerous 
emails and phone calls that meant so much to me and almost made me feel at 
home even though I was so far away.  
 
 
 
 
 
 
 
 
 
 
 
 
 V 
Table of Contents 
Peptide-mediated delivery of nanoparticles and proteins into 
lysosomes of mammalian cells 
Table of Contents................................................................................................. V 
List of Figures ...................................................................................................... X 
List of Tables...................................................................................................... XII 
List of Tables...................................................................................................... XII 
List of Abbreviations.......................................................................................... XIII 
Summary .................................................................................................................. 1 
Chapter 1 .................................................................................................................. 5 
Introduction.............................................................................................................. 5 
1.1 Lysosomal storage diseases and therapies ....................................................6 
1.1.1 Membrane structure...............................................................................12 
1.1.2 The cell and its organelles .....................................................................16 
1.1.3  Lysosomes............................................................................................16 
1.2 Transport mechanisms to the lysosomes......................................................20 
1.2.1 Intracellular vesicle traffic.......................................................................20 
1.2.2 Endocytosis ...........................................................................................20 
1.2.3 Endocytosis pathways ...........................................................................22 
Clathrin-mediated endocytosis ...............................................................22 
Macropinocytosis ...................................................................................27 
Phagocytosis..........................................................................................28 
1.2.4 Principal components of endocytic pathway ..........................................31 
1.3 Protein sorting to the lysosomal system........................................................32 
1.3.1 Properties of lysosomal sorting signals..................................................33 
1.3.1.1 Recognition of lysosome target signals ..........................................34 
1.3.1.2 YXXØ signal ...............................................................................35 
1.3.1.3  NPXY signal ..............................................................................39 
1.4 Peptide-mediated delivery systems ..............................................................43 
1.4.1 Cell-Penetrating Peptides (CPPs)..........................................................45 
 VI 
1.4.1.1 TAT peptide................................................................................46 
1.4.1.2 Penetratin peptide ......................................................................51 
1.5 Metal Nanoparticles ......................................................................................53 
1.5.1 Gold nanoparticles (AuNPs) ..................................................................54 
1.5.1.1 Gold nanoparticles (AuNPs) and their advantages.....................54 
1.5.1.2 Hybrid NPs in intracellular delivery.............................................55 
1.6 Green Fluorescent Protein as a protein model cargo in intracellular delivery57 
1.7 Summary of the research project ..................................................................61 
Chapter 2 ................................................................................................................ 64 
Peptide Synthesis .................................................................................................. 64 
2.1 Introduction ...................................................................................................65 
2.1.1 t-Boc solid phase peptide synthesis.......................................................71 
2.2 Materials and Methods..................................................................................72 
2.2.1 Materials ................................................................................................72 
2.2.2 Methods.................................................................................................73 
2.2.2.1 t-Boc amino acids ...........................................................................73 
2.2.2.2 Resin Preparation...........................................................................73 
2.2.2.3 Peptide synthesis ...........................................................................74 
2.2.2.4 Ninhydrin analysis ..........................................................................75 
2.2.2.5 Deprotection prior to HF cleavage ..................................................76 
2.2.2.6 Hydrogen fluoride cleavage ............................................................76 
2.2.2.7 Peptide extraction...........................................................................77 
2.2.3 Peptide Analysis ....................................................................................78 
2.2.3.1 High Performance Liquid Chromatography (HPLC)........................78 
2.2.3.2 Mass spectrometry .........................................................................78 
2.3 Results..........................................................................................................81 
2.3.1 Peptide synthesis evaluation .................................................................81 
2.3.2  A typical data set for peptide synthesis....................................................83 
2.4 Discussion.....................................................................................................87 
Chapter 3 ................................................................................................................ 90 
Peptide-mediated delivery of gold nanoparticles into lysosomes .................... 90 
 VII 
3.1 AuNPs...........................................................................................................91 
3.1.1 AuNP delivery using signal peptides......................................................91 
3.1.2 AuNPs as therapeutic for LSDs .............................................................92 
3.1.3 Overview of Chapter ..............................................................................93 
3.2 Materials .......................................................................................................95 
3.3 Methods ........................................................................................................96 
3.3.1 Peptide synthesis...................................................................................96 
3.3.2 AuNPs synthesis and peptide conjugation.............................................96 
3.3.3 Cell Culture ............................................................................................98 
3.3.4 Fluorescence spectrophotometry studies ............................................101 
3.3.5 Fluorescence microscopy ....................................................................102 
3.3.6 Transmission Electron Microscopy (TEM) ...........................................103 
3.3.7 Cytotoxicity assay ................................................................................104 
3.3.8 Data and statistical analysis.................................................................105 
3.4 Results........................................................................................................105 
3.4.1 AuNPs synthesis and peptide conjugation...........................................105 
3.4.2 Fluorescence spectrophotometry studies ............................................108 
3.4.2.1 Uptake of FITC-AUNPs-peptide conjugates in CHO cells ............108 
3.4.2.2 Uptake of FITC-AUNPs-peptide conjugates in HeLa cells............111 
3.4.3 Fluorescence microscopy studies........................................................114 
3.4.3.1 Intracellular localisation of FITC-AuNP conjugates in CHO cells..114 
3.4.3.2 Intracellular localisation of FITC-AuNP conjugates in HeLa cells .120 
3.4.4 TEM .....................................................................................................127 
3.4.5 Cytotoxicity assay ................................................................................130 
3.4.5.1 Pen combinations .........................................................................130 
Cytotoxicity of Pen peptide combinations in CHO and HeLa cells when                   
conjugated with AuNPs ........................................................................130 
3.4.5.2 TAT combinations.........................................................................130 
Cytotoxicity of TAT peptide combinations in CHO and HeLa cells when                   
conjugated with AuNPs ........................................................................130 
3.5 Discussion...................................................................................................134 
3.5.1 AuNP synthesis and peptide conjugation ............................................135 
 VIII 
3.5.2 Cell penetration as observed by quantitative and visualisation 
approaches. ..................................................................................................136 
3.5.3 Lysosome Penetration – Pen vs TAT ..................................................138 
3.5.4 Mechanism of increased penetration into the lysosomes ....................138 
3.5.5 Differences between the lysosome sorting signals. .............................140 
3.5.5.1 L1 signal interaction......................................................................140 
3.5.5.2 L2 signal interaction......................................................................141 
L1 signal vs L2 signal ...............................................................................142 
3.5.6 Cell toxicity...........................................................................................143 
3.6 Summary.....................................................................................................143 
Chapter 4 .............................................................................................................. 147 
Peptide-mediated delivery of green fluorescent protein into lysosomes ....... 147 
4.1 Introduction .................................................................................................148 
4.1.1 Aim of this chapter ...............................................................................149 
4.2 Materials and Methods:...............................................................................150 
4.2.1 Materials ..............................................................................................150 
4.2.2 Methods...............................................................................................151 
4.2.2.1 Growth conditions for expression of GFP .....................................151 
4.2.2.2 Preparation of Whole Cell Lysates ...............................................151 
4.2.2.3 Purification of GFP using IMAC Chromatography ........................152 
4.2.2.4 Regeneration of the IMAC column................................................153 
4.2.2.5 Concentration and Buffer exchange of IMAC-purified protein.......154 
4.2.3 SDS Polyacrylamide Gel Electrophoresis Analysis of purified GFP.....154 
4.2.3.1 Estimation of Protein Content using the Bradford Assay ..............155 
4.2.3.2 Conjugation of peptides with GFP using SMCC ...........................156 
4.2.3.3 Cell Culture...................................................................................157 
4.2.3.4 Fluorescence spectrophotometry studies .....................................157 
4.2.3.5 Fluorescence microscopy.............................................................158 
4.2.3.6 MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide] 
assay ........................................................................................................159 
4.2.3.7 Data and statistical analysis .........................................................160 
4.3 Results........................................................................................................160 
 IX 
4.3.1 IMAC purification of expressed GFP protein........................................160 
4.3.1.1 Bradford protein assay .................................................................161 
4.3.2 Fluorescence spectrophotometry studies ............................................164 
4.3.2.1 Uptake of GFP-peptide conjugates in CHO cells..........................164 
4.3.2.2 Uptake of GFP-peptide conjugates in HeLa cells .........................167 
4.3.3 Fluorescence microscopy ....................................................................168 
4.3.3.1 Intracellular localisation of GFP-conjugates in CHO cells.............170 
4.3.3.2 Intracellular localisation of GFP-conjugates in HeLa cells ............176 
4.3.4 Cytotoxicity assay ................................................................................181 
4.3.4.1 Cytotoxicity assay of Pen peptide combinations...........................181 
4.3.4.2 Cytotoxicity assay of TAT peptide combinations ..........................184 
4.4 Discussion...................................................................................................186 
4.4.1 IMAC purification of expressed GFP protein........................................186 
4.4.2 Comparision of GFP-peptide conjugates uptake in CHO and HeLA cells
......................................................................................................................187 
4.4.3 Pen better than TAT ............................................................................188 
4.4.4 L1 peptide mechanism.........................................................................190 
4.4.5 L2 peptide mechanism.........................................................................191 
4.4.6 Difference between L1 and L2.............................................................191 
4.4.7 Cytotoxicity assay ................................................................................192 
4.5 Summary.....................................................................................................193 
Chapter 5 .............................................................................................................. 195 
Final Discussion and Future Directions ............................................................ 195 
References: ..............................................................................................206 
Appendix A .......................................................................................................229 
 X 
List of Figures 
Figure 1-1. Basic structure of lysosome................................................................... 15 
Figure 1-2. Views of a cell membrane...................................................................... 18 
Figure 1-3.  Intracellular vesicle transport. ............................................................... 24 
Figure 1-4. Mechanism of endocytosis. ................................................................... 25 
Figure 1-5. Utilization of different coats in vesicular traffic. ...................................... 26 
Figure 1-6 Clathrin assembly ................................................................................... 30 
Figure 1-7.  Structure of YXXØ-µ2 complexes......................................................... 39 
Figure 1-8. Translocation of CPP conjugates across the plasma membrane. ......... 52 
Figure 1-9. Interactions of TAT with the membrane. ................................................ 53 
Figure 1-10.  The solid-state structure of GFP......................................................... 61 
Figure 2-1. Schematic representation of peptide synthesis. .................................... 73 
Figure 2-2 HPLC chromatogram of TAT control sequence ...................................... 86 
Figure 2-3 Mass spectrum of TAT control sequence ............................................... 87 
Figure 3-1. Schematic representation of the assembly of nanoconjugates............ 101 
Figure 3-2. TEM analysis of FITC-AuNP conjugates. ............................................ 108 
Figure 3-3. Absorption spectral analysis of FITC-labelled AuNP-peptide 
conjugates............................................................................................. 109 
Figure 3-4. TEM analysis FITC-labelled AuNP-peptide conjugates. ...................... 111 
Figure 3-5. Quantitative analysis of nanoconjugate uptake into CHO cells by 
spectrofluorimetry.................................................................................. 111 
Figure 3-6. Quantitative analysis of nanoconjugate uptake into HeLa cells by 
spectrofluorimetry.................................................................................. 112 
Figure 3-7. Intracellular localisation of FITC-AuNP-CPP conjugates. .................... 117 
Figure 3-7(a) Magnified image of lysosomes as red dots in CHO cells containing     .
        Lysotracker Red dye                                                                              118    
Figure 3-8. Intracellular localisation of FITC-AuNP-CPP conjugates containing L1 
peptide. ................................................................................................. 120 
Figure 3-9. Intracellular localisation of FITC-AuNPs-CPP conjugates containing 
L2 peptide. ............................................................................................ 122 
Figure 3-10. Intracellular localisation of FITC-AuNPs-CPP conjugates in HeLa 
cells....................................................................................................... 124 
Figure 3-11.  Intracellular localisation of FITC-AuNPs-CPP conjugates containing 
 XI 
L1 peptide in HeLa cells........................................................................ 126 
Figure 3-12.  Intracellular localisation of FITC-AuNPs-CPP conjugates containing 
L2 peptide in HeLa cells........................................................................ 129 
Figure 3-13.  Cellular localisation of the AuNP-conjugates observed by TEM in 
CHO cells.............................................................................................. 131 
Figure 3-14.  Cytotoxicity assay of Pen peptide combinations in both CHO and 
HeLa cells. ............................................................................................ 135 
Figure 3-15.  Cytotoxicity assay of TAT peptide combinations in both CHO and 
HeLa cells. ............................................................................................ 136 
Figure 4-1.  SDS- PAGE electrophoresis of GFP containing eluants..................... 166 
Figure 4-2.  Western Blot of purified GFP protein. ................................................. 167 
Figure 4-3.  Quantitative analysis of GFP-peptide conjugates in CHO cells by 
fluorescence spectrophotometry. .......................................................... 170 
Figure 4-4.  Quantitative analysis of nanoconjugate uptake into HeLa cells by 
fluorescence spectrophotometry. .......................................................... 173 
Figure 4-5. Intracellular localisation of GFP-CPP conjugates in CHO cells. .......... 176 
Figure 4-6.  Intracellular localisation of GFP-CPP conjugates containing L1 
peptide in CHO cells. ............................................................................ 177 
Figure 4-7.  Intracellular localisation of GFP-CPP conjugates containing L2 
peptide in CHO cells. ............................................................................ 179 
Figure 4-8.  Intracellular localisation of GFP-CPP conjugates in  HeLa cells......... 181 
Figure 4-9.  Intracellular localisation of GFP-CPP conjugates containing L1 
peptide in HeLa cells............................................................................. 183 
Figure 4-10.  Intracellular localisation of GFP-CPP conjugates containing L2 
conjugates in  HeLa cells. ..................................................................... 186 
Figure 4-11.  Cytotoxicity assay for Pen peptide combinations in CHO and HeLa 
cells....................................................................................................... 187 
Figure 4-12.  Cytotoxicity assay for TAT peptide combinations in CHO and HeLa 
cells....................................................................................................... 189 
 XII 
List of Tables 
Table 1-0-1 Organelles and their functions. ............................................................. 14 
Table 1-0-2.  Lysosome sorting signals. .................................................................. 38 
Table 1-0-3.  YXXØ-type signals (Bonifacino and Traub, 2003). ............................. 43 
Table 1-0-4. NPXY- type signal(Bonifacino and Traub, 2003b). .............................. 44 
Table 1-0-5. Amino acid sequences of cell-penetrating peptides............................. 51 
Table 1-0-6. Fusion-GFPs used in subcellular targeting .......................................... 62 
Table 2-0-1. List of synthetic peptides used in this study......................................... 81 
Table 2-0-2.  Peptide synthesis evaluation chart. .................................................... 83 
 
 XIII 
List of Abbreviations 
λmax  Wavelength with maximum absorbance 
AP  Heterotetrameric clathrin adaptor protein complexes 
AuNP  Gold nanoparticle 
BBB               Blood Brain Barrier 
BSA  Bovine serum albumin 
C  Carboxy 
CHO  Chinese Hamster Ovary  
CNS              Central Nervous system 
CPP  Cell Penetrating Peptide 
DIEA  N, N’-diisopropylethylamine 
DMEM Dulbecco’s minimum essential medium 
DMF  N,N-dimethylformamide 
DMSO  Dimethylsulphoxide 
DNA  Deoxyribonucleic acid 
GAG            Glycosaminoglycan 
EDTA  Ethylenediamine tetraacetate 
ER  Endoplasmic reticulum 
FITC     Fluorescein isothiocyanate 
GFP  Green Fluorescent Protein 
HBTU             O-Benzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluoro- 
                        phosphate           
 XIV 
HeLa  Human cervical cancer cell 
HIV-1   Human immunodeficiency virus type-one 
HOBT  1- Hydroxybenzotriazole  
IMAC            Immobilized Metal Ion Affinity Chromatography 
kDa  kiloDalton 
LAMP-1 Lysosome associated membrane protein-1 
LSD               Lysosomal storage disorders 
LSP  Lysosomal signal peptide 
MALDI-TOF Matrix-assisted laser desorption ionisation time of flight 
MPP  Mitochondria penetrating peptides 
MTT  [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide]  
N              Amino 
NCS  Newborn calf serum 
PBS  Phosphate buffered saline 
Pen  Penetratin 
SDS  Sodium dodecyl sulphate 
SMCC Sulphosuccinimidyl 4-N-maleimidomethyl cyclohexane-1-   
                      carboxylate 
TAT  Transactivator of transcription 
t-Boc  (t)ert-(b)utyl(o)xy(c)arbonyl 
TEM  Transmission electron microscope 
TFA            Trifluoroacetic acid 
TGN  trans-Golgi network 
 XV 
Amino acid codes and abbreviations 
Nonpolar and Uncharged   
A Ala Alanine 
F Phe Phenylalanine 
G Gly Glycine 
I Ile Isoleucine 
L Leu Leucine 
M Met Methionine 
P Pro Proline 
V Val Valine 
W Trp Trptophan 
Polar and Uncharged   
C Cys Cysteine 
N Asn Aspargine 
Q Gln Glutamine 
S Ser Serine 
T The Threonine 
Y Tyr Tyrosine 
Positively charged 
(basic)   
H His Histidine 
K Lys Lysine 
R Arg Arginine 
Negatively charged 
(acidic)   
D Asp Aspartic Acid 
E Glu Glutamic Acid 
 1 
Summary 
Although the molecular basis of the pathogenesis of a huge range of human 
diseases is well-understood, effective treatments, especially targeted therapy 
within cells, remains problematic.  One class of diseases that could be treated 
using this targeted therapy approach are the lysosomal storage diseases which 
occur due to a deficiency or malfunction of one or more enzymes associated with 
the degradative functions of this organelle. 
The primary objective of this project was to target cargo to the lysosomes using 
peptides as delivery vectors.  This targeted delivery system could underpin the 
development of a novel strategy for the treatment of lysosomal storage diseases 
by exploiting the large surface area of nanoparticles to deliver drugs or 
replacement proteins directly to the lysosomes. This approach could have a 
therapeutic potential that current treatments lack, as the cargo would be able to 
cross the blood brain barrier (BBB) with the help of synthetic cell-penetrating 
peptides (CPPs) and directed to the diseased lysosomes through synthetic 
lysosomal signal peptides (LSPs). 
This study provides a novel intracellular cargo delivery system that can effectively 
deliver cargo such as gold nanoparticles (AuNP) and proteins across the cell 
membrane, followed by targeted delivery into the lysosomes using a combination 
of CPPs and LSPs.  The design, synthesis, and characterisation of the peptides 
and, the preparation of peptide-nanoparticle conjugates and proteins are 
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explained.  The intracellular movement and localisation of these conjugates were 
studied using a combination of fluorescence spectrophotometry, fluorescence 
microscopy, and transmission electron microscopy.  Data from these studies are 
presented to demonstrate that these nanoconjugates were successfully targeted 
to the lysosomes in mammalian cells in vitro. 
In Chapter 1, background information about lysosomal storage disorders (LSDs) 
and the need for targeted delivery of cargo to the lyosomes was discussed.  It 
was proposed that this targeted delivery of cargo to the lysosomes could be 
achieved through LSPs in combinations with CPPs.  The formulation and role of 
each peptide was summarised.  The preference for AuNP and Green Fluorescent 
Protein (GFP) as cargo molecules was highlighted.    
In Chapter 2, the CPPs Pen and TAT were synthesised according to the literature 
(Frankel and Pabo 1988).  The LSPs L1 and L2 were designed and synthesised 
using t-Boc chemistry for peptide synthesis.  The approach of using LSPs for 
lyososome targeting was novel because specific targeting to the lysosomes was 
achieved just by using C-terminal end amino acids of lysosome protein, rather 
than using the entire lysosome protein.  The importance of short synthetic LSPs 
in lysosome targeting of cargo was demonstrated.  This is the first study showing 
that short LSPs instead of the entire lysosomal protein can direct coupled cargo 
to the lysosomes and will open a new era in the field of lysosome targeting.  
Appropriate control sequences were used for each test peptide.  Synthetic 
peptides were modified for ease of cargo coupling.  An extra Cys was 
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incorporated at the –C terminal ends of the peptides, except for L2 (-N terminal 
end), to favour binding of peptides to the surface of the AuNP.  The purity of the 
synthesised peptides was analysed and characterised by Reverse Phase High 
Performance Chromatography (RP-HPLC) and Matrix-Assisted Laser 
Desorption/Ionization–Time of Flight (MALDI-TOF) Mass spectrometry (MS).  
In Chapter 3, the efficiency of these LSPs combined with CPPs was tested for 
their ability to deliver AuNPs specifically to the lysosomes.  AuNPs with an 
average size of 13 nm were synthesised by standard procedures, followed by the 
addition of Fluorescein isothiocyanate (FITC) and thereafter peptides.  FITC was 
incorporated for ease of detection of AuNPs due to its fluorescent nature.  For 
their intracellular targeting capability to the lysosomes, these nanoconjugates 
were examined in CHO (Chinese Hamster Ovary) and HeLa (Human cervical 
cancer) cell lines.  Techniques used to monitor the cellular uptake and lysosomal 
accumulation were fluorescence spectrometry, fluorescence microscopy and 
Transmission electron microscopy (TEM). 
In Chapter 4, this peptide-mediated delivery into the lysosomes was tested using 
the protein GFP instead of AuNPs.  Histidine-tagged GFP was expressed in E. 
coli and purified.  SDS-gel electrophoresis and Western Blotting were used 
confirmed the high purity of the GFP.  The purified GFP was conjugated to the 
CPP and LSP peptides using succinimidyl 4-[N-maleimidomethyl] cyclohexane-1-
carboxylate, (SMCC) crosslinker.  The uptake of GFP cross-linked to synthetic 
peptides in combinations was tested in CHO and HeLa cells.  The accumulation 
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of GFP-peptide conjugates inside the cells and lysosomes was evaluated by 
fluorescence spectrophotometry and fluorescence microscopy.   
Chapter 5 integrates these studies and provides an overview of prospects for the 
use of these delivery systems for therapeutic use in future. 
In summary, the effective intracellular targeting of exogenous cargo into 
lysosomes using a combination of synthetic cell penetrating peptides and 
lysosomal signal peptides has been achieved for the first time in this thesis.    
This novel targeted delivery system could underpin the development of a new 
strategy for the treatment of lysosomal storage diseases by exploiting the large 
surface area of nanoparticles to deliver drugs or replacement enzymes  directly 
to the lysosomes.  
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Chapter 1    
       Introduction 
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1.1 Lysosomal storage diseases and therapies 
A lysosome is a spherical organelle bounded by a single membrane.  The 
lyososmal matrix consists of a mixture of lytic enzymes such as hydrolases, 
lipases, amylases and proteases that are responsible for the degradation of 
intracellular waste.  The deficiency or misfolding of lytic enzymes leads to 
lysosomal storage disorders (LSDs).  The signs and symptoms of LSDs include 
loss of motor skills, dementia, muscular and neurological deterioration.  Systemic 
treatments for LSDs, such as enzyme replacement therapy (ERT), substrate 
reduction therapy (SRT) and gene therapy are available.  However, none of the 
current therapies have gained efficacy over the neurological symptoms, which 
pose the greatest challenges for LSD treatment due to the failure of large 
molecules to cross the blood-brain barrier.  Due to the limitations in current 
treatments, the aim of this research was to develop an improved and alternate 
therapeutic strategy that can deliver cargo attached to cell-penetrating peptides 
(CPPs) across the cell membrane, with lysosomal signal peptides (LSPs) attached 
to direct cargo to the lysosomes.  This novel approach could have therapeutic 
potential, as the cargo would be able to cross the blood-brain barrier with the help 
of the synthetic CPPs and be directed to the diseased lysosomes by the synthetic 
LSPs.  
Although the molecular basis of the pathogenesis of a huge range of human 
diseases is well-understood, effective treatments, especially targeted therapy 
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specifically to affected areas within the cells, remains problematic.  Many life-
threatening diseases occur due to defective genes or enzyme(s), leading to 
abnormalities in the functions of cells.  One such well-known type are lysosomal 
storage disorders (LSDs), which occur due to defects in or absences of lysosomal 
enzymes, mainly lytic enzymes, lyososomal hydrolases and lysosomal transport 
protein, thus impairing appropriate lysosomal function.  Lysosomal storage 
diseases occur due to a deficiency or malfunction of one or more enzymes 
associated with the degradative functions of this organelle (Grabowski and 
Hopkin, 2003).  More than 40 LSDs have been investigated (Begley et al., 2008).  
Most of the LSDs involve the central nervous system (CNS) and lead to substrate 
accumulation in the brain, resulting in CNS cell death, lysosomal enlargement and 
neuropathology.  CNS-related LSDs include Krabbe’s disease 
(galactocerebrosidase deficiency), Pompe disease (α-glucosidase deficiency), A 
and B Niemann-Pick diseases (sphingomyelinase deficiency), GM2 gangliosidosis 
(β-hexosaminidase deficiency) and many more (Heese, 2008).  
Currently, there is no effective therapy for these diseases, especially for those 
involving the CNS.  Enzyme replacement therapies (ERT) are being developed, 
including acid phosphatase and α-glucosidase replacement therapy for LSDs not 
involving the CNS (Desnick, 2004).  Enzyme replacement therapies for LSDs 
depend on the uptake of recombinant enzymes (injected into the blood circulation) 
by the cell surface receptors, namely mannose or mannose-6-phosphate 
receptors, that recognize sugar residues present on the recombinant enzymes.  
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Inadequate glycosylation of recombinant enzymes and deficiencies in appropriate 
receptors in LSD target cells create obstacles affecting efficient enzyme delivery.   
Alternative approaches developed include gene therapy by gene transfection, in 
which an appropriate gene is introduced into the patient to correct the enzyme to 
be produced and thus correct the gene defect.  Yet abnormal processing of newly 
synthesized lysosomal proteins by gene transfection is an obstacle.  Binding of 
chaperonin molecules to the misfolded enzymes can stabilise them, thereby 
avoiding degradation and favouring increased residual enzyme activity in the 
endoplasmic reticulum (ER) (Caillaud and Poenaru, 2000; Clarke, 2008).  All 
these current therapies do not target the affected lysosomes in the CNS and that 
is a possbile reason for their low effectiveness and severe side effects (Cheng 
and Smith).  Therefore, to obtain better therapeutic results, targeted delivery of 
replacement enzymes into the lysosomes of cells is likely to be a more effective 
therapy than the systemic delivery approaches currently used (Bou-Gharios et al., 
1993; Muro et al., 2006).   
There are several problems with existing methods for the delivery of therapeutics, 
especially biological compounds such as proteins, especially enzymes, which are 
often prevented from reaching the lysosomes because their large size and 
negative charge lead to poor permeability through the cell membrane.  There is 
therefore a need to develop new techniques to deliver enzymes and/or diagnostic 
probes directly to the lysosomes.  The types of therapeutics that could be 
delivered using a targeted delivery approach include replacement 
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enzymes, protein-based drugs, nanoparticles, short interfering RNA, antisense 
compounds that target RNA splicing and other biomolecules. 
Several studies have explored the targeted delivery of drugs and proteins to 
cellular compartments, including mitochondria and the nucleus (Rajendran et al., 
2010).  Targeting of nanoparticles (NPs) and fluorescent derivatives has been 
achieved using signal peptides including KDEL/HDEL retention signals, SKL and 
N-terminal amphipatic helix peptides into endoplasmic reticulum (ER) (Kaasch 
and Joiner, 2000), perioxisomes (Mullen et al., 1997) and mitochondria (Horton et 
al., 2008a) respectively.  However, to date there has been no study that describes 
the targeted delivery of molecules to lysosomes using signal peptides.  The aim of 
this research project was to design and synthesise lysosomal signal peptides 
(LSPs) and use them with cell-penetrating peptides (CPPs) and to test their ability 
to target a carrier cargo as an approach for the cure of lysosome-related disease.  
The delivery of the cargo across the cell membrane was mediated by short 
peptide sequences CPPs followed by lysosomal targeting by LSPs. 
At first glance it may seem illogical to use peptides as delivery vehicles, due to 
their inability to penetrate the cell’s impermeable nature, as occurs with several 
drug/protein molecules, due to their large size or negative charge.  The cellular 
entry of these therapeutic molecules is a goal for drug-delivery research (Frankel 
et al., 1988).  An innovative development towards this goal was the use of 
naturally occurring short peptide sequences (CPPs) to deliver proteins across the 
cell membrane by taking advantage of their amphipatic nature and net positive 
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charge (Fonseca et al., 2009a).  Most CPPs are relatively inert, with limited 
cellular side effects and so of low toxicity.  TAT peptides, derived from HIV-1 
transcriptional activator protein, and penetratin (Pen), derived from Drosophila 
antennapedia (Antp) transcription protein, were the first cell-penetrating peptides 
(CPPs) to be characterised (Frankel et al., 1988).  Since the discovery of TAT and 
Pen, many other natural peptides have been designed and tested.  Examples are 
the herpesvirus tegument protein VP22, peptide inv3 from Mycobacterium 
tuberculosis, chimeric CPPs such as transportan (a chimera of the neuropeptide 
galanin and wasp venom toxin mastoparan), totally synthetic CPPs such as the 
model amphipathic peptide (MAP) and arginine oligomers. 
Lysosomal membrane receptors such as low density lipoprotein receptor (LDL) or 
lysosomal-associated membrane protein, such as lysosome-associated 
membrane protein-1 (LAMP-1), contain specific LSPs (also called tyrosine sorting 
signals) for sorting and localisation into the lysosomes (Bonifacino and Traub, 
2003b).  LSPs are derived from the C-terminal end of cytoplasmic domain 
sequences of lysosomal membrane receptors and lysosome-associated 
membrane proteins.  It is proposed that the LSPs are recognised by clathrin-
interacting adaptor proteins and directed into the lysosomes through clathrin-
coated pits.  LSPs have the general formula NPXY and YXXǾ, where X is any 
amino acid and Ǿ is a bulky hydrophobic amino acid (Bonifacino and Traub, 
2003a).  They are recognized by adaptor proteins (APs) especially AP-2 and 
NPXY, which in turn are recognized by the accessory clathrin adaptor protein 
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Disabled-2 (Dab-2) (Morris and Cooper, 2001).  In theory, it should be possible to 
use the general formula for LSPs to design and synthesise LSPs so that they and 
their attached molecules are directed into lysosomes inside cells.  Using these in 
conjunction with CPPs should enable even bulky molecules to enter cells and then 
specifically the lysosomes, potentially delivering therapeutic molecules.  
In this study, two LSPs were coupled to two model cargoes, fluorescein 
isothiocyanate labelled-gold nanoparticles (FITC-AuNPs) and green fluorescent 
protein (GFP) along with CPPs and tested for lyosome-specific delivery and 
accumulation using fluorescence and electron microscopy.  If successful, this 
approach has potential for the effective delivery of therapeutic small molecules, 
drugs and enzymes, especially when used in combination with CPPs.   
This thesis therefore reviews relevant literature on lysosomal functions, cell and 
lysosomal membrane transport, the design and use of cell-penetrating peptides 
(CPPs), lyososomal sorting signals/peptides (LSPs), metal nanoparticles and the 
use of gold nanoparticles (AuNP) and green fluorescent protein (GFP) as model 
cargo to test the peptides designed to direct cargo to the lysosomes.  The 
research questions were:  
1. Is it possible to synthesise cell-penetrating peptides (CPPs) and to design 
and synthesise lysosome signal peptides (LSPs) using t-Boc chemistry 
(Chapter 2)? 
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2. Are the LSPs equally effective in targeting gold nanoparticles (AuNPs) to 
the lysosomes of mammalian cells in vitro when used in combination with 
CPPs, as judged using fluorescence and transmission electron microscopy 
(Chapter 3)? 
3. Are the LSPs equally effective in targeting GFP, a model protein cargo, to 
the lysosomes of mammalian cells in combination with CPPs, as judged 
using fluorescence microscopy (Chapter 4).? 
1.1.1 The cell and its organelles 
The cell is the basic structural and functional unit of all living organisms.  It is the 
smallest building block of life (Orgel, 1998).  Cellular organization is either 
unicellular, like bacteria, or multicellular, like humans.  The cell contains different 
organelles for performing various functional activities of the well-being of the cell 
(Table 1-0-1).  Thus, the entire cell system is a co-ordinated team of the various 
organelles in the cell.  If there is a defect or malfunctioning of any one of the 
organelles, it hampers the overall well-being of the cell and finally the entire 
organism.  The function of lysosomes is to degrade complex materials, including 
proteins and polysaccharides (Table 1-0-1) (Alberts, 2002) 
1.1.2 Membrane structure 
Cell membrane integrity and normal functioning is crucial for the healthy activity of 
the cell membrane.  Each organelle is maintained within its membrane(s) with 
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its characteristic contents due to the presence of the membrane structure(s 
)surrounding it.  The plasma membrane encloses the cytosol and separates it 
from the extracellular environment of the cell.  The plasma membrane has 
proteins that sense external signals, allowing the cell to change its behaviour 
when needed (Alberts, 2002).  Protein sensors or receptors transfer the proteins 
and materials across the membrane and so are essential for the cells’ proper 
functioning (Fig. 1-2) 
All biological membranes are made up of non-covalent interactions between lipids 
and proteins.  The fluid structure of the plasma membrane is maintained by the 
lipids.  Lipids are arranged as a continuous double layer that serves as a relatively 
impermeable barrier to the passage of most water-soluble molecules (Devaux, 
1993).  Protein molecules that span this lipid bilayer are called transmembrane 
proteins and transport specific molecules across it, catalyze membrane-
associated reactions such as ATP synthesis, support the structure by linking the 
cytoskeleton with the extracellular matrix or adjacent cells and serve as receptors 
that detect and transfer information into the cell (Singer and Nicolson, 1972).  
Hence when a foreign molecule comes in contact with the plasma membrane, it 
interacts with the membrane components and performs its coded function in 
transport across the membrane.   
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Table 1-0-1 Organelles and their functions. 
 
Organelle Main function Structure 
Endoplasmic 
reticulum 
Translation and folding of new proteins (rough 
endoplasmic reticulum), expression of lipids 
(smooth endoplasmic reticulum) 
Single-membrane 
compartment 
Golgi apparatus Sorting and modification of proteins 
Single-membrane 
compartment 
Lysosome 
Breakdown of large molecules (e.g., proteins + 
polysaccharides) 
Single-membrane 
compartment 
Mitochondrion Energy production 
Double-membrane 
compartment 
Nucleus DNA synthesis+ maintenance, RNA transcription 
Double-membrane 
compartment 
Peroxisome Breakdown of metabolic hydrogen peroxide 
Single-membrane 
compartment 
Vesicle Material transport 
Single-membrane 
compartment 
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Figure 1-1. Views of a cell membrane.  
(A) An electron micrograph of a plasma membrane (of a human red blood cell) 
seen in cross section (Stevenson et al., 1986)  (B and C) Two-dimensional (B)  
and three-dimensional (C)  views of a cell membrane(Alberts, 2002).  
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1.1.3 Lysosomes 
Lysosomes are one of the digestive organelles of the cell (Fig. 1-1).  These 
digestive organelles are present in cytoplasm as dense bodies having spherical, 
ovoid or tubular (occasionally) shapes surrounded by a dense membrane 
(Bainton, 1981) that contain an osmiophilic dense fluid matrix. They vary in size 
from less than one to several micrometres (Callahan et al., 2009; Olea et al., 
1991).        
Lysosomes are the sites for degradation of variety of macromolecules that are 
internalized from the extracellular space by endocytosis, delivered by fusion with 
phagosomes and derived from the biosynthetic pathways (Winchester, 2001).  
Typical intracellular positions of lysosomes are at the bile canaliculus in the 
hepatocytes, in the supranuclear cytoplasm in the renal proximal tubule cells and 
in the perinuclear cytoplasm in cultured fibroblasts (Lüllmann-Rauch, 2007).  
Different cell types have different numbers of lysosomes, depending on their 
respective functions.  For example, in normal fibroblasts lysosomes occupy less 
than 0.5% of the total cytoplasmic volume, as they do not need to recycle their 
macromolecules quickly (Kiyoshi et al., 1980), whereas in macrophages the 
volume of lysosomes is >10% of the cytoplasmic volume, as the function of  
macrophages is to degrade foreign material and pathogens, and hence the 
macromolecules recycle quickly (Knapp and Swanson, 1990).  Thus, the number 
and volume of lysosomes varies with different cell types based on the cell 
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functions. 
Lysosomes contain a variety of enzymes to perform their function.  Acid 
hydrolases are predominant (AJ Barrett, 1977).  The dense membrane 
surrounding lysosomes prevents the leakage into the cytoplasm.  The lysosomal 
lumen contains many other hydrolytic enzymes, each with a characteristic acidic 
optimum pH and high substrate specificity (Mancini, 2007).  The lysosomal 
membrane consists of cholesterol and dolichol derivatives, bi-monoacylglycerol 
and phospholipids, including sphingomyelin, as the major lipids of the 7-10 nm 
thick lipid bilayer of the lysosomal membrane (Werth et al., 2001).  This typical 
single phospholipid bilayer controls the entry of materials into and out of 
lysosomes and it has the ability to fuse with other digestive vacuoles, for example 
endosomes.  The lysosomal membrane is impermeable to macromolecules but 
small molecules up to 200 Da diffuse freely (Lloyd, 2000). 
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                      Figure 1-2. Basic structure of lysosome. 
                      Electron micrograph of lysosome (Friend and Farquhar, 1967) 
 
                
 
       
500 nm 
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The accumulation of non-degraded material in the lysosomes causes variation in 
their size and frequency in the cell.  This condition occurs when overloading of 
lysosomes occurs with non-physiological substrates that interfere with 
intralysosomal degradation (Jeyakumar et al., 2005).  Such conditions lead to 
states called lysosomal storage disorders (LSDs) (Vellodi, 2005).  LSDs are 
caused by the absence of functional hydrolases due to mutations in the genome 
encoding for the enzymes, which causes non-specific accumulation of substrates 
in the lysosomes (Pastores and Barnett, 2005).  Lysosomal storage disorders 
have a broad spectrum of clinical phenotypes. 
Lysosomal storage disorders are mainly divided into (Berg, 2007): 
1) Defects in glycan degradation 
2) Defects in lipid degradation 
3) Defects in protein degradation 
4) Defects in lysosomal transporters 
5) Defects in lysosomal trafficking. 
Currently there is no cure for lysosomal storage diseases and treatments are at a 
very preliminary level.  Bone marrow transplantation and enzyme replacement 
therapy (ERT) have shown some success (Callahan et al., 2009; Clarke and 
Iwanochko, 2005).  ERT is available for three lysosomal disorders but not for 
others (Silvia Muro 2006).  Substrate reduction therapy, a method used to 
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decrease the accumulation of storage material, is currently being evaluated for 
some of these diseases (Andersson et al., 2004).  Also, chaperone therapy, a 
technique used to stabilize the defective enzymes produced by patients, is being 
examined for certain of these disorders (Suzuki, 2006).  This and gene therapy 
are being tested (Ponder and Haskins, 2007).  LSDs occur due to the failure of 
synthesis of the necessary enzymes or improper functioning of the transport 
mechanisms to the lysosomes from the ribosomes. 
 
1.2 Transport mechanisms to the lysosomes 
1.2.1 Intracellular vesicle traffic 
Cells communicate with the surrounding medium and quickly respond to the 
environment, using receptors, ion channels and transporters to communicate with 
the surrounding medium and the external molecules from the cell surface 
(LaBella, 1983).  Hence when proteins come in contact with the cell, they are 
sorted to the organelles by transport vesicles.  Transport vesicles have continuous 
activity, budding off from one membrane and fusing with sorting components 
(proteins or other components) to deliver cargo to subcellular organelles 
(Mellman, 1996).  This movement is highly organized and directional (Fig. 1-3) 
and occurs in three fundamentally different ways: gated transport, transmembrane 
transport and vesicular transport, the last of which includes transport to the 
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lysosomes and depends on endocytosis.  
1.2.2  Endocytosis 
Endocytosis is defined as the process of cellular uptake of macromolecules and 
particulate substances by localised regions of the plasma membrane that 
surround the substance and pinch off to form an intracellular vesicle (Besterman 
and Low, 1983).  The mechanism of endocytosis depends on structure and 
function of the external molecules.  Each cell of the body uses this mechanism,  
as large polar molecules cannot pass through the hydrophobic plasma membrane.  
After endocytosis, the endosomes deliver the material to the organelles, including 
to the lysosomes for degradation.  Materials sent to the lysosomes include 
vitamins, lipids, iron, cholesterol and proteins taken up by the process of 
endocytosis.  For each protein, there is a specific receptor on the plasma 
membrane (Janvier and Bonifacino, 2005).  Proteins containing internal sorting 
codes are sorted to the endocytosis machinery in combination with the receptor.  
After the interaction of the receptor-protein complexes with the endocytosis 
machinery, they are transported to the lysosomes.  The transported protein is 
degraded in the lysosome by its acidic pH and enzymes, while the receptor is 
recycled back to the plasma membrane (Fig. 1-4) (van Meel and Klumperman, 
2008).  The proteins destined for degradation in the lysosomes are sorted by  
these specific receptors (von Figura, 1991).  Well-known examples are acidic 
hydrolase enzymes, which are synthesised in the trans-Golgi network and 
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attached to mannose-6-phosphate groups (Janvier and Bonifacino, 2005).  
Mannose-6-phosphate groups are recognized by the mannose–6-phosphate 
receptors present in the trans-Golgi network, which sorts the acid hydrolases to 
the endosomes.  In the endosomes, the acidic pH disrupts the enzyme-receptor 
complex and mannose-6-phosphate is transported back to the trans-Golgi network 
(Janvier and Bonifacino, 2005).  Thus, in the trans-Golgi network route, newly 
synthesized proteins are sorted by sorting signals present in them that direct them 
to the plasma membrane etc, or sort them to lysosomes.  There are three main 
types of endocytosis, which are differentiated by the size of the vesicle formed 
and the cellular machinery involved (Merrifield, 2004). 
 
1.2.3 Endocytosis pathways 
Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis is mediated by a characteristic crystalline complex 
protein coat called clathrin (Marsh and McMahon, 1999).  Transport vesicles have 
a vesicle diameter of 100 nm and are formed by the specialised coated pits of the 
membrane, around which they bud off.  These coated pits are composed of 
special types of proteins, which cover their cytosolic surface.  Coated pits 
concentrate large extracellular molecules and have different receptors responsible 
for the receptor-mediated endocytosis of ligands such as low density lipoprotein, 
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transferrin, growth factors, antibodies and many others (Wileman et al., 1985).   
There are three types of coat vesicles: clathrin- coated, COPI-coated and COPII– 
coated (Fig. 1-5)(Schmid, 1997).  Clathrin-coated vesicles mediate transport from 
the plasma membrane to the lysosomes and COPI and COPII mediate transport 
between the ER and the Golgi apparatus (Schmid, 1997).  
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Figure 1-3.  Intracellular vesicle transport. 
Proteins can move from one compartment to another by gated transport (red), 
transmembrane transport (blue), or vesicular transport (green) (Alberts, 2002). 
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1)  Lysosome proteins (containing internal sorting codes) 
 
2) Recognition of the sorting codes in the lyososome proteins by the receptor on 
the plasma membrane 
 
 3) Formation of protein-receptor complex 
 
4) Uptake of protein-receptor complex by the endosomes (part of the endocytosis 
machinery) 
 
5) Transport of protein-receptor complex to lysosomes through endosomes 
  
   
6) Dissociation of protein from the receptor 
 
 7) Recycling of receptor back to the plasma membrane  
 
Figure 1-4. Mechanism of endocytosis. 
  
26 
 
       
              
 
 
 
Figure 1-5. Utilization of different coats in vesicular traffic. 
Different coat proteins select different cargo and shape the transport vesicles that 
mediate the various steps in the biosynthetic- secretory and endocytic pathways 
(Alberts, 2002). 
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Clathrin-coated vesicles contain the protein clathrin, and each clathrin subunit 
consists of three large and three small polypeptide chains that form a three-legged 
structure called a triskeleton.  These further get assembled into basket-like 
structures of hexagons and pentagons to form coated pits on the cytosolic surface 
of membranes (Jackson, 2008; Kirchhausen, 2000; Schmid, 1997).  The clathrin 
coat is bound to the membrane by adaptor proteins; cargo is attached to 
transmembrane proteins (receptors), which are in turn attached to the adaptor 
proteins.  Thus, the cargo along with adaptor proteins is trapped in the clathrin-
coated pits (Fig. 1-6a).  Adaptors are heterotetrameric complexes of two large 
100-150 kDa subunits (α, β, γ, δ, ε), one 50-kDa medium chain (µ1, µ2, µ3 and 
µ4) and a small 20-kDa subunit (σ1, σ2, σ3 and σ4) that interact with the 
cytoplasmic domains of membrane cargo proteins, by selectively concentrating 
them by interacting with their receptors.  There are four adaptor proteins, each 
specific for distinct sets of cargo receptors (Owen et al., 2004).  Adaptor proteins 
capture the receptors as they move laterally through the membrane.  The adaptor 
proteins bind clathrin triskelions and membrane-bound cargo receptors, thereby 
mediating the selective recruitment of both membrane and cargo molecules into 
the vesicle  (Roth, 2006).   
The pinching-off of the bud to form a vesicle involves membrane fusion; this is 
helped by the GTP-binding protein dynamin, which assembles around the neck of 
the bud.  The coat of clathrin and adaptor proteins around the vesicle is removed 
rapidly shortly after the vesicle forms and is pinched off by depression (Alberts, 
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2002) (Fig. 1-6b).  Receptors or protein molecules that do not have the "right" tail 
region (signal) are not allowed to pass through into the respective organelle.  
Therefore, in lysosomal disease states, where the receptors are not recognised by 
coated pits, there may be a defect in the exposed receptor tail region (Whistler et 
al., 2001). 
Caveolae-mediated endocytosis 
Caveolae-mediated endocytosis is budding from the non-clathrin coated plasma 
membrane and occurs in, many, but not all, cell types.  Caveolae consist of 
membrane enriched with the cholesterol-binding protein caveolin, with a bilayer 
enriched in cholesterol and glycolipids.  Caveolae are small flask-shaped pits in 
the plasma membrane having an approximate diameter of 50 nm that resemble 
the shape of a cave, hence the name caveolae.  They are abundant in smooth 
muscle, type I pneumocytes, fibroblasts and adipocytes.  Uptake of extracellular 
molecules is specifically mediated via receptors in caveolae (Anderson, 1998a). 
Macropinocytosis 
Macropinocytosis usually occurs from highly ruffled regions of the plasma 
membrane and is the invagination of the cell membrane to form a pocket, which 
then pinches off into the cell to form a vesicle having a 0.5-5 µm diameter filled 
with large volume of extracellular fluid various and molecules like microparticles 
and large proteins within it.  This occurs in a non-specific manner (Swanson and 
Watts, 1995).  The vesicle then travels into the cytosol and fuses with other 
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vesicles such as endosomes and lysosomes. 
Phagocytosis 
 Phagocytosis is the process by which cells bind and internalize particulate matter 
larger than around 0.75 µm in diameter, such as small-sized dust particles, cell 
debris, micro-organisms and even apoptotic cells, and only occurs in specialized 
cells (Sbarra and Karnovsky, 1959).  These processes involve the uptake of larger 
membrane areas than clathrin-mediated endocytosis and the caveolae pathway. 
All the process discussed above finally target molecules to the lysosomes.  
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a) 
 
 
 
 
 
 
 
 
 
    Protein cargo containing internal sorting signals  
                       Receptor present on the plasma membrane 
                        Adaptor protein complexes (AP) 
                        Clathrin triskeleton                   
  Figure 1-6 Clathrin assembly  
a) Interaction between cargo and  the clathrin machinery b) The assembly 
and disassembly of a clathrin coat(Alberts, 2002).                          
Plasma membrane 
Clathrin coated 
vesicles  
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b) 
 
 
 
Figure 1-6 Clathrin assembly  
a) Interaction between cargo and  the clathrin machinery b) The assembly and 
disassembly of a clathrin coat(Alberts, 2002).  
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1.2.4 Principal components of endocytic pathway 
The endocytic pathway of mammalian cells has distinct membrane compartments 
that internalize molecules from the plasma membrane and recycle them back to 
the surface (early endosomes and recycling endosomes) or sort them to 
degradation (late endosomes and lysosomes) (Besterman and Low, 1983) (Fig.1-
3). 
• Early endosomes are the first component on the endocytic pathway.  Early 
endosomes are often located in the periphery of the cell receive most 
types of vesicles coming from the cell surface and have a mildly acidic pH 
(Gruenberg and Maxfield, 1995).  They are principally sorting organelles 
where many ligands dissociate from their receptors in the acid pH of the 
lumen and from which many of the receptors recycle to the cell surface 
(Fig.3) (Schmid et al., 1988).  
• Late endosomes receive internalized material from early endosomes in the 
endocytic pathway, from the trans-Golgi network (TGN) in the biosynthetic 
pathway, and phagosomes in the phagocytic pathway (Fig.3) (Gruenberg 
and Maxfield, 1995).  Late endosomes contain many membrane vesicles 
or membrane lamellae and proteins characteristic of lysosomes, including 
lysosomal membrane glycoproteins and acid hydrolases (Schmid et al., 
1988).  Late endosomes are acidic (pH 5.5). They are thought to mediate a 
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final set of sorting events prior to delivery of material to lysosomes.  
• Lysosomes are the last compartment of the endocytic pathway.  They have 
an acidic (pH 4.8) inner environment and by electron microscopy (EM) 
usually appear as large vacuoles (1-2 µm in diameter) containing electron 
dense material (Bainton, 1981).  They have a high content of lysosomal 
membrane proteins, active lysosomal hydrolases, and hydrolytic enzymes.  
They are generally regarded as the principal hydrolytic compartments of 
the cell (AJ Barrett, 1977). 
 
1.3 Protein sorting to the lysosomal system  
Protein sorting occurs through sorting signals that are recognised by sorting 
receptors.  Thus the sorting signal acts as a key that sorts the protein to the 
desired location.  Sorting signals consist of signal sequences, which are 1-60 
consecutive amino acids long (Mellman, 1996).  They can be located terminally, 
i.e. at the N- terminal end of the protein, in the form of multiple internal sequences 
that form three-dimensional arrangements called a signal patch (Marsh and 
McMahon, 1999).  Proteins destined for lysosomes have tyrosine motif 
sequences, which contain mainly tyrosine, leucine, and arginine-rich sequences.  
Even though the amino acid sequences vary greatly, the signal sequences of all 
proteins or cargo targeted to the lysosomes are functionally interchangeable.  
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These signal sequences are recognized by complementary sorting receptors that 
target proteins to lysosomes.  The receptors function catalytically; after targeting 
they return to their point of origin in the cell membrane. 
1.3.1 Properties of lysosomal sorting signals 
Lysosomal sorting signals are present in the domains of the transmembrane 
proteins.  The various signals are recognised by receptor molecules and directed 
to the lysosomes.  Lysosomal sorting signals consist of short sequences of amino 
acids (generally four to seven amino acids) that are not conserved sequences but 
degenerate motifs or patterns.  Within these amino acid sequences, the bulky and 
hydrophobic amino acids, are critical to the sorting function (Bonifacino and Traub, 
2003b).  These sorting signals are low-affinity binding signals (Bonifacino and 
Dell'Angelica, 1999).  The major differentiating characteristic of these signals is 
that they are found only within the cytosolic domain of the transmembrane 
proteins, unlike other protein motifs (Trowbridge et al., 1993). Most of the sorting 
signals are peptide-motif recognition-domain interactions.  Not all the sorting 
signals, however, are short peptide motifs and collinear; some are folded 
structures, as in the case of the protein ubiquitin (Roth and Davis, 2000). 
The two most important and major signals for lysosomal sorting are based on the 
critical amino acid residues present in them, which are as follows:  
1. The tyrosine sorting signal, which has tyrosine as the critical amino acid (Marks 
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et al., 1996) 
2. The dileucine sorting signal, which has two leucine moieties as critical amino 
acids (Marks et al., 1996) 
1.3.1.1 Recognition of lysosome target signals 
The NPXY or YXXØ lysosomal target signal present in the receptor is recognised 
by the clathrin-coated pits and the adaptor protein AP-2 complex on the plasma 
membrane (Bonifacino and Traub, 2003a; Owen and Evans, 1998a).  After 
receptor binding, to the AP-2 complex the plasma membrane invaginates and the 
clathrin-coated pit becomes rounded, containing the molecule to be transported 
into the lysosome.  Clathrin thus plays a very important role in recruiting cargo 
proteins into the transport intermediates.  A special family of proteins called  
adaptor proteins  specifically recognises tyrosine-based sorting signals (Aguilar et 
al., 2001).  In the tyrosine sorting signals, the key  is the tyrosine residue (Marks 
et al., 1997). The tyrosine motifs are:  
(i) YXXØ,  where Y is tyrosine, X is any amino acid and is Ø is an amino 
acid with a bulky hydrophobic side chain (Canfield et al., 1991) (Table 
1-0-2). 
(ii)  NPXY,  where N is aspargine and P is proline (Chen et al., 1990) 
(Table 1-0-2).  The tyrosine sorting signals mediate rapid internalisation 
from the plasma membrane to the endosomes and finally into the 
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lysosomes. 
1.3.1.2 YXXØ signal  
 Recognition of the tyrosine signals by the adaptor protein was pioneered by 
Glickman et al. (1989), who demonstrated that tyrosine  in the cytosolic tail of the 
mannose-6-phosphate receptor interacted with the AP-2 complex present on the 
plasma membrane (Glickman et al., 1989). 
Using the yeast two-hybrid system, it was identified that the YXXØ signal is 
recognised by the µ2 subunit of AP-2 (Ohno et al., 1995).  This was precise and 
selective only for tyrosine.  Leucine is the preferred residue at the Ø position but 
residues like isoleucine, phenylalanine, methionine and valine are tolerated 
(Collawn et al., 1990; Ohno et al., 1996).  At the X position, many residues are 
tolerated, although proline and arginine are favoured (Ohno et al., 1998).  If all the 
above criteria are met then there should be optimal functioning for internalisation 
of these YXXØ signals along with the AP-2 protein (Boll et al., 1996).  Structural 
and functional analyses of µ2 indicated that this polypeptide has a bipartite 
structure, with a -NH2 terminal in which 1-145 amino acid residues are involved in 
the assembly with β2, and the rest of the 164-435 amino acid residues interact 
with the YXXØ signals (Fig.1-7).  The crystalline structure of the interaction of 
YXXØ signals with µ2 demonstrated that the signal-binding domain of µ2 has a 
banana-shaped structure of 16 β sheet strands arranged into two subdomains 
(Bonifacino and Traub, 2003a).  YXXØ signals bind in an extended confirmation, 
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with Y and Ø having pockets for binding,  like a plug fitting into a two-holed socket 
(Waksman et al., 1993). 
Tyrosine has an aromatic ring that is involved in the hydrophobic interactions with 
the µ2 residues phenylalanine 174 and tryptophan 421 and it stacks on the 
guanidinium group of arginine 423 (Bonifacino and Dell'Angelica, 1999).  Also, the 
phenolic hydroxyl group of tyrosine forms hydrogen bonds with aspartic acid 176, 
lysine 203 and arginine 423 of the µ2 molecule.  Hence phenylalanine or 
phosphotyrosine cannot be substituted for tyrosine (Bonifacino and Traub, 2003).  
Phenlyalanine would fail to establish hydrogen bonds with the residues at the 
bottom of the pocket.  Phosophotyrosine is too bulky to fit into the pocket and 
does elicit electrostatic repulsion by aspartic acid 176 (Owen and Evans, 1998b) 
The Ø pocket lining consists of leucine173, leucine175, valine401, leucine404, 
valine422, and the aliphatic portion of lysine420.  Due to the hydrophobic and flexible 
nature of these side chain residues, different bulky hydrophobic residues are 
accommodated but leucine is preferred the most as it is best fitting (Bonifacino 
and Dell'Angelica, 1999). 
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Table 1-0-2.  Lysosome sorting signals. 
Signal type Proposed recognition 
protein or domain 
Functions 
DXXLL VHS domain of the 
GGAs 
TGN-to-endosomes sorting 
[DE]XXXL[LI] µ and/or β subunits of 
AP complexes 
Internalization, lysosomal 
targeting, basolateral targeting 
NPXY Clathrin terminal 
domain, µ2 subunit of 
AP-2, PTB domain of 
Dab2 
Internalization 
Ubiquitin UIM, UBA, and UBC 
domains 
Internalization, 
lysosomal/vacuolar targeting 
YXXØ µ subunits of AP 
complexes 
Internalization, lysosomal 
targeting, basolateral targeting 
 
Amino acid residues are designated according to the single letter code as follows: 
A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, 
glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, 
asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; 
W, tryptophan, and Y, tyrosine. X stands for any amino acid and Ø stands for an 
amino acid residue with a bulky hydrophobic side chain. Abbreviations: PTB, 
phosphotyrosine-binding; Dab2, disabled-2; AP, adaptor protein; VHS domain 
present in Vps27p, Hrs, Stam; GGAs, Golgi-localized, γ-ear-containing,;UBA, 
ubiquitin associated; UBC, ubiquitin conjugating; UIM, ubiquitininteraction motif 
(Bonifacino and Traub, 2003b). 
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Figure 1-7.  Structure of YXXØ-µ2 complexes.  
(A) Ribbon diagram of the carboxy-terminal domain of µ2 in a complex with the 
DYQRLN peptide from TGN38. Notice the orientation of the Y and L residues 
toward µ2. (B) Binding of the DYQRLN peptide from TGN38 to the surface of µ2. 
The peptide binds in an extended conformation with the Y and L residues fitting 
into two hydrophobic pockets (i.e.the “two-pinned” plug model) (Owen and Evans, 
1998a; Owen et al., 2001).  
 
. 
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Hence the critical parts of the peptide are the Y and the Ø residues, but the R 
residue at the second X position is involved in hydrophobic interactions with W421, 
I419 and in hydrogen bonding with K420 (Ohno et al., 1996).  The NPXY signal can 
be accommodated in the YXXØ binding domain of the µ2 subunit of AP-2 as this 
is very specific only for YXXØ binding (Warren et al., 1998).  NPXY signals  bind 
to the terminal domain of clathrin by linking through the Disabled–2 (Dab2) 
molecule (Kibbey et al., 1998; Mishra et al., 2002a).  YXXØ signal- binding 
domains have been discovered in a wide range of organisms, ranging from fruit 
flies to humans (Table 1-0-3). 
1.3.1.3  NPXY signal  
NPXY signals are the minimal motifs that are present in all protein families 
containing this type of signal.  The critical residues are  aspargine (Chen et al., 
1990) and  tyrosine (Table 1-0-4). 
NPXY signals are mostly present within medium-length cytosolic domains ranging 
from about 40-200 amino acids residues, with exceptions like signalling receptors 
such as those for insulin and epidermal growth factor (EGF) (Trowbridge et al., 
1993).  The distance of the NPXY signals from the transmembrane domains is 
variable.  They are also never found exactly at the C-terminus of the protein 
(Bonifacino and Traub, 2003b).  The best studied example of such a protein 
receptor is the Low-Density Lipoprotein (LDL) receptor, which has the NPXY 
signal.  This  and other proteins with this signal are internalized via clathrin-coated 
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pits (Roth et al., 1976) (Anderson et al., 1977). Nuclear magnetic resonance 
spectroscopy (NMR) has shown that NPXY signals bind directly to the globular, 
amino-terminal domain (TD) of the clathrin heavy chain (Kibbey et al., 1998).  As 
the tyrosine is critical the interactions occur with an equilibrium dissociation 
constant (KD) of ~0.1 mM.  The signal binds to clathrin cages, in which it adopts a 
type 1 β structure.  The clathrin is associated not only with the plasma membrane 
but also with the trans-Golgi network and endosomes. 
An alternative hypothesis suggests that AP-2, along with other adaptors that 
interact with the NPXY signal, is present between the clathrin lattice and the 
membrane.  This was suggested by Surface Plasmon Resonance Spectroscopy 
(SPR) and photoaffinity labelling binding of the signals to AP-2.  Binding was 
dependent on the tyrosine residues (Boll et al., 2002). 
Recent work has suggested yet another hypothesis: that the NPXY signals are not 
directly recognized by the AP-2 adaptor protein, but by proteins containing a 
domain known as the phosphotyrosine-binding (PTB) or phosphotyrosine-
interacting domain (PID).  These PTBs have greater selectivity for NPXY signals 
and function in receptor internalization (Howell et al., 1999).  Dab2, a protein that 
participates in neural migration and cortical lamination in the brain, is a good 
example, as this protein co-localizes with the clathrin coat components in the 
steady state (Mishra et al., 2002b).  Dab-2 proteins are also involved in tyrosine 
kinase signaling.  The families of Dab proteins contain an amino-terminal PID/PTB 
(Gotthardt et al., 2000; Howell et al., 1999).  These Dab proteins have 
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important functions in signal transduction and endocytosis.  The Dab-2 PTB 
domain has the ability to bind to signal peptides containing NPXY sequences 
(Trommsdorff et al., 1998).  Thus Dab-2 binds to the ear domain at the carboxy-
terminal region of α-adaptin in the AP-2 complex and mediates the interaction; 
hence it is associated with AP-2 clathrin-coated pits.  Thus Dab-2 may function as 
a linker molecule that links the NPXY signal to AP-2 and thus to clathrin (Morris 
and Cooper, 2001).  Dab-2 establishes a protein-protein interaction web at the 
clathrin bud site.  These multitasked connections may be a critical aspect of 
ensuring the fidelity of cargo incorporation into assembling coated buds (Morris 
and Cooper, 2001).   
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Table 1-0-3.  YXXØ-type signals (Bonifacino and Traub, 2003). 
Protein Species Sequence 
Acid phosphatase Human Tm-RMQAQPPGYRHVADGEDHA 
Asialoglycoprotein receptor H1 Human MTKEYQDLQHL-29-Tm 
CD1 Rat Tm-RKRRRSYQDIM 
CD1c Human Tm-KKHCSYQDIL 
CD63 Human Tm-KSIRSGYEVM 
CD68 Human Tm-RRRPSAYQAL 
CD-MPR Human Tm-40-PAAYRGVGDD-16 
CI-MPR Human Tm-22-SYKYSKVNKE-132 
CTLA-4 Human Tm-10-TGVYVKMPPT-16 
Cystinosin Human Tm-HFCLYRKRPGYDQLN 
Endolyn Rat Tm-KFCKSKERNYHTL 
Endolyn Drosophila Tm-KFYKARNERNYHTL 
Furin Human Tm-17-LISYKGLPPE-29 
GMP-17 Human Tm-HCGGPRPGYETL 
GMP-17 Mouse Tm-HCRTRRAEYETL 
gp41 HIV-1 Tm-13-RQGYSPLSFQT-144 
HLA-DM β Human Tm-RRAGHSSYTPLPGS-9 
LAMP Drosophila Tm-RRRSTSRGYMSF 
LAMP-1 Human Tm-RKRSHAGYQTI 
LAMP-2a Human Tm-KHHHAGYEQF 
LAMP-2a Chicken Tm-KKHHNTGYEQF 
LAMP-2b Chicken Tm-RRKSRTGYQSV 
LAMP-2c Chicken Tm-RRKSYAGYQTL 
LIMP-II Dictyostelium Tm-RKTFYNNNQYNGYNIIN 
TGN38 Rat Tm-23-ASDYQRLNLKL 
Transferrin receptor Human 16-PLSYTRFSLA-35-Tm 
TSC403 Human Tm-KIRLRCQSSGYQRI 
TSC403 Mouse Tm-KIRQRHQSSAYQRI 
 
  
44 
 
 
 
Table 1-0-4. NPXY- type signal(Bonifacino and Traub, 2003b). 
  
Protein Species Sequence 
APLP1 Human Tm-33-HGYENPTYRFLE-3 
APP Human Tm-32-NGYENPTYKFFE-4 
APP-like Drosophila Tm-38-NGYENPTYKYFE-3 
EGR receptor (1) Human Tm-434-GSVQNPVYHNQP-96 
EGR receptor (2) Human Tm-462-TAVGNPEYLNTV-68 
EGR receptor (3) Human Tm-496-ISLDNPDYQQDF-34 
Insulin receptor Human Tm-36-YASSNPEYLSAS-379 
Integrin β (1) Drosophila Tm-26-WDTENPIYKQAT-11 
Integrin β (2) Drosophila Tm-35-STFKNPMYAGK 
Integrin β-1 (1) Human Tm-18-DTGENPIYKSAV-11 
Integrin β-1 (2) Human Tm-30-TTVVNPKYEGK 
LDL receptor Human Tm-10-INFDNPVYQKTT-29 
LRP1 Drosophila Tm-43-GNFANPVYESMY-38 
LRP1 (1) Human Tm-21-VEIGNPTYKMYE-64 
LRP1 (1) C. elegans Tm-54-TTFTNPVYELED-91 
LRP1 (2) Human Tm-55-TNFTNPVYATLY-33 
LRP1 (2) C. elegans Tm-140-LRVDNPLYDPDS-4 
Megalin (1) Human Tm-70-IIFENPMYSARD-125 
Megalin (2) Human Tm-144-TNFENPIYAQME-53 
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1.4 Peptide-mediated delivery systems 
The main issues of gene therapy today are safe, targeted delivery and stable and 
persistent gene expression (Anderson, 1998b; Boucher, 1999; Ennist, 1999; K. 
Takeda, 2009).  Due to the limitations of gene delivery systems, peptide-based 
delivery is an alternative, due to its flexibility.  Peptide-based systems can deliver 
small molecules, nucleic acids and proteins that can interact at any level to study 
genetics and biochemistry (Bonetta, 2009; Rapoport and Lorberboum-Galski, 
2009) . 
Desirable features of peptide-based delivery systems are that they (Schwartz and 
Zhang, 2000): 
 have greater safety levels 
 have an efficient passage into cells in vivo 
 help in stable delivery of cargo at the sub-cellular level without degradation 
 have no size limitations for the cargo  
 help in sustained, stable and regulation gene expression if the cargo is a 
gene 
 can be easily synthesized at a  high purity 
 have site-directed targeting 
 are not-immunogenic, antigenic or inflammatory 
 are adaptable to different cell types  
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 are biocompatible, being non-toxic and biodegradable  
 have a sufficient serum half-life. 
With peptide-based delivery systems, the delivery of molecules such as drugs 
attached to cell-penetrating peptides (CPPs) has been a goal in delivery 
technology (Järver and Langel, 2006). 
1.4.1 Cell-Penetrating Peptides (CPPs) 
The plasma membrane surrounding the cells is a selective permeable barrier that 
allows restricted entry of molecules.  This phospholipid bilayer is essential for cell 
organization, but it is a major challenge for intracellular delivery of cargo.  When 
delivering therapeutics, it is essential to retain their activity and so understanding 
and identifying a translocation strategy is required (Wender et al., 2008).  CPPs 
have become the most popular and efficient therapy for achieving intracellular 
access to cells.  CPPs are generally short cationic sequences and they are 
derived from naturally occurring proteins or designed as constructs (Table 1-0-5) 
(Christie and Grainger, 2003).  The initial CPP discovered was transactivator of 
transcription (TAT) of human immunodeficiency virus in 1988; this is the 
transactivator from HIV translocates through the cell membrane and thus gains 
intracellular access (Frankel and Pabo, 1988; Green and Loewenstein, 1988).  
The protein was shortened to a few amino acids without sacrificing the 
translocation efficiency and was referred to as the TAT (49-57) peptide (Fawell et 
al., 1994; Vives et al., 1997).  The penetratin peptide was discovered later on, in 
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1994 (Derossi et al., 1994).  Penetratin was slightly longer peptide than TAT 
peptide.  The most commonly used CPPs are penetratin, TAT, polyarginine and 
transportan (Table 1-0-5).  Several CPPs have been proposed for delivery of 
polypeptides and proteins into cells through either of two strategies: covalent or 
complexed in a non-covalent fashion. Members of the PEP family are primary 
amphipathic peptides which have been shown to deliver peptides and 
proteins into a wide variety of cells through formation of non-covalent complexes.  
MPG and CADY are secondary amphipathic peptides which have been 
demonstrated to deliver short nucleic acids, in particular siRNA with high 
efficiency (Kurzawa et al., 2010).  These CPPs have been used in the delivery of 
various cargoes such as proteins, nucleic acids, quantum dots and MRI contrast 
agents (Rozenzhak et al., 2005; Santra et al., 2004). 
The mechanism of entry into cells by CPPs remains unclear.  Properties of 
peptides, such as molecule length and charge delocalisation, and properties of the 
attached cargo can affect the mechanism of the peptide uptake and it also 
depends on cell type (Mueller et al., 2008).  The major modes of uptake of CPPs 
are categorised as energy-dependent endocytosis and energy-independent 
uptake, which is direct translocation across the cell membrane (Fig. 1-8). 
1.4.1.1 TAT peptide 
The HIV virus codes for the regulatory protein TAT, which is a transactivator of 
transcription protein, capable of translocating through the cell membrane.  It has 
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been is widely studied by virologists since 1988 (Frankel and Pabo, 1988; Green 
and Loewenstein, 1988), as it is essential for viral replication.  It is an 86 amino 
acid nuclear protein that binds to the viral trans-activation responsive (TAR) 
region, thereby increasing RNA polymerase processing (Jeang et al., 1999).  A 
peptide was synthetised with the important TAT structural regions, such as an N-
terminal portion containing basic highly conserved amino acids at positions 49-59, 
in which an amphipatic α-helix type configuration could be adopted, as 
demonstrated from circular dichroism studies (Loret et al., 1991).   
A different peptide, 38-60 amino acids long, was synthesized and internalised in 
variety of cell lines (Mann and Frankel, 1991).  These experiments now have 
demonstrated that the basic amino acid sequence at positions 48-60 was needed 
for efficient delivery of peptides into the cells (Vives et al., 1997).  This sequence 
was still effective when shortened and finally it was concluded that only a 9-mer 
basic (RKKRRQRRR) sequence was sufficient for the peptide to be taken up 
efficiently by cells.  There are various hypotheses on the mechanism of cell 
uptake of TAT.  One hypothesis is that absorptive endocytosis is the process by 
which TAT was internalised in HeLa cells because electrostatic interactions with 
cell surface components facilitate the uptake of TAT (Mann and Frankel, 1991).  
That an alternative mechanism to endocytosis might be involved was indicated 
because at 40C incubation Tat was not taken up by HeLa cells by contrast with  
H9 cells (Mann and Frankel, 1991).  In neurons, low-density lipoprotein receptor-
related protein (LRP) interacted with TAT through its core domain (38-48 amino 
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acid residues).  TAT was internalized by endocytosis and transported to the 
neuronal nuclei (Liu et al., 2000).  The importance of cell surface receptors, ATP 
and temperature dependence indicated that the uptake of TAT involved 
endocytosis (Richard et al., 2005).  A comprehensive study of the uptake of CPPs, 
including TAT, indicated that TAT might not only use different endocytic routes but 
also use non-endocytic entry routes for cellular entry (Fig. 1-8) (Duchardt et al., 
2007; Fonseca et al., 2009b). 
The basic amino acids in TAT, in particular arginine and lysine, are the most 
important, as deletion or substitution of any of the basic amino acids leads to 
strong reduction in intracellular fluorescence signals of translocated peptides 
(Vives et al., 1997).  The basic amino acids arginine and lysine cannot be 
substituted by any other amino acids as the cellular uptake decreased significantly 
(Su et al., 2009; Wender et al., 2000).  This indicates the importance of cationic 
charges.  Some cationic polymers such as poly-arginine, poly-lysine, poly-histidine 
and poly-ornithine also result in cellular uptake, with poly-arginine uptaken the 
most (Mitchell et al., 2000; Sheldon et al., 1995).  This study indicated that several 
cationic charges are needed and that arginine, which has a guanidinium group, is 
highly preferred (Mitchell et al., 2000), as it facilitates membrane transduction due 
to the bidentate bonds it forms with the anionic cell surface (Rothbard et al., 
2005).  In the basic amino acid  lysine, the lysyl E-amino group interacts with the 
anionic cell surface ( Fig. 1-9), which is enough for endocytosis, but the 
guanidinium group of arginine is important for cytosolic transfer (Zaro and Shen, 
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2003).  The guanidinium group should have an appropriate exposure in the 
peptide to interact with the cell membrane.  
  
 
Table 1-0-5. Amino acid sequences of cell-penetrating peptides (Fonseca et 
al., 2009b). 
Cell-penetrating peptide Amino acid sequence 
 
Penetratin RQIKIWFQNRRMKWKK 
 
Polyarginines RRRRRRRRR (R9) 
 
Tat49–57 RKKRRQRRR 
 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
 
Pep1 KETWWETWWTEWSQPKKKRKV 
 
CADY GLWRALWRLLRSLWRLLWRA 
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  1                               2                                                            3                       4 
                                                       
                                                          Endosomes 
 
Figure 1-8. Translocation of CPP conjugates across the plasma membrane.  
Translocation of CPPs can occur via endocytic mechanisms 1) Pinocytosis 
2) Clathrin-mediated endocytosis 3) Caveolea-mediated endocytosis 4) 
Energy independent mechanism  
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Figure 1-9. Interactions of TAT with the membrane. 
Interactions of TAT peptide with the anionic cell surface (glycoproteins) 
.(a)Anionic charges of proteins (either exposed or inserted into the membrane), 
(b)anionic glycosylated chains of extracellular glycoprotein, or (c) membrane 
phospholipidsheads could interact with the cationic charges of the Tat peptide 
prior cellular uptake (Vives, 2003) 
 
 
(a) Surface-exposed 
proteins 
(b) Anionic cell surface 
due  to glycoprotein 
 (c) TAT peptide  
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1.4.1.2 Penetratin peptide 
Homeoproteins are a class of transcription factors involved in multiple biological 
processes and characterized by their DNA-binding domain (Krumlauf, 1994), a 
homeodomain that is highly conserved across species(Gehring et al., 1994). The 
homeodomain of Antennapedia, a Drosophila transcription factor, is internalized 
by cultured cells (Joliot et al., 1991).  Antennapedia has 60 amino acids and 
consist of three alpha helices.  The third alpha helix mainly binds to DNA and so 
is responsible for targeting the nucleus.  This third alpha helix is called penetratin 
as it is a cell-penetrating peptide.  Penetratin has the ability to cross the 
cytoplasm and enter the nucleus without degradation.  The mechanism of uptake 
of penetratin into the cells is mainly believed to be by endocytosis (Duchardt et 
al., 2007; Maiolo et al., 2005), though there are different hypotheses (Fonseca et 
al., 2009).  Penetratin has the required high content of the basic amino acids 
lysine and arginine together with hydrophobic residues (tryptophan) for 
membrane translocation.  The role of hydrophobic residues in the uptake process 
was explained by the poor membrane translocation when tryptophan was 
replaced by phenylalanine (Derossi et al., 1994).   
Penetratin interacts directly with the lipid vesicles more strongly than TAT due to 
hydrophobic interactions by tryptophan (Persson et al., 2003),(Ziegler et al., 
2003).  Penetratin shows membrane- destabilizing properties, since it aggregates 
the cell surface (Zhang and Smith, 2005).  The cell surface is surrounded by 
highly negatively charged carbohydrates such as heparin and 
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heparin sulfate that prevent peptide access to the membrane.  A proposed model 
of penetratin internalisation suggests that it interacts with these negatively 
charged carbohydrates and lipids by an electrostatic interaction followed by the 
destabilization of the lipid bilayer membrane (Rothbard et al., 2004; Rothbard et 
al., 2005).  This destabilisation results in the membrane forming inverted micelles 
in which penetratin become trapped.  The micelles then open up at the 
cytoplasmic side and release the contents into the cytoplasm (Bellet-Amalric et 
al., 2000).  As the peptide aggregates at the surface, the increase in its 
concentration favors the interaction with phospholipids of the membrane and 
hence translocation (Binder and Lindblom, 2004; Rothbard et al., 2005).  The 
charged groups bind to the lipids and the tryptophan destabilizes the lipid 
membrane, helping the translocation (Letoha et al., 2005). 
1.5   Metal Nanoparticles  
Metal nanoparticles are used for cellular delivery because they are easily 
available, compatible with most of the cell types and provide a wide surface area 
for therapeutic targeting.  Widely studied metals used in these nanoparticles are 
gold, iron, titanium and silver (Dobson, 2006b).  These nanoparticles can be 
surface-modified with different functional groups such as carboxyl, amine and 
biotin and with antibodies to make them excellent candidates for drug delivery 
(Dobson, 2006a; Surujpaul et al., 2008). 
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1.5.1 Gold nanoparticles (AuNPs) 
Colloidal gold has been used since ancient times for cosmetic, decorative and 
medicinal purposes (Wagner et al., 2000).  Aurum potable or drinkable gold was 
used in the middle Ages to cure diseases like tumors, epilepsy and syphilis.  Gold 
has healing properties and has been widely used in the treatment of arthritis 
since 1927.  Faraday in 1857 demonstrated the colour of colloidal gold by 
reduction of an aqueous solution of chloroaurate (AuCl4) using phosphorus 
(Faraday, 1857).  This led to the discovery that metallic gold could be made into 
nanoparticles by reduction.  Since then different methods for synthesizing gold 
nanoparticles in a simple way with uniform and controllable size have been 
devised (Hayat, 1991; Turkevich J, 1951).  All use tetrachloroauric acid but use 
different reducing agents concentrations, temperatures and the mixing rates of 
reagents.  The final size of the nanoparticle depends on the number of 
icosahedral nuclei formed at the beginning of the reaction compared to shell 
condensation method (Turkevich J, 1951). 
1.5.1.1 Gold nanoparticles (AuNPs) and their advantages 
Inorganic nanoparticles have gained importance during the last 20 years.  Due to 
their nanoscale size, they are used in various physical, chemical and biological 
applications (Katz and Willner, 2004; Taton et al., 2000).  In the field of medicine, 
nanoparticles(NPs) have  revolutionized treatment therapies as reviewed by 
Bhattacharya and Mukherjee, 2008.  Biomolecules like DNA and proteins can be 
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attached to the NPs through electrostatic binding, covalent interaction and 
physical adsorption.  AuNPs have been favored because they are inert, non-toxic 
and easy to synthesize.  AuNPs can be easily functionalized by thiol linkage and 
less preferably by amine linkage (Ghosh et al., 2008).  Conjugation of antigen-
antibodies has been used in the development of immunological detection studies 
(Lin et al., 2005).  In immunostaining, structures or molecules are labelled with 
AuNPs in excess so that they provide greater contrast.  This has wide 
applications for transmission electron microscopy (TEM) imaging with high lateral 
resolution (De Mey et al., 1982). 
1.5.1.2 Hybrid NPs in intracellular delivery 
The visualisation of cellular tissue and components by TEM has been 
revolutionised by labelling targeting molecules with NPs.  This has helped to 
advance cell imaging as reviewed in Ghosh et al., 2008.   AuNPs have also been 
used in photothermal therapy to kill tumors.  Targeted aggregates of nanorods 
can kill bacteria (Zharov et al., 2006) and cancer cells (Zharov et al., 2005) when 
irradiated with a focused laser in the near-infrared region.  Due to their optical 
properties, they can be visualised easily and sensors are based on surface 
plasmon resonance(Sperling et al., 2008).  Cationic tetraalkyl ammonium 
functionalised AuNPs by electrostatic interaction recognise the surface of anionic 
protein thereby inhibiting its activity (Verma et al., 2004) 
AuNPs can carry peptides and proteins of interest into the cells. AuNPs are 
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widely preferred due to their simple synthesis, stability (Daniel and Astruc, 2004) 
and large surface area for conjugating secondary tags such as peptides, ligands 
and proteins to target in cells selectively (Levy et al., 2004; Wang et al., 2005).  
AuNPs have been carriers for insulin for transmucosal delivery (Bhumkar et al., 
2007).  Hybrid NPs are also used in drug delivery. NPs conjugated antibodies 
have been used for specific binding of cancerous cells (Kam et al., 2005).  
Peptide and ligand functionalised NPs have been used for targeted delivery.  
Ligand–specific NPs such as transferrin–coated AuNPs bind to membrane-bound 
transferrin receptors (Wagner et al., ; Yang et al., 2005).  Thus cancer cells that 
express particular receptors can be targeted selectively by AuNPs when coated 
with receptor-specific ligands.  The pioneering work of Feldherr and Akin in 1999 
has opened up the possibility of using AuNPs modified with the nuclear 
localisation signal (NLS) from SV40 virus for nuclear transport (Feldherr and 
Akin, 1999).  TAT also efficiently transports AuNPs to the nucleus (de la Fuente 
and Berry, 2005).  The conjugation of AuNPs to peptides or drugs would enhance 
the delivery of the drug to the cell due to the large numbers of peptides 
molecules on them.  There is no particle corrosion.  Thus AuNPs are more 
promising delivery agents than the old delivery vehicles that are viral delivery 
vectors (Ghosh et al., 2008).  Having a nanoconjugate that could target the 
lysosomes as specifically as cell penetrating peptide targets the membrane 
would give the capability of devising therapeutics for LSDs.  
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1.6 Green Fluorescent Protein as a protein model cargo 
in intracellular delivery 
AuNP-conjugates have the disadvantage that they need TEM studies for exact 
localisation, which can be time-consuming compared with fluorescence 
microscopy.  GFP has been used as a model protein due to its easy 
quantification and detection by fluorescence spectrometry and fluorescence 
microscopy.  GFP, has been conjugated to a variety of cargo molecules and 
receptors to locate them in the cell structure by its fluorescence (Table 1-0- 6). 
Green Fluorescent Protein (GFP) was isolated from coelenterates such as the 
Pacific jellyfish, Aequorea victoriae (Morin and Hastings, 1971). GFP consists of 
238 amino acids.  It has an excitation maximum at 395 nm and emission at 475 
nm.  GFP was the first chromophore to be cloned and expressed in E. coli and C. 
elegans (Prasher et al., 1992).  Upon calcium binding ,the protein complex 
aquorin, which emits blue light, changes to GFP, which emits green fluorescence 
(Prasher, 1995).  Later studies demonstrated that GFP was formed through a 
rarely observed intramolecular autocatalytic post-translational cyclisation of a 
peptide from its own backbone structure and does not require a cofactor (Chalfie 
et al., 1994).  The amino acids Ser 65, Tyr 66 and Gly 67 are responsible for the 
chromophore formation (Chalfie et al., 1994; Prasher et al., 1992) and make up 
the cyclic tripeptide, derived from a Ser-Tyr-Gly sequence, in the primary protein 
sequence.  GFP will only fluoresce when the chromophore is embedded within 
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the GFP protein.  It has a unique 11 β-sheet barrel-like structure with 24o 
Angstrom in diameter and 42o A in height (Zimmer, 2002) (Fig. 1-10).  The β-
sheets form the walls of the barrel, and an alpha helix runs diagonally through the 
can. In the centre of the 11 β-sheets lies the chromophore, which is linked by the 
alpha helix that runs through the centre of the barrel. 
GFP is widely used in cell biology, medicine, drug delivery and molecular biology. 
It is a very useful biological marker due to its stability.  In most of the cases, 
fusion of GFP with other molecules such as proteins and peptides does not alter 
their function of the original protein (Del Gaizo and Payne, 2003).  GFP is used in 
many biological applications mainly as a reporter for gene expression as a 
marker for studying cell lineage during development, as a tag to localise proteins 
in cells and as model cargo to test various delivery vectors to and inside cells 
(Rizzuto et al., 1996; Stearns, 1995). 
GFP has been widely used to tag for tagging of proteins to various subcellular 
organelles (Table 6) (Gerdes and Kaether, 1996).   GFP can be fused to the N- 
or C- terminus of proteins, as the chromophore is mainly formed by cyclic 
tripeptide derived from a Ser-Tyr-Gly sequence in the primary protein sequence.  
Truncation of amino acids at both ends is tolerated to a certain level without 
altering the fluorescence (De Giorgi et al., 1996).  Another method of fusing GFP 
to other proteins or peptides by recombinant technology is by chemical coupling 
using crosslinkers.  Peptides and oligonucleotides can be coupled in vitro to 
  
61 
proteins via covalent linking (Mok and Park, 2008) and in this study GFP was 
coupled to lysosomal test peptides to be used for subcellular localisation. 
 
 
  
Figure 1-10.  The solid-state structure of GFP. 
The chromophore (green) is located in the centre of the 11-sheet β-barrel 
(blue)and is shown with a CPK representation (Zimmer, 2002). (Coordinates for 
the figure were obtained from the (Protein Database Bank) PDB, code 1GFL). 
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Table 1-0-6. Fusion-GFPs used in subcellular targeting 
The name of the chimera refers to the position of GFP in the fusion construct (GFP-X, N-
terminal GFP, X-GFP, C-terminal GFP). The fusion partner is the protein or polypeptide 
tagged with GFP.  (Gerdes and Kaether, 1996) 
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1.7 Summary of the research project 
Targeting cargo to organelles using CPPs and organelle-specific peptides would 
be useful for therapeutics, since the therapeutic cargo will be targeted to a 
particular location to function.  An example of this strategy is the import of 
antioxidants into mitochondria via the N-terminal amphipatic helices and by 
mitochondria-penetrating peptides (MPPs)(Horton et al., 2008).  To target the 
nucleus, AuNPs have been modified with nuclear localisation signal (NLS) from 
SV-40 virus have to study nuclear transport(Garcia-Bustos et al., 1991).  
However, to date there has been no study that describes the targeted delivery of 
molecules to lysosomes using signal peptides.  The main aim of this work was to 
direct AuNPs and GFP to the lysosomes using cell-penetrating peptides and 
lysosomal signal peptides in combination.  This could lead to controlled 
localisation of the cargo in the lysosomes for therapeutic purposes in lysosome 
diseases, e.g. Niemann-Pick type A and B, Pompe disease, Cytinosis etc.  
Lysosomal diseases result from deficiency of one of the many enzymes involved 
in the normal, step-wise breakdown of macromolecules.  Most cases of LSDs are 
due to deficiency of a lysosomal enzyme, the deficiency of a protein assisting one 
or more lysosomal enzymes in their catalytic function by activation and/or 
stabilisation, or by substrate presentation, the deficiency or dysfunction of a 
lysosomal membrane carrier protein essential for the export of degradation 
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products from the lysosomal interior to the cytoplasm or defective targeting of 
lysosomal proteins to the lysosome.  Studies in vitro have shown that cells from 
enzyme-deficient patients can be corrected by addition of the missing enzyme 
(Platt and Lachmann, 2009).  The aim of this research project was to develop a 
targeting strategy for delivering model cargo (AuNPs and GFP) to the lysosomes 
with the help of synthetic peptides to replace or augment the current therapies for 
curing LSDs like ERT, substrate reduction therapy, chaperone therapy and gene 
therapy, the combination of these with synthetic peptide therapy could result in a 
synergistic effect in managing the diseases precisely. 
In Chapter 2 the objective was to design and synthesize cell-penetrating peptides 
(CPPS) and lysosomal signal peptides (LSPs).  The sequence of CPPs was 
obtained from the literature and synthesised.  CPPs (TAT and Penetratin) along 
with a test and control sequence of both were synthesised by t-Boc peptide 
chemistry.  Protein molecules that are targeted for lysosomes rely on intrinsic 
lysosomal targeting sequences within the protein sequence that can be 
recognised during intracellular sorting and localization to the lysosomes.  These 
intrinsic lysosomal signal peptides (LSPs) (also called as lysosome targeting 
sequences) were obtained from the literature and peptides were synthesised. 
Two LSPs, L1 (YQRLC) and L2 (CNPGY), were synthesised along with a 
lysosomal control (CEGWA) by t-Boc peptide chemistry.  The crude peptides 
were analysed for purity by High Performance Liquid chromatography (HPLC) 
and Mass spectrometry (MALDI-TOF).   
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In Chapter 3 the synthetic peptides namely CPPs and LSPs were conjugated to 
gold nanoparticles (AuNPs) to assess their intracellular localisation.  The AuNPs 
were fluorescently labelled using fluorescein isothiocyanate (FITC) before 
addition of the synthetic peptides in Chinese Hamster Ovary (CHO) and HeLa( 
Human cervical cancer) cell lines.  The localisation and efficiency of the AuNP- 
peptide conjugates combinations in the cells was assessed by fluorimetry.  The 
uptake of AuNPs into the cells and their accumulation in the lysosomes was 
studied by fluorescence microscopy and transmission Electron microscopy.   
In Chapter 4, CPPs and LSPs were conjugated to Green Fluorescent Protein 
(GFP).  GFP was expressed in E.coli and purified by chromatography.  The purity 
of the GFP was checked by SDS- gel electrophoresis and Western Blotting.  The 
purified GFP was conjugated to the synthetic peptides using succinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate, (SMCC) crosslinker.  The cross-
linked GFP-peptide conjugates were added to CHO and HeLa cell lines. The 
intracellular uptake and lysosomal localisation of GFP conjugates was assessed 
by fluorescence spectrometry and fluorescence microscopy.  
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Chapter 2  
Peptide Synthesis 
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2.1 Introduction 
The intracellular targeting of cargo using signal peptides to organelles is an 
emerging field with tremendous potential for the targeted delivery of therapeutic 
agents.  These signal peptides are able to compete with other targeting agents 
like antisense modulators, due to their capability to recognise specific protein 
domains (Yoshikawa et al., 2008).  These signal peptides include (a) the C-
terminal KDEL/HDEL retention signal for resident ER proteins (Pelham, 1989), 
(b) import of proteins into mitochondria via the N-terminal amphipathic helices 
(Glick et al., 1992), (d) targeting into peroxisomes via C-terminal SKL (de Hoop 
and Ab, 1992), (e) post-translational γ-carboxylation of glutamic acid in blood-
clotting factors via a conserved propeptide recognition sequence (Furie and 
Furie, 1991), (f) nuclear localisation through single and bipartite basic residue 
stretches(Garcia-Bustos et al., 1991) and (g) vacuolar targeting of yeast 
carboxypeptidase containing the tetrapeptide sequence QPRL within the 
enzyme(Valls et al., 1990). 
Advances in the chemical synthesis of peptides and proteins has inspired the 
development of a variety of delivery systems that use different cell penetrating 
sequences to transport cargo into the cells and further targeting to sub-cellular 
organelles such as the nucleus and mitochondria (Boddapati et al., 2008).  
Studies on the sorting of molecules to lysosomes have reported the presence of 
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tyrosine signals present within them.  Examples include the cytoplasmic domains 
of transmembrane proteins/receptors such as the low density lipoprotein receptor 
(LDL) and lysosomal associated membrane proteins (LAMP-1)(Honing et al., 
1996; Hunziker et al., 1996; Patel et al., 2003).  The aim of this research study 
was to target gold nanoparticles and green fluorescent protein specifically to the 
lysosomes in an in vitro system by conjugating cell-penetrating peptides (CPPs) 
and lysosomal-signal peptides (LSPs) to the cargo.  The sequences of the CPPs 
namely, TAT and Penetratin (Pen) were chosen based on the results of previous 
studies (Derossi et al., 1994; Green and Loewenstein, 1988; Schwarze et al., 
1999).  The control TAT and Pen peptides were designed such that the positively 
amino acids namely Lys and Arg in the test were replaced by Ala in control 
sequences.  The LSPs L1 (YQRL) and L2 (NPXY) were designed from studies on 
nascent protein molecules that are targeted for lysosomes which have specific 
signal sequences that can be recognised during intracellular sorting and 
localisation (Bonifacino and Traub, 2003; Traub, 2009). These sorting signals 
consist of short peptide sequences such as NPXY and YXXǾ where X is any 
amino acid and Ǿ is a bulky hydrophobic amino acid (Bonifacino and Traub, 
2003).  The control LSP was designed choosing random amino acids present 
apart from the test LSP sequences.  All synthetic peptide analogues contained a 
Cys at their C-terminal except of NPXY where Cys was at N-terminal to facilitate 
directional binding to the AuNP surface.  
Peptides are synthesised by the coupling reaction of the carboxyl group (the C-
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terminus) of one amino acid to the amino group (N-terminus) of another amino 
acid (Fig 1).  During this process, other potentially reactive functional groups of 
the side chains of some amino acids are protected to minimise side reactions. 
(Merrifield, 1985b).  Chemical peptide synthesis starts at the C-terminal end of 
the peptide and ends at the N-terminus. This is the opposite of protein 
biosynthesis, which starts at the N-terminal end in synthesis occurring in 
ribosomes. Three basic methods for the synthesis of peptide synthesis have 
been developed: 
 Solution base synthesis 
 Reverse proteolysis 
 Solid phase synthesis 
Amongst these, solid-phase peptide synthesis (SPPS) developed by Merrifield 
(Merrifield, 1985a) is the best known and most widely used due to its ease and 
efficiency.  SPPS allows the synthesis of natural peptides that are difficult to 
express in living organisms like bacteria, and the chemistry allows the 
incorporation of unnatural amino acids such as D-amino acids, peptide backbone 
modifications, and synthesis of branched and cyclic peptides (Humphrey and 
Chamberlin, 1997). 
There are two types of SPPS used, based on the protecting group present on 
the α-amino group of the amino acid: 
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 Fmoc (base -labile α -amino protecting group)  
 t-Boc (acid -labile α -amino protecting group) 
The methods differ in the types of resins and side chain-protected amino acid 
derivatives and subsequent cleavage/deprotection steps (Kent, 1988).  
The methods use small insoluble porous beads (resin), which contain functional 
units (linkers) on which peptide chains can be built.  The peptide remains 
covalently attached to the resin until cleaved from it in the presence of an acid, 
such as hydrogen fluoride (HF) in t-Boc chemistry and TFA (trifluoroacetic acid) 
in F-moc chemistry (Carpino and Han, 1972; Fischer and Zheleva, 2002).  The 
synthesised peptide is thus 'immobilised' on the resin bead, which acts as a solid 
phase, and amino acids are sequentially activated and added to assemble the 
sequence.  The activated amino acids are added in excess to promote efficient 
coupling. The excess reactants are flushed out by washing with a solvent, while 
the assembled protected peptide is retained on the resin.  SPPS involves 
repeated cycles of activation, coupling and deprotection.  In the first cycle, the 
unprotected N-terminal amino group of the amino acid already attached to the 
solid phase is coupled to an incoming N-protected amino acid containing an 
activated carboxyl group (Fig.2-1).  This dipeptide is then deprotected, revealing 
a new N-terminal amino group to which a further amino acid may be following 
activation of its carboxyl group.  Following complete assembly of the peptide 
sequence, the peptide is cleaved from the resin, with the concurrent cleavage of 
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all side-chain protecting groups, to give the crude free peptide. After cleavage 
from the resin, peptides are usually analysed and purified by reversed phase 
HPLC (Niidome et al., 1994).   
2.1.1 t-Boc solid phase peptide synthesis 
Merrifield published his first t-Boc solid phase peptide synthesis protocols in 1963 
(Merrifield, 1963).   The Nα protecting group used in Merrifield’s chemistry is the 
t-Boc group which is the shortened name for (t)ert-(b)utyl(o)xy(c)arbonyl.  The 
Boc group from the assembled peptide chain is removed under acidic conditions, 
usually concentrated TFA.  The deprotection of the side-chain protecting groups 
and the peptide chains from the resin is achieved by the use of anhydrous HF.  
Resins such as (4-methylbenzhydrylamine-polystyrene/ 1% divinyl benzene co-
polymer (mBHA–HCl) are used for the synthesis of t-Boc carboxamide peptides.  
The synthesis begins with the attachment of an activated amino acid to the resin.  
The amino acid can be activated as an active ester using a reagent such as 2-
(1H-benzotriazol-1-yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate HBTU) 
or a mixture of HBTU and HOBT. The bond formed between the first amino acid 
and the resin is very stable but can be cleaved using a strong acid such as 
hydrogen fluoride (HF) or trifluromethanesulfonic acid (TFMSA). The Boc 
protecting group on the primary amino group of the amino acids can be removed 
with an acid such as Trifluoroacetic acid (TFA).  After deprotection by TFA, the 
resin is neutralised using a tertiary amine, usually N, N-diisopropylethylamine 
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(DIEA). 
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    Figure 2-1. Schematic representation of peptide synthesis. 
In an alternative synthesis strategy, the next activated amino acid can be coupled 
in the presence of DIEA (in situ neutralisation) (Schnolzer and Kent, 1992).This 
reduces the time required for each cycle. After all of the amino acids have been 
added and the desired peptide is synthesised, the peptide is completely 
deprotected and cleaved from the resin using HF. 
The purity of the final product is evaluated using reversed-phase high 
performance liquid chromatography (RP-HPLC) using either a C4, C8 or C18 
column depending on the size and polarity of peptides using an acteonitrile 
gradient.  The peptide can be analysed by matrix assisted laser 
desorption/ionization – time of flight (MALDI-TOF) mass spectrometry, or other 
mass spectrometry techniques to confirm whether or not, the desired peptide has 
been synthesised(Pan et al., 2008). 
2.2 Materials and Methods 
2.2.1 Materials 
All reagents used were of peptide synthesis grade unless stated otherwise.  N, N’ 
dimethylformamide (DMF), trifluoroacetic acid (TFA) and N, N’-
diisopropylethylamine (DIEA) were purchased from Auspep, Melbourne, 
Australia. Dichloromethane (DCM) was obtained from Mallinckrodt Baker, Inc., 
Kentucky,USA.  2-(1H-Benzotriazol-1-yl)-1, 1, 3, 3-tetramethyluronium 
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hexafluorophosphate (HBTU) was procured from Auspep and 1-
hydroxybenzotriazole (HOBT) was obtained from Fluka, Switzerland. The Nα-t- 
Butyloxycarbonyl (t-Boc) protected L-amino acids were purchased from Bachem, 
California, USA, except Boc Nα- protected aspartic acid, cysteine, arginine and 
glutamic acid which were obtained from Peptide Institute Inc., Osaka, Japan.  
The side chain protecting groups used on amino acids were Glu (OBzl), Asp 
(OBzl), Arg (Tos), Lys (Cl-Z), Tyr (Bzl), Trp (CHO), Cys (4-Me-Bzl), Ser (Bzl), Thr 
(Bzl).  The resin used for the attachment of peptides was 4-
methylbenzylhydrylamine.HCl polystyrene containing 1% divinyl benzene co-
polymer (mBHA-HCl), 100-200 mesh size, with a substitution level of 0.89 meq/g, 
obtained from Peptide Institute Inc., Osaka, Japan.  Anhydrous hydrogen fluoride 
(HF) was obtained from Matheson Gases, USA.  The scavengers p-cresol and p-
thiocresol was obtained from Sigma-Aldrich, St-Louis, MO.  Acetonitrile (ACN) 
was purchased from Mallinckrodt Baker, Inc., Kentucky, USA. 
All other reagents used in this research were of analytical grade or higher. 
2.2.2 Methods 
2.2.2.1 t-Boc amino acids 
All of the required t-Boc amino acids (2 mmoles) were weighed and stored in 
labelled scintillation vials. 
2.2.2.2 Resin Preparation 
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Dry mBHA-HCl resin (0.5 mmol) was weighed out and placed in a reaction vessel 
and swollen in DMF by a DMF flow wash for 30 seconds. The resin was then 
neutralised with 1 ml DIEA for 1 minute and flow washed again with DMF. The 
neutralisation step was repeated along with a further extended flow wash step 
with DMF. 
2.2.2.3 Peptide synthesis  
The synthesis was initiated by activating 2 mmoles of the first t-Boc protected 
amino acid derivative using 4 ml of 0.5 M HBTU.  If Arg, Asp and Gln were to be 
used then they were activated with 4 ml of 0.5 M HOBT containing 0.5 M HBTU.  
Immediately after the addition of activation agent(s), 470 µl DIEA was added for 
in situ neutralisation and reacted for 3 min at room temperature. 
The activated amino acid derivative mixture was added to the resin and allowed 
to couple for 10-15 min except for Asn, Glu, Arg and Lys, in which case, the 
coupling time was 15-20 minutes.  After coupling, the resin was drained under 
vacuum, flow washed with DMF followed by removal of a sample of the amino 
acid-resin (< 5 mg) for coupling efficiency analysis.   
If the coupling efficiency was 99.5% or above, the Boc-protected peptide was 
deprotected by removal of the Boc group using approximately 10 ml of anhydrous 
TFA for 1 min with shaking.  The TFA was then drained from the reaction vessel 
and the deprotection step was repeated.  After the TFA was drained the second 
time, the reaction vessel was filled with DMF and drained.  This was followed by 
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vigorous flow-washing of the peptide-resin with DMF for 30 secs to remove all 
traces of TFA.  
Deprotection, activation, neutralisation and coupling steps were repeated for 
each amino acid that was added.  Double couplings were performed if required. 
 
At the completion of the synthesis, the final peptide-resin was extensively flow 
washed for 2 minutes in DMF followed by 2 minutes of flow washing in DCM, 
dried under vacuum, weighed and stored at -20°C until required for HF cleavage. 
2.2.2.4 Ninhydrin analysis  
Approximately 5 mg of resin was removed at the end of each coupling cycle to 
calculate the coupling percentage as described by(Sarin et al., 1981).  The resin 
sample was washed thrice with 1:1 ratio of DCM: methanol mixture and dried 
under vacuum.  The dried resin was added to a pre-weighed culture tube and 
weighed followed by the addition of 2 drops of phenol solution, 4 drops 20 mM 
KCN and 2 drops of ninhydrin 0.28 M(Sarin et al., 1981). A blank tube was also 
prepared using the same reagents, without the resin.  Both tubes were placed in 
a heating block at 100oC for 5 min for the reaction to occur, then removed from 
the heating block followed by addition of 3 ml of 60% (v/v) ethanol to each tube.  
After the resin had settled to the bottom of each test tube, the absorbance of the 
solution was measured at 570 nm on a dual beam spectrophotometer (Hitachi U-
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2000, Hitachi Ltd., Tokyo, Japan).  The weight of the resin sample and 
absorbance of the solution were finally entered into the ‘Pepmate’ program to 
determine the coupling percentage for each cycle of the peptide synthesis. 
‘Pepmate’ is a QuickBasic program that was written by Dr John Fecondo in 
collaboration with HH Software, Melbourne.  If the percentage of coupling was 
below 99%, a double coupling procedure was carried by activating a further 2.0 
mmoles of the same amino acid as used before and following the same steps 
prior to the next deprotection step. 
2.2.2.5 Deprotection prior to HF cleavage 
Prior to HF cleavage, a pre-weighed amount (in the range 300-400 mg) of dried 
peptide-resin was transferred to a clean glass manual synthesis reaction vessel.  
The Nα  t-Boc group on the peptide-resin was removed by the addition of 10 ml of 
anhydrous TFA and mixing for 1 min.  The resin was flow washed with DCM for 
30 sec.  A second 10 ml aliquot of anhydrous TFA was added and allowed to 
react for a further 1 min to ensure complete removal of the t-Boc group from the 
α- NH2 groups of the peptide-resin.  The resin was then neutralised with 10 ml of 
10% (v/v) DIEA in DCM for 1 min, followed by a further 1 min DCM flow wash. 
The formyl group (the protecting group on the side chain of tryptophan) if present, 
was removed by treating the peptide-resin with 10% (v/v) piperidine in DMF at 
0oC ( on ice) for 2 h, followed by a 10 ml of DMF flow wash and DCM flow wash 
thereafter for 1 min and dried in vacuo for 30 min. 
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2.2.2.6 Hydrogen fluoride cleavage  
Initially, 0.5 mL aliquots of each of the scavengers p-cresol and p-thiocresol were 
added to the partially deprotected dried peptide-resin in the HF manifold reaction 
vessels (Peptide Institute Inc., Osaka, Japan).  After freezing of the scavengers, 
stir bars were added followed by connection of the reaction vessels to the HF 
cleavage manifold. A negative air pressure was maintained in the apparatus at -
270 torr.  Approximately 25 ml of anhydrous HF was slowly released from the 
cylinder and condensed into the reservoir using a liquid nitrogen trap.  The HF 
condensed in the reservoir was subsequently evaporated by gentle warming of 
the vessel to 50-55o C and condensed into the reaction vessels containing the 
peptide-resin samples and scavengers until approximately 10 mL of HF were 
condensed in each reaction vessel.  The peptides were completely deprotected 
and cleaved from the resin by reacting with anhydrous HF for 1 h at 0oC under 
vacuum.  HF was then carefully removed from the reaction vessels by 
evaporation under vacuum at 0°C. 
2.2.2.7 Peptide extraction  
Diethyl-ether was used to extract the cleaved peptide from the resin and to 
remove the scavengers and traces of HF, by washing the cleaved peptides twice 
with approximately 40 ml of anhydrous diethyl ether .The cleaved peptides were 
extracted with a minimal volume of 10-20% (v/v) acetic acid and collected into 
round-bottomed flasks. The peptide solutions were frozen using liquid nitrogen 
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and lyophilised overnight, weighed and stored at -20 oC until required for analysis 
or testing. 
2.2.3 Peptide Analysis  
2.2.3.1 High Performance Liquid Chromatography (HPLC) 
The HPLC solvents were degassed and filtered through a 0.45 µm  nylon filter 
directly into the solvent bottles prior to use .  Approximately 100 µg of peptide 
was dissolved in 100 µL in 0.1 % TFA.  A 20 µl of sample was injected into an 
HPLC system fitted with a Perkin Elmer Series 200 pump with an attached 
Aquapore RP-300 C8 or Aquapore RP-300 C18 column(s) for analysis (Brownlee 
Labs, Foster City, USA). 
The mobile phase gradient used was by altering the acetonitrile from 0-60% 
/0.1% TFA over 30 minutes with a flow rate of 1 ml/min and monitored at 214 nm 
using an Applied Biosystems 785A Programmable Absorbance Detector. 
The chromatograms were acquired using Turbochrom Software (Perkin Elmer) 
with a PE Nelson 900 Series Interface. 
2.2.3.2 Mass spectrometry  
MALDI-TOF mass spectrometry analysis was performed using a Bruker Biflex II 
MALDI-TOF mass spectrometer (Brüker, Bremem, GmbH) with an automated 
MALDI ion source.  The mass spectrometer was operated with a 337 nm nitrogen 
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laser using the reflectron mode.  Two microlitres of each sample dissolved in 
0.1% (v/v) TFA was deposited on a UV-absorbing matrix on a stainless steel 
target and allowed to dry. The matrix used was α-cyano-4-hydroxycinnamic acid 
matrix and the target could hold 26 sample spots at a time. The mass spectra 
were obtained by striking laser light (337 nm) on to the target so that ions and 
neutral molecules were desorbed.  The laser light at 337 nm was irradiated from 
the nitrogen laser at a frequency of 1 GHz.  The resultant ions were accelerated 
to 20 kV, as recorded in the SCOUT source.  The signal from a minimum of 250 
shots was averaged to achieve the reported intensities.  The data were examined 
in WSearch32 software. 
 
Seven peptides were synthesised using these protocols (Table 2-0- 1). 
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Table 2-0-1. List of synthetic peptides used in this study. 
 
 
 
 
 
Class of Peptide 
 
Peptide Name 
 
Amino acid sequence 
 
Penetratin Test 
 
CRQILIWFQNRRMKWKK 
 
Penetratin Control 
 
CRQILIFFQNAAMKFAA 
 
TAT test 
 
CYGRKKRRQRRR 
 
Cell Penetrating peptides 
(CPPs) 
 
TAT control 
 
CYGRKAAQAAA 
 
L1 Test 
 
YQRLC 
 
L2 Test 
 
CNPGY 
 
Lysosome signal 
peptides 
(LSPs)  
Lyso Control 
 
CSEWA 
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2.3 Results  
2.3.1 Peptide synthesis evaluation  
A summary of all peptide synthesis data for all the seven peptides is presented in 
Table 2-0-2. 
The summary of the peptide synthesis data presented in Table 2-0-2 indicate that 
the average coupling efficiency data for all syntheses exceeded the desired 
minimum average coupling efficiency per residue of 99.0%, ranging from 99.18 to 
99.80%, apart from the Pen control synthesis with an average coupling efficiency 
of 98.76%.  The retention time of the peptides on the HPLC chromatogram varied 
from 9.0 min to 17.5 min with Pen test having the longest retention time of 17.5 
min.  MS analysis confirmed the identity of all peptides apart from then TAT 
control, Pen control and L2 test control that had two major peaks as indicated in 
Table 2-0-2.  
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Table 2-0-2.  Peptide synthesis evaluation chart. 
Peptide Name 
Average 
coupling/cycle (%) 
Retention time** on 
HPLC *  (min) 
MS Analysis 
m/z 
1138 
TAT control 99.61 10, C18 
1160 
TAT test 99.80 9.8, C18 1662 
1927 
Pen control 98.76 15.8, C18 
2040 
Pen test 99.18 17.5, C18 2350 
Lyso control 99.80 9.0, C8 441 
L1 test 99.75 11.5, C8 550.61 
552 
L2 test 99.35 12.2, C8 
574 
 
*HPLC column – C18, C8 
         ** of the major peak 
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2.3.2  A typical data set for peptide synthesis  
A typical data set for the TAT control peptide synthesis shown in Figs. 2-2 to 2-4 
that describes the coupling efficiency data, the chromatogram of the crude 
peptide obtained from RP- HPLC analysis on a C18 column and the mass 
spectral data to confirm the identity of the peptide.  Coupling varied from 99.0 to 
99.5% (Fig. 2-2) with an average coupling per residue of 99.61%.  Analysis by 
RP-HPLC revealed one major peak in the chromatogram (Fig. 2-3).  Mass 
spectral analysis (Fig. 2-4) confirmed the identity of TAT control as calculated 
from its molecular mass however, there was another major peak at m/z 1160 in 
the mass spectrum.  (The peptide synthesis data for the remaining peptides is 
attached in the appendix). 
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TAT control  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 Coupling percentage of TAT (control) sequence 
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Figure 2-0-2 HPLC chromatogram of TAT control sequence  
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 Figure 2-0-3 Mass spectrum of TAT control sequence 
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2.4 Discussion  
In this research project, a set of seven peptide analogues were manually 
synthesised using highly optimised t-Boc synthesis protocols based on those 
developed by Schnölzer and Kent, 1992. (Schnolzer and Kent, 1992).  These 
protocols are characterised by rapid coupling times (2-3 minutes), in situ 
neutralisation and rapid t-Boc deprotection using 100% TFA, resulting in 
complete cycle times of 20-25 minutes/residue.  
All of the peptides contained Cys at their N-terminus except for the L1 signal 
peptide which contained a Cys residue at the C-terminus.  The terminal Cys was 
incorporated into the sequences to facilitate the directional attachment of 
peptides on the AuNPs surface.  Addition of the Cys residues did not affect the 
cell penetrating activity of the CPP peptides, consistent with the findings of Villa 
et al (Villa et al., 2000) nor the lysosome targeting activity of the LSPs peptides 
as described later in this thesis. 
The average coupling efficiency of these syntheses was in the range 99.18% to 
99.80% for all the peptides except for Pen control. The coupling efficiency 
decreased for the Pen control peptide synthesis due to the presence of Lys and 
Ile residues which have bulky side chains, potentially interfering with the coupling 
process.  The RP-HPLC chromatogram of the Pen control peptide contained a 
major peak and several minor peaks that are likely due to the presence of 
scavengers during the peptide extraction.  The mass spectral analysis indicated a 
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major peak at 1927.0 and 2040.0, both m/z values indicated deletion of either 
leucine or isoleucine likely to have occurred during the synthesis resulting in a 
deletion peptide. Nevertheless, since the Pen control peptide was a control 
sequence, the peptide was not re-synthesised.  The TAT control peptide was 
successfully synthesised with an average coupling per residue of 99.61%, and a 
mass spectrum containing a major peak at m/z of 1138 correspondling exactly to 
its molecular mass.  However the presence of a peak at m/z 1160 could have 
been an additional peptide peak.  
In addition, the average coupling efficiency of the Pen test peptide was slightly 
reduced (99.18%) than the TAT test peptide (99.8%) due to the presence amino 
acids Arg, Lys, Trp and Ile, all with bulky protecting groups and side chains that 
may interfere in the coupling process (Kent, 1988).  In addition, there was a 
repeated occurrence of Arg and Lys adjacent to each other resulting in difficulty 
for the incoming amino acid to be incorporated into the peptide chains.  These 
undesirable problems originate from intermolecular aggregation of protected 
peptide chains and possible formation of β-sheet secondary structures thereby 
decreasing the access of the incoming activated amino acid reflected in low 
coupling efficiency data (Merrifield et al., 1988).  However the Pen test peptide 
was an acceptable synthesis since the m/z spectrum revealed its exact molecular 
mass 
In the case of the lysosomal signal peptides, the Lyso control and L1 test 
peptides had an overall coupling efficiency of 99.80% for Lyso control and 
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99.75% for L1 test.  However the RP-HPLC analysis indicated several minor 
peaks that could be due to the scavengers and incomplete removal of the 
protecting groups during the peptide extraction process.  Mass spectral analysis 
confirmed the identity of L1 peptide although there was a presence of other major 
peak at m/z 681 indicating an incomplete deprotection of the xanthyl group of Gln 
during the HF cleavage of the peptide.  The Lyso control peptide mass spectral 
data contained a major peak at m/z of 441 indicating that Trp oxidation could 
have occurred during the extraction procedure (Sharp et al., 2003). 
The RP- HPLC analysis showed the presence of L2 with negligible impurities and 
but in the mass spectrum analysis indicated two major peaks at m/z 574 and 552.  
The major peak at 552 confirmed the identity of L2 peptide but the major peak at 
574 suggested some complex side reactions that could have possibly occurred 
during the HF cleavage procedure.  
The overall purity of the end product of each synthesis is sequence-dependent 
due to the interactions of peptide chains with each other, resin matrix and the 
incomplete removal of side chain protecting or t-Boc groups or incomplete 
coupling of the activated amino acids (Kent, 1988; Milton et al., 1990).  
These synthesised peptides were conjugated with gold nanoparticles and tested 
for their ability to promote penetration of the cell membrane and subcellular 
localisation in mammalian cells in vitro in the following chapter.  
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Chapter 3  
Peptide-mediated delivery of 
gold nanoparticles into 
lysosomes 
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3.1 AuNP modifications 
Nanoscale size gold nanoparticles (AuNPs) have gained importance due to their 
physical, chemical and biological properties (Ghosh et al., 2008).  AuNPs are 
chosen due to their simple synthesis, inertness, non-toxicity and large surface 
area for conjugating secondary tags such as peptides, ligands and proteins to 
target to cells selectively (Levy et al., 2004).  AuNPs can be easily functionalized 
by biomolecules through thiol linkage.  Thiols in proteins allow electrostatic 
binding, covalent interaction and physical adsorption on AuNPs (Niemeyer and 
Ceyhan, 2001).   
3.1.1 AuNP delivery using signal peptides 
Signal sequences have the ability to direct proteins to subcellular compartments, 
even when they are not part of an entire protein.  They are utilized for cargo 
delivery, drug delivery to specific cellular compartments (Yoshikawa et al., 2008).  
Targeting cargoes to the organelles using cell- penetrating peptides (CPPs) and 
especially organelle-specific peptides has received less attention.  At present 
commonly used approaches utilise nanoparticles as a carrier along with a 
particular signal peptide to localise nanoparticles to the desired intracellular 
compartment (Bhattacharya and Mukherjee, 2008).  The pioneering work of 
Feldherr suggested the possibility of directing AuNPs modified with the SV40 
virus nuclear localisation signal (NLS) to the nucleus (Feldherr and Akin, 1999).  
Targeted delivery to the nucleus has been attempted by complexing SV40 
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NLS with AuNPs (de la Fuente and Berry, 2005), but was not achieved as the 
endosomal pathway could not be broken and the components were degraded in 
the endosomes (Berry et al., 2007).  Another study achieved targeting AuNPs to 
the nucleus using TAT peptides only, but in TEM studies there were difficulties 
observing AuNPs due to their small size and background staining (de la Fuente 
and Berry, 2005).   
Recently mitochondria penetrating peptides (MPPs) were only able to deliver 
zwitterionic small molecules and negatively charged molecules to mitochondria 
(Horton et al., 2008).  Lipoamide dehydrogenase (LAD) was delivered 
successfully to mitochondria using TAT and MPP, resulting in the accumulation 
of LAD into mitochondria over time by repeated dosing (Vyas and Payne, 2008).  
This type of strategy would be useful in designing carriers for efficient 
biomolecular delivery into lysosomes affected by LSDs.  A similar strategy was 
explored in this research as a therapeutic approach for lysosomal storage 
disorders (LSDs) using AuNPs as model cargo instead of an active enzyme. 
3.1.2 AuNPs as therapeutic for LSDs 
Deficiency or malfunctioning of one or more enzymes in lysosomes leads to LSD. 
Krabbe’s disease (galactocerebrosidase), Pompe disease (α-glucosidase), A and 
B Niemann-Pick disease (sphingomyelinase), GM2 Gangliosidosis (β-
hexosaminidase) and many more are the well known examples of lysosomal 
storage diseases (Platt and Lachmann, 2009).  Every year thousands of people 
  
94 
are diagnosed with LSDs worldwide but it’s more common in Australia, affecting 
1 out of every 1000 randomly selected humans (Ford, 2003). Currently, there is 
no permanent cure for these diseases.  Commonly used treatments include gene 
therapy, enzyme replacement therapy and stabilisation of defective enzymes 
using chaperonin molecules (Burrow et al., 2007; Macauley and Sands, 2009a; 
Nathan and Orkin, 2009; Pastores and Barnett, 2005).  All these therapies being 
used today do not target lysosomes, particularly those involved in the central 
nervous system (CNS) and do not cross the blood-brain barrier, which could be a 
reason for their poor effectiveness and severe side effects (Macauley and Sands, 
2009b).  Therefore, to obtain better therapeutic results, targeted delivery of 
replacement enzymes into the lysosomes of cells is likely to be a more effective 
therapy than the systemic delivery approaches currently used.  Thus designing 
and testing a working model for lysosome-specific targeting of AuNP cargo with 
CPPs and LSPs was attempted here. 
3.1.3 Overview of Chapter  
Targeting any molecule into an intracellular compartment can be divided into two 
processes.  The first process involves entry into the cell by crossing the 
phospholipid bilayer of the cell membrane. This task could conceivably be 
achieved by using CPPs. There are a number of CPPs that efficiently transport 
large molecules across the cell membrane including TAT, Penetratin (Pen), 
Multiple Antigenic Peptide (MAP) and Transportan (Brooks et al., 2009).  The 
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second is to direct the molecule to the required subcellular organelle (lysosome) 
by designing and using LSPs. Theoretically, any exogenously synthesised 
peptide that contains a required recognition sequence could be targeted to 
lysosomes.  It could be used to navigate conjugated nanoparticles attached with 
drugs or enzyme towards lysosomes inside the cell.  
The aim of this research was to test, the targeted delivery of 13 nm AuNPs to the 
lysosomes using CPPs to cross the cell membrane followed by intracellular 
targeting mediated by LSPs, with the resulting accumulation of the nanoparticles 
into the lysosomes.  This study was conducted to demonstrate the potential use 
of AuNPs targeted to the lysosomes in the cells, as they are easy to synthesise 
and have a large surface area to carry cargo such as enzymes.  AuNPs were 
modified with fluorescein isothiocyanate (FITC) for their easy detection in the 
cells and conjugated with CPPs and LSPs.  The CPPs were chosen as they are 
well known and cited in the literature (Lewin et al., 2000; Marsh and McMahon, 
1999).  Two different CPPs, namely Pen and TAT, were used due to their 
different cell-penetrating capacity, based on their basic charges from Arg and Lys 
within them (Lindgren et al., 2000). To investigate the effectiveness of the 
designed and synthesised LSPs, namely L1 and L2, along with CPPs, LSPs were 
conjugated with FITC-AuNPs so that their targeting efficiency into the lysosomes 
could be monitored.  FITC-AuNP were easily quantified by fluorescence 
spectrophotometry and tracked by fluorescence microscopy.  This was a novel 
approach as because using FITC-AuNP-CPP-LSP conjugates relied on CPPs to 
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cross the cell membrane and then LSPs to target AuNPs to the lysosomes.  
Further, the lysosome localisation of non-FITC-AuNPs was monitored by 
Transmission Electron Microscopy (TEM). 
3.2 Materials  
All glassware was scrupulously clean. Glass and plastic containers and stirrers 
were cleaned in Aqua-regia and thoroughly washed in MilliQ water. Aqua regia 
(3:1 HCl: HNO3) was made fresh each time for gold nanoparticle synthesis.  All 
chemicals used were analytical grade laboratory reagents. All the reagents were 
prepared with Milli-Q water. Volumes upto 1.5 mL or less was centrifuged at 
2,000 x g with an Eppendorf microcentrifuge 5415C. Larger volumes upto 50 mL 
were centrifuged in a Beckman J2-21 M/E centrifuge for 45 min at 10,000 x g. 
Absolute ethanol and methanol, sodium citrate, aurochloric acid (HAuCl4 : 
3H2O),fluorescein isothiocyanate and MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5 
diphenyltetrazolium bromide] reagent were procured from Sigma-Aldrich Ltd., 
USA.  Lysotracker ™ was purchased from (Molecular Probes, Carlsbad, CA, 
USA), Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) 
new born calf serum (NCS) was bought from Gibco BRL, Carlsbad, CA. Spurr’s 
resin, osmium tetroxide  and propylene oxide were procured from Prosciences, 
Queensland, Australia. 
All reagents were of high quality analytical grade and were filtered immediately 
before use.  CHO (Chinese Hamster ovary) and HeLa (a human cervical cancer 
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cell line) cells were obtained from ATCC, Manassas, VA, USA.  Tissue culture 
plates (6-well and 48-well) and 25 cm2 culture flasks were purchased from 
Greiner-Bio-one GmBH, Germany. 
3.3 Methods 
3.3.1 Peptide synthesis 
The CPPs Penetratin, TAT and LSPs L1, L2 and control peptides that were all 
manually synthesised as carboxamide derivatives using highly optimised t-Boc 
solid phase peptide synthesis chemistry in Chapter 2 were tested in cell assays.  
Prior to testing, all peptides were desalted using a PD-10 column (GE 
Healthcare, Uppsala, Sweden) and molecular masses were confirmed by 
analysis on a Bruker Biflex II MALDI-TOF mass spectrometer (Brüker, Bremem, 
GmbH). 
3.3.2  AuNPs synthesis and peptide conjugation 
The AuNPs were synthesised by the citrate reduction method (Turkevitch et al 
1951) and characterised by analysis of the visible absorption spectrum of the 
particles in the range of 400-800 nm in a Hitachi U-2000 UV visible absorption 
spectrophotometer (Hitachi Ltd., Tokyo, Japan) to identify the characteristic 
wavelength peak at 520 nm and for their monodispersity.   
The AuNPs were labelled with fluorescein isothiocyanate (FITC) for fluorescence 
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studies (Shukla et al., 2005) and further conjugated with peptides (Fig. 3-1).  The 
AuNP-FITC concentration was calculated by comparing it with standard plot of 
FITC.  Increasing concentration of FITC was added to 7.4 nm AuNPs in the 
range of 0 to 1.2 µM to determine the maximum saturation of FITC on AuNPs.  
The FITC fluorescence on the AuNPs was compared by using a standard curve 
generated from solutions containing 0-2 µM of FITC in 10 mM phosphate buffer.   
A graph of optimised FITC on gold surface is added in the appendix section.  
From the graph it is clear that at 0.5 µM FITC-AuNP, the gold surface is not 
saturated by FITC hence peptides could be added as depicted in Fig 3.3. If the 
peptide concentration is increased then there will be aggregation of gold 
nanoparticles leading to the wavelength shift in the visible region. The final 
composition of FITC-gold nanoparticles and peptides onto them is calculated 
based on previous reports (Shukla et al., 2005, Liu et al., 2007). 
The surface coverage of the peptides and FITC on the AuNPs was determined 
as indicated in previous studies (Liu et al., 2008).  Using optimised conditions, 
100 µl (0.5µM) of FITC was added to 7.4 nM of 13 nm citrate-coated gold 
nanoparticles, producing a molar ratio of FITC to AuNPs of 96:1 (refer to 
Appendix).  The FITC-AuNP conjugates were mixed, stirred and incubated at 4 
°C for 12 h in darkness to avoid photo- and thermo-deactivation.  Unbound FITC 
molecules in the FITC-AuNP conjugate mixture were removed by centrifugation 
at 10,000 x g for 45 min.  The supernatant fluid was discarded, and the pellet was 
resuspended in 0.8 ml of 10 mM phosphate buffer (NaCl [8 g/L], KCl [0.2 g/L], 
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Na2HPO4 [1.44 g/L], and KH2PO4 [0.24 g/L] in water) at pH 7.4. 
The peptides (Table 3-1) were directionally conjugated to the FITC-AuNPs 
through N- or C-terminal cysteine (–SH) binding to the gold surface.  Peptides 
were added to the FITC AuNPs in a ratio of 2:4:1 (CPP: LSP: FITC-AuNP) and 
incubated overnight at 4o C.  For example, 100 µl of 10 µM CPP in 10 mM PB 
and 100 µl of 20 µM LSP in 10 mM PB was added to 0.8 ml of 7.4 nM FITC-
labelled AuNPs.  The nanoconjugates were centrifuged at 10,000 x g for 45 min 
and the FITC-labelled-AuNP-peptide pellet was redispersed in 10 mM PB pH 7.4.  
The optimized molar ratio of FITC-AuNP: CPP: LSP conjugation of the peptides 
to AuNPs was confirmed by a shift in the absorption peak from 520 nm to 680 nm 
and TEM analysis.  The FITC-AuNP was incubated with an optimal amount of 
each CPP and LSP that resulted in maximum surface coverage whilst minimizing 
nanoparticle aggregate formation and added to the cells.  The localisation of the 
AuNP conjugates was analysed using quantitative fluorescence 
spectrophotometry and fluorescence microscopy.  TEM analysis was performed 
with AuNPs: CPPS: LSPs (no FITC) having the same molar ratios as for 
fluorescence spectrophotometry and fluorescence microscopy.  As the 
concentration of FITC-AuNPs-peptides had to be kept constant for fluorimetry, 
microscopy studies hence it was more appropriate to measure FITC-AuNP rather 
than gold levels directly as gold nanoparticle cannot be viewed by fluorescence 
microscopy on its own.  
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3.3.3 Cell Culture 
CHO (Chinese Hamster Ovary) and HeLa (human cervical cancer) cells (ATCC, 
USA) was used in AuNP-peptide conjugate studies at a density of 1x105 cells /ml.  
Cells were grown to ~75% confluence on glass cover slips and placed in 6-well 
plastic plates supplied with Dulbecco’s modified Eagle medium (DMEM) for CHO 
and RPMI 1640 (Gibco-BRL, Gaithersburg,MD) for growing HeLa cells containing  
non-essential amino acids supplemented with 10% (v/v) new calf serum 4 mM L-
glutamine, 10 mM HEPES pH 6.8 (Grzelak et al., 2001) and cells were grown 
without addition of antibiotics at 37°C in a humidified atmosphere of 5%(v/v) 
CO2.and 95% air. 
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3.3.4 Fluorescence spectrophotometry studies 
The uptake of FITC-labelled AuNP-peptides was measured by a quantitative 
fluorescence method (Holm et al., 2006; Huang et al., 2002).  FITC-labelled-
AuNP-peptide conjugates having a volume of  10 µl were added to 1x105 cells/ml 
CHO and HeLa cells and incubated at 37°C for 12 h followed by removal of non-
internalised surface-bound AuNP-conjugates by treatment with 0.1% (v/v) 1x 
trypsin (Invitrogen, Carlsbad, CA, USA) for 10 min at 37°C. The amount of 
internalised FITC-labelled AuNP-peptide conjugates was quantified by analyzing 
the cell lysate in a fluorescence platereader (Spectra Fluor, Tecan Group Ltd., 
Männedorf, Switzerland).  The fluorescence measurement was performed at 494 
nm excitation and 521 nm emission with reference to a standard curve containing 
0.1–20 µM FITC–labelled-AuNP in a cell lysate solution (1x105 cells untreated 
CHO or  HeLa cells dissolved in 1 mL of the Triton X-100 solution) (Huang et al., 
2002).  The concentration of internalised AuNP was determined by measurement 
of specific fluorescence expressed as fluorescence/µg total cell protein by 
extrapolation of a standard curve containing 0–20 µM FITC-AuNP in 1x105 
cells/ml CHO and HeLa cells.  The protein content of the cell lysate was 
measured using the Bradford protein assay (Bradford, 1976).  The uptake of 
these FITC-AuNP-peptide conjugates by CHO and HeLa cells was initially 
assessed quantitatively by measuring FITC fluorescence [excitation (ex) 491 nm, 
emission (em) 521 nm] of the nanoconjugates within the cells.  Using this 
technique, the cell uptake of different FITC-AuNP-peptide conjugates was 
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measured to be in the range of 0.2 µM- 1.0 µM per µg of total cell protein after 12 
h of incubation. 
3.3.5 Fluorescence microscopy 
Intracellular movement and localisation of the FITC-labelled-AuNP-peptide 
conjugates into the lysosomes was measured by co-localisation studies using 
LysoTracker Red™ (Ex-Em 577 nm-590 nm) (Molecular Probes, Carlsbad, CA, 
USA).  The AuNPs were modified with FITC (Shukla et al., 2005)  (Ex-Em 494 
nm-521 nm) and peptides in the molar ratio of 1:2:4 (FITC-AuNP: CPP: LSP), 
prepared exactly as mentioned in the AuNP synthesis and peptide conjugation 
protocol above and were added to 1x105 cells/ml CHO and HeLa cells grown on 
glass cover slips and placed in 6 well plastic plates and incubated at 37°C for 12 
h in the dark conditions.  A set of FITC-labelled AuNP-peptide conjugates was 
prepared in the ratio 1:2 of FITC-AuNP: CPP, namely FITC-AuNP-TAT test, 
FITC-AuNP-TAT control, FITC-AuNP-Pen test and FITC-AuNP-Pen control.  A 
FITC-AuNP:Lyso control was also prepared in a 1:4 ratio.  Further FITC-AuNP-
TAT test-L1 test, FITC-AuNP-Pen test-L1 test, FITC-AuNP-TAT test-L2 test, 
FITC-AuNP-Pen test -L2 test were also prepared in the ratio of 1:2:4 (AuNP-
FITC: CPP: LSP).  All of the prepared nanoconjugates were added to 1 x 105 
cells/ml CHO and HeLa cells that were cultured up to 75% confluency and 
subsequently incubated for 12 h.  A further 74 nM Lysotracker Red dye was 
added to the nanoconjugates treated cells after four washes with cold phosphate 
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buffered saline solution (PBS) (pH 7.4) to terminate the uptake of nanconjugates 
and incubated at 37°C for 30 min.  After four washes with ice-cold PBS, the cells 
were fixed in 3.7% paraformaldehyde for 20 min, afterwards repeating four 
washes with PBS as described before.  Treated cells were mounted with Dako 
mounting media and coverslipped.  The cells were visualised in an Olympus AX 
Fluorescence Microscope (Olympus, Tokyo, Japan) at 600 nm and the image 
analysis was performed using Spot Software version 4.7(Sterling Heights, MI 
48314,USA).  The intracellular localisation of different FITC-AuNP-peptide 
conjugates to the lysosomes was confirmed by co-localisation by merging the 
green and red fluroscence of the particles with the LysoTracker Red™ dye and 
by fluorescence microscopy.  Co-localisation studies were done as a first step to 
monitor the movement of AuNP-peptide conjugates and their sub-cellular 
localisation.  As Lysotracker Red dye is specific for lysosomes, the presence of 
AuNP-FITC (green) in the lysosomes can be observed by merging red and green 
fluorescence.  In this technique, it is important to note that single nanoparticles 
could not be observed due to the small size of the AuNPs used, but when several 
AuNPs clustered in a specific location within the cell then detection using this 
technique was possible (Shukla et al., 2005).   Due to the detection limit of the 
fluorescence microscopy technique, further work with TEM was carried out in 
order to determine single AuNPs.   
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3.3.6 Transmission Electron Microscopy (TEM) 
The AuNPs (non-FITC)-peptide conjugates were incubated with 1x105  cells/ml 
for 12 h as described before, but only in CHO cells with Pen combinations.  Cells 
with Pen combinations were incubated for 12 h with the AuNPs only (control), 
AuNP-Pen control, AuNP-Pen test and AuNP-Pen test-L1/L2/Lyso control.  Cells 
were fixed in 0.05 M PBS  pH 7.4 solution containing 4% (v/v) glutaraldehyde for 
2 h at room temperature followed by 4 x 15 min washes with 0.05 M PBS , then 
embedded in 2% (w/v) agarose gel,  refixed in 1% (v/v) osmium tetroxide solution 
for 1 h washed 3 x 15 min in distilled water. Cells were further dehydrated in a 
graded series of ethanol solutions ranging from 10%, 25%, 50%. 75%, 95% upto 
100% (v/v) for 15 min each.  They were infiltrated with propylene oxide and 
absolute ethanol (1:1) for 1 h, then Spurr’s (Spurr, 1969) resin with daily changes 
of resin for 3 days.  The cells were embedded in fresh resin and baked at 70°C 
for 48 h.  Ultrathin sections (60-90 nm thick) were cut using a Leica Ultracut 
ultramicrotome (Leica, Tokyo,Japan) and glass knives, post-stained with 5% 
(w/v) uranyl acetate in 50% (v/v) methanol and 2% (w/v) Reynolds lead citrate 
solution (Venable and Coggeshall, 1965) and visualised with a Jeol 1010 
transmission electron microscope (Jeol, USA). 
3.3.7 Cytotoxicity assay  
The peptides and AuNPs, alone and also in combination, were measured for their 
potential cytotoxic effects on the CHO and HeLa line after 12 h of incubation.  
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MTT ([3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide) having 5 
mg/ml concentration was dissolved in PBS (pH 7.4) was added to the treated 
cells  for 4 h (Mosmann, 1983) and absorption was measured 
spectrophotometrically at 570 nm using a UV-visible absorption 
spectrophotometer. (Hitachi U-2000, Hitachi Ltd., Tokyo, Japan).  CHO and HeLa 
cells incubated with no added conjugate or particles and 1 % (w/v) SDS were 
used as negative and positive controls respectively. 
3.3.8 Data and statistical analysis 
All plotting and statistical analysis of data was performed using GraphPad Prism 
software v. 5.00 (Graph Pad Software, San Diego, USA).  A one-way ANOVA 
with Bonferroni’s multiple comparison test were used to identify significant 
differences in the uptake of nanoconjugates and two-way ANOVA for cytotoxicity 
comparison among test groups in CHO and HeLa cell lines. 
 
3.4 Results 
3.4.1 AuNPs synthesis and peptide conjugation 
AuNPs were monodispersedin nature and their average size was estimated as 
13 nm when examined by TEM (Fig. 3-2).  These AuNPs were first modified with 
FITC for use in fluorescence studies.  Binding of FITC was achieved through the 
interaction of the thiocyanate group of FITC with the gold surface (Shukla et 
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al., 2005).  FITC-AuNPs displayed a single absorption peak of 520 nm (Fig. 3-3) 
that is typical for AuNPs of this size range (Tullman, 2007; Wang et al., 2005). 
FITC-AuNPs CPPs and LSPs were added in varying molar ratios between 
01:01:01 and 01:04:04 FITC-AuNP: CPP: LSP to optimise the ratios between the 
FITC-AuNPs and peptides.  As the peptide ratio was increased during conjugate 
formation, there was a decrease in the absorbance peak at 520 nm to a broad 
peak in the range of 560-680 nm as observed with  01:03:04 and 01:04:04 FITC-
AuNP: CPP: LSP samples.  Above the optimized molar ratio (1:02:04 FITC-
AuNP: CPP: LSP), the FITC-AuNPs aggregrated, resulting in a colour change 
from red to blue due to plasmon resonance effects and associated shifts in λmax at 
600 nm.  This molar ratio resulted in a uniform monolayer of peptides on the 
FITC-AuNP surface.  
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Figure 3-2. TEM analysis of FITC-AuNP conjugates. 
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Figure 3-3. Absorption spectral analysis of FITC-labelled AuNP-peptide 
conjugates. 
 
  
110 
FITC-AuNP-peptide conjugates had some chain-like structures and clusters (Fig. 
3-4) unlike the monodispersed FITC-AuNP particles (Fig. 3-2).  These results 
suggest that FITC-AuNPs were coated with peptides and that aggregate 
formation was possible due to localised charge interactions between the bound 
peptides, similar to that observed in previous studies using peptide-coated 
AuNPs (Tullman, 2007; Wang et al., 2005) 
3.4.2 Fluorescence spectrophotometry studies 
3.4.2.1 Uptake of FITC-AUNPs-peptide conjugates in CHO cells  
As seen in Fig. 3-5, the uptake of bare FITC-AuNPs was negligible compared 
with FITC- AuNP-CPP-LSP (test) samples.  A similar trend was observed in the 
FITC- AuNP-TAT control compared with the FITC- AuNP-TAT test that had 6.9- 
fold increased uptake in the cells.  When the LSPs L1 and L2 were added in 
combination with FITC-AuNP-TAT test conjugates, there was no significant 
enhancement in uptake efficiency of either FITC- AuNP-TAT-L1 or FITC- AuNP-
TAT-L2 conjugates compared with FITC- AuNP-TAT only.  However, noteworthy 
increases in the cellular uptake of both FITC- AuNP-TAT -L1 (14 fold) and FITC- 
AuNP- TAT -L2 (12.6 fold) were observed relative to the FITC- AuNP-Lyso 
control.  Nonetheless cellular uptake of FITC- AuNP-L1 (P< 0.0001) and FITC- 
AuNP-L2 resulted in a significant increase (P< 0.0001) in uptake compared with 
FITC-AuNP-TAT-LSP. 
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Figure 3-4. TEM analysis FITC-labelled AuNP-peptide conjugates.  
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Figure 3-5. Quantitative analysis of nanoconjugate uptake into CHO cells by 
spectrofluorimetry.  
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
AuNP-peptide conjugates.  One way ANOVA was used to analyse concentration 
for AuNP-peptide conjugates within the CHO cell line, followed by Boneferroni 
post-test analysis to determine which means differed significantly (P<0.0001), as 
indicated by letters a-d.  
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Furthermore, for FITC-AuNP-Pen-LSP combinations, spectrofluorimetric analysis 
revealed a 9.4 fold increase in the uptake of FITC-AuNP-Pen test than that of the 
FITC-AuNP-Pen control indicating greater accumulation of FITC-AuNPs in the 
cells.  With Pen rather than TAT, a 1.3- fold increase in the uptake of FITC-
AuNP-Pen-L1 (P<0.01) and 1.2-fold increase in FITC-Pen –L2 (P>0.05) was 
observed when compared to FITC-AuNP-Pen only.  Moreover a 23.4 fold 
increase in the uptake of FITC-AuNP-Pen-L1 (P<0.001) and 21.7-fold increase in 
FITC-AuNP-Pen-L2 (P< 0.001) were observed over that FITC-AuNP control.  
FITC-AuNP-Pen-L1 uptake was 9.3-fold greater than FITC-AuNP-L1 (P<0.001) 
and 8.2 fold greater than FITC-AuNP-L2 (P<0.001). 
The cellular uptake of both FITC-AuNP-(CPP -LSP) test treatments were 
significantly greater than all of the FITC-AuNP-(CPP-LSP) controls and FITC-
AuNP-(L1/L2) test treatments alone. 
3.4.2.2 Uptake of FITC-AUNPs-peptide conjugates in HeLa cells  
As seen in Fig. 3-6, in HeLa cells, the uptake of bare FITC-AuNPs was negligible 
compared with FITC- AuNP-CPP-LSP (test) samples.  A similar trend was 
observed in FITC-AuNP-TAT control compared to FITC- AuNP-TAT test 
treatments, which had 5-fold increased uptake in the cells.  When the LSPs L1 
and L2 were added in combination with FITC-AuNP-TAT conjugates, there was 
no significant enhancement in uptake efficiency of either FITC- AuNP-TAT-L1 or 
FITC- AuNP-TAT-L2 conjugates compared with FITC- AuNP-TAT only.  
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However, increases in the cellular uptake of both FITC- AuNP-TAT-L1 test (10-
fold) and FITC- AuNP- TAT-L2 (7.6-fold) were observed relative to the FITC-
AuNP-Lyso control.  Nonetheless cellular uptake of FITC- AuNP-L1 (P< 0.0001) 
and FITC- AuNP-L2 resulted in a significant increase (P< 0.0001) in uptake 
compared to FITC-AuNP-TAT-LSP. 
Furthermore, for FITC-AuNP-Pen-LSP combinations, spectrofluorimetric analysis 
revealed a 5.8- fold increase in the uptake of FITC-AuNP-Pen test over that of 
the FITC-AuNP-Pen control, indicating greater accumulation of FITC-AuNPs in 
the cells.  With Pen rather than TAT, a 1.1 fold increase in the uptake of FITC-
AuNP-Pen test-L1 test (P<0.01) and increase in FITC-Pen -L2 (P>0.05) was 
observed when compared to FITC-AuNP-Pen test only.  Moreover an 18.8- fold 
increase in the uptake of FITC-AuNP-Pen-L1 (P<0.001) and a 15-fold increase in 
FITC-AuNP-Pen-L2 (P< 0.001) was observed over the FITC-AuNP control.  The 
FITC-AuNP-Pen-L1 uptake was 7.6-fold greater than the FITC-AuNP-L1 
(P<0.001) and 6.9-fold greater than FITC-AuNP-L2 (P<0.001) treatments. 
Cellular uptake of both FITC-AuNP-(CPP -LSP) test was significantly greater 
than all of the FITC-AuNP-(CPP-LSP) controls and FITC-AuNP-(L1/L2) test 
alone. 
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Figure 3-6. Quantitative analysis of nanoconjugate uptake into HeLa cells 
by spectrofluorimetry.  
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
AuNP-peptide conjugates.  One way ANOVA was used to analyse concentration 
by with AuNP-peptide conjugates within the HeLa cell line, followed by 
Boneferroni post test analysis to determine which means differ significantly 
(P<0.0001), as indicated by letters (a-d).  
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Overall, the FITC-AuNPs conjugated with both Pen and L1/L2 peptides were the 
most efficient combinations.  L1 containing FITC-AuNP conjugates were more 
effectively taken up by the cells when Pen but not TAT was used.  FITC-AuNP-
Pen-L2 was not significantly different from FITC-AuNP-Pen test as observed from 
the graph and statistical analysis data in both CHO and HeLa. 
3.4.3 Fluorescence microscopy studies     
3.4.3.1 Intracellular localisation of FITC-AuNP conjugates in CHO cells 
For both FITC-AuNP-Pen and FITC-AuNP-TAT, the test treatments showed the 
uptake of Lysotracker Red dye (Figs 3-7.2a, 3-7.4a) as seen as red dots refer to 
Fig 3-7(a) relative to the corresponding control treatments (Figs 3-7.1a, 3-7.3a).  
The test treatments increased the uptake of FITC-AuNPs into the cells (Figs 3-
7.2b, 3-7.4b) relative to the controls (Figs 3-7.1b, 3-7.3b).  Co-localisation of 
lysosomal dye and FITC-AuNP showed that nanoconjugates were not localised 
into lysosomes inside the cells, but rather scattered throughout the cytoplasm 
(Figs 3-7.2c, 3-7.4c) indicating that the Pen/TAT peptide promoted the uptake of 
AuNPs into the cells but no subcellular localisation into the lysosomes.  No co-
localisation of both Lysotracker and FITC-AuNP in control treatments (Figs 3-
7.1c, 3-7.3c) was observed except for a few green areas that indicated FITC-
AuNP might be attached to the cell membrane.   
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Figure 3-7. Intracellular localisation of FITC-AuNP-CPP conjugates in CHO 
cells. 
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green). c, Co-localisation of FITC-AuNP 
conjugates and Lysotracker red.  
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Figure 3-7(a) Magnified image of lysosomes as red dots in CHO cells 
containing Lysotracker Red dye.  
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For both FITC-AuNP-CPPs test -L1test peptide had a uptake of Lysotracker Red 
(Figs 3-8.2a, 3-8.4a) along with FITC-AuNP-CPPs-Lyso control peptide (Figs 3-
8.1a, 3-8.3a).  The penetration of FITC-AuNP-CPP test-L1 test (Figs 3-8.2b, 3-
8.4b) was enhanced and more concentrated as green spots of AuNP-FITC 
relative to FITC-AuNP-CPP test-Lyso control (Figs 3-8.1b, 3-8.3b), which was 
dispersed throughout the cells.  In contrast, the addition of L1 peptide to FITC-
AuNP-Pen test and FITC-AuNP-TAT test resulted again in significant cellular 
uptake but this time predominant accumulation into the subcellular particles 
similar in size and shape to lysosomes, corresponding to the co-localisation of 
FITC-AuNP and Lysotracker Red (Figs 3-8.2c, 3-8.4c).  In FITC-AuNP-CPP test-
Lyso control treatment, negligible co-localisation of FITC-AuNP and Lysotracker 
was observed, with a fuzzy distribution of AuNPs everywhere inside the cells 
(Figs 3-8.1c, 3-8.3c).  In addition, the overlay of FITC-AuNP-Pen test-L1 test 
showed highly concentrated orange and yellow overlapping areas in the size and 
shape of lysosomes relative to FITC-AuNP-TAT test-L1 test (Figs 3-8.1c, 3-8.3c).   
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Figure 3-8. Intracellular localisation of FITC-AuNP-CPP conjugates 
containing L1 peptide in CHO cells.  
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green). c, Co-localisation of FITC AuNP 
conjugates and Lysotracker red.  
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The treatments for both FITC-AuNP-CPPs-L2 test peptides showed staining of 
Lysotracker Red (Figs 3-9.2a, 3-9.4a) over that of FITC-AuNP-CPPs-Lyso control 
peptide (Figs 3-9.1a, 3-9.3a).  Correspondingly, the FITC-AuNP-CPP test-L2 test 
(Figs 3-9.2b, 3-9.4b) combination promoted the uptake of FITC-AuNPs inside the 
cells relative to the scattered FITC-CPP test-Lyso control (Figs 3-9.1b, 3-9.3b).  
The micrographs of FITC-AuNP-Pen test and FITC-AuNP-TAT with L2 peptide 
test revealed greater cell penetration again but this time localisation into 
lysosomes as observed by merging of FITC-AuNP and Lysotracker Red 
fluorescence (Figs 3-9.2c, 3-9.4c) by contrast to FITC-AuNP -CPP test-Lyso 
control that was scattered all over the cells (Figs 3-9.1c, 3-9.3c).  Furthermore 
the sharp localisation of AuNP-FITC-Pen test-L2 test was observed as yellow 
and orange spots compared to the AuNP-FITC-TAT test-L2 test (Figs 3-9.2c, 3-
9.4c).  The addition of L2 peptide to FITC-AuNP -Pen test and FITC-AuNP -TAT 
test resulted again in cellular uptake but predominantly accumulated into the 
lysosomes, corresponding to the co-localisation of FITC-AuNP and Lysotracker 
Red (Figs 3-9.2c, 3-9.4c).  In the FITC-AuNP -CPP test-Lyso control treatment, 
negligible co-localisation of FITC-AuNP and Lysotracker was observed, with 
AuNPs distributed everywhere inside the cells (Figs 3-9.1c, 3-9.3c).  In addition, 
overlap of FITC-AuNP -Pen test-L2 was slightly greater and more concentrated 
as observed by orange and yellow overlapping areas relative to FITC-AuNP-TAT 
test-L2 test (Figs 3-9.1c, 3-9.3c).   
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Figure 3-9. Intracellular localisation of FITC-AuNPs-CPP conjugates 
containing L2 peptide in CHO cells. 
 a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green). c, Co-localisation of FITC AuNP 
conjugates and Lysotracker red.  
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3.4.3.2 Intracellular localisation of FITC-AuNP conjugates in HeLa cells 
In HeLa cells, with both FITC-AuNP-Pen test and FITC-AuNP-TAT the uptake 
pattern  of Lysotracker Red dye (Figs 3-10.2a, 3-10.4a) was similar to the 
corresponding control treatments (Figs 3-10.1a, 3-10.3a).  In addition, 
fluorescence from FITC-AuNPs in test treatments was scattered everywhere 
inside the cells (Figs 3-10.2b, 3-10.4b) in comparison with the FITC-AUNP-CPP-
control (Figs 3-10.1b, 3-10.3b).  The co-localisation pattern of lysosomal dye and 
FITC-AuNP showed that nanoconjugates were not contained into lysosomes 
within the cells, but rather distributed throughout the cytoplasm (Figs 3-10.2c, 3-
10.4c) indicating that the Pen/TAT peptide promoted the uptake of AuNPs into 
the cells but no subcellular localisation into the lysosomes.  No co-localisation of 
both Lysotracker and FITC-AuNP in control treatments (Figs 3-10.1c, 3-10.3c) 
was observed except for some green parts that indicated FITC-AuNP possibly 
aggregated to the cell membrane.   
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Figure 3-10. Intracellular localisation of FITC-AuNPs-CPP conjugates in 
HeLa cells. 
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green). c, Co-localisation of FITC AuNP 
conjugates and Lysotracker red. d, bright-field image. 
 
 
1 
2 
3 
FITC AuNP- Pen control  
 FITC AuNP-Pen test 
FITC AuNP-TAT control  
FITC AuNP-TAT test  4 
 10µm 
  
125 
Both FITC-AuNP-CPP-L1 test peptide resulted in a typical uptake pattern of 
Lysotracker Red (Figs 3-11.2a, 3-11.4a) as an intense red dots in the cells 
relative to the hazy uptake of the FITC-AuNP-CPPs-Lyso control peptide (Figs 3-
11.1a, 3-11.3a).  Likewise, the distinctive accumulation with FITC-AuNP-
CPPtest-L1 test (Figs 3-11.2b, 3-11.4b) of green fluorescent dots was more 
apparent than FITC-AuNP-CPP test-Lyso control (Figs 3-11.1b, 3-11.3b) that 
was dispersed throughout the cells.  In contrast, the addition of L1 peptide to 
FITC-AuNP-Pen test and FITC-AuNP-TAT test resulted again in large cellular 
uptake but in this instance predominant accumulation into the lysosomes 
corresponding to the merging of FITC-AuNP and Lysotracker Red (Figs 3-11.2c, 
3-11.4c).  In the FITC-AuNP -CPP test-Lyso control treatment, slight co-
localisation of FITC-AuNP and Lysotracker dye was observed, with AuNPs 
distributed everywhere inside the cells (Figs 3-11.1c, 3-11.3c).  In addition the 
overlap of FITC-AuNP-Pen test-L1 test was superior and more concentrated as 
observed by orange and yellow overlapping areas relative to FITC-AuNP-TAT 
test-L1 test (Figs 3-11.1c, 3-11.3c) that did accumulate into the lysosomes, 
though the FITC-AuNPs were distributed everywhere, as seen from green 
fluorescence.   
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Figure 3-11.  Intracellular localisation of FITC-AuNPs-CPP conjugates 
containing L1 peptide in HeLa cells. 
 a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green).  c, Co-localisation of FITC AuNP 
conjugates and Lysotracker red.   
 
1 
2 
3 
FITC AuNP-Pen test-L 
control  
FITC AuNP-Pen test-L1 
test 
FITC AuNP-TAT test-L 
control  
FITC AuNP-TAT test-L1 
test   4 
10µm 
  
127 
Tthe treatment for FITC-AuNP-CPPs-L2 test peptides indicated the subcellular 
concentration of Lysotracker Red (Figs 3-12.2a, 3-12.4a) over that of FITC-
AuNP-CPPs-Lyso control peptide (Figs 3-12.1a, 3-12.3a).  Correspondingly the 
FITC-AuNP-CPP test-L2 test (Figs 3-12.2b, 3-12.4b) combination promoted the 
uptake of FITC-AuNPs inside the cells and concentration into dots relative to the 
dispersed FITC-AuNP-CPP test-Lyso control (Figs 3-12.1b, 3-12.3b).  FITC-
AuNP-Pen and FITC-AuNP-TAT-L2 peptide test showed cellular uptake with less 
significant accumulation into the lysosomes than with L1, as observed by 
merging of FITC-AuNP and Lysotracker Red fluorescence (Figs 3-12.2c, 3-
12.4c).  By contrast, FITC-AuNP-CPP test-Lyso control fluorescence was 
scattered all over the cells (Figs 3-12.1c, 3-12.3c).  The FITC-AuNP-TATtest-
L2test nanoconjugates were localised to lysosomes, compared with the FITC-
AuNP-TAT test-Lyso control nanoconjugate uptake seen in Fig 3-12.4c, but less 
than with the FITC-AuNP-Pen test-L2 combination Fig 3-12.2c in HeLa cells.   
Overall, the analysis of the results obtained using these various FITC-AuNP-CPP 
and FITC-AuNP-CPP-LSP nanoconjugate combinations revealed that the uptake 
of the particles across the cell membrane of CHO and HeLa cells was similar but 
FITC-AuNP-Pen-LSP combinations were more efficient than FITC-AuNP-TAT-
LSP combinations in translocating the particles into the lysosomes.  In terms of 
lysosomal accumulation of particles, the L1 test sequence was better than L2 test 
sequence in both CPPs and cell lines.  The unchanged morphology of the cells 
indicated the compatibility of the nanoconjugates with both the cell lines.  Also, 
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differences in the uptake of the nanoconjugates in CHO and HeLa cells explain 
the preferential selectivity of these cell lines in allowing the entry of 
nanoconjugates inside the cells (Jones et al., 2005).  These data are consistent 
with the enhanced uptake of FITC-AuNPs into the cells with LSPs and CPPs in 
combinations obtained in fluorescence spectrophotometry method.  
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Figure 3-12.  Intracellular localisation of FITC-AuNPs-CPP conjugates 
containing L2 peptide in HeLa cells.  
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of FITC-
labelled AuNP conjugates in cells (green). c, Co-localisation of FITC AuNP 
conjugates and Lysotracker red. 
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3.4.4 TEM 
The intracellular localisation of non-FITC-labelled AuNP-Pen-LSP conjugates 
was also observed by TEM microscopy, but was performed only with   CHO and 
only for Pen combinations, since they showed the greatest selective 
accumulation in subcellular particles inside the cells.  The cells were intact and 
viable, as seen from the intact cell membrane, e.g. Fig. 3-13a.  The accumulation 
of AuNP alone was negligible, which with AuNP-Pen control showed AuNPs 
accumulating around the outside of the plasma membrane (Fig. 3-13b).  With 
AuNP-Pen test, AuNPs were concentrated into aggregate clusters inside the cells 
(Fig. 3-13c), as expected from the cell penetrating activity of the Pen peptide.  
Equally there was no penetration of the particles with AuNP-Pen-Lyso control 
(Fig. 3-13d) with most AuNPs adhering to the cell membrane or shortly inside it.  
With AuNP-Pen test-L1 test, AuNPs were targeted specifically to the lysosomes 
(Fig.3-13e).  Similarly, the addition of the L2 peptide in the AuNP-Pen test 
resulted in lysosomal accumulation (Fig 3-13f) but of fewer particles than the L1 
peptide and the AuNPs also accumulated outside the cells.  The intracellular 
accumulation of AuNP-Pen test-L1 test into lysosomes was greater than that with 
L2 test conjugates, confirming previous observations using fluorescence 
microscopy.  Thus the L1 peptide was superior to L2 in targeting nanoconjugates 
to the lysosomes of CHO cells by TEM.  
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Figure 3-13.  Cellular localisation of the AuNP-conjugates observed by TEM 
in CHO cells.  
a, AuNP only b, AuNP-Pen control conjugates. c, AuNP-Pen test conjugates d, 
AuNP-Pen test-Lyso control conjugates e, AuNP-Pen test – L1 test conjugates f, 
AuNP-Pen test-L2 test conjugates. Key: N= nucleus, L=lysosmes, E= 
endosomes, AuNP= gold nanoparticles  
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Figure 3-13.  Cellular localisation of the AuNP-conjugates observed by TEM 
in CHO cells.  
a, AuNP only b, AuNP-Pen control conjugates. c, AuNP-Pen test conjugates d, 
AuNP-Pen test-Lyso control conjugates e, AuNP-Pen test – L1 test conjugates f, 
AuNP-Pen test-L2 test conjugates. Key: N= nucleus, L=lysosmes, E= 
endosomes, AuNP= gold nanoparticles  
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3.4.5 Cytotoxicity assay  
3.4.5.1 Pen combinations 
Cytotoxicity of Pen peptide combinations in CHO and HeLa cells when                   
conjugated with AuNPs        
With Pen, cell viability ranged from 18% (postitive control) to 100% (negative 
control) in both the cell lines (Fig. 3-14).  CHO and HeLa cells showed almost 
100% viability with the negative control, L1 and L2 test peptides.  Cell viability 
was reduced significantly by treatment with AuNP-Pen test-L1 test of the 13 
treatments in both the cell lines (F= 26.09, P<0.0001 by two-way ANOVA).  
Adding AuNPs to Pen-test, Pen test-L2 test and AuNP-Pen control had no effect 
on cell viability.  Adding L1, L2 or Lyso control peptides alone or conjugated to 
AuNPs had no effect on cell viabililty.  
3.4.5.2 TAT combinations 
Cytotoxicity of TAT peptide combinations in CHO and HeLa cells when                   
conjugated with AuNPs              
With TAT, cell viability ranged from 17% (positive control) to 100% (negative 
control) in both the cell lines (Fig. 3-15).  CHO and HeLa cells showed almost 
100% viability in the presence of negative control, L1 and L2 test peptides.  Cell 
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viability was reduced significantly by treatment only with AuNP-TAT test-L1 test 
of the 13 treatments in both the cell lines (F= 32.15, P<0.0001 by two-way 
ANOVA).  Adding AuNPs to TAT-test, TAT test-L2 test had no effect on cell 
viability.  The cells were viable on addition of L1, L2 or Lyso control peptides 
alone or conjugated to AuNPs.  
Overall, there was minimal cytotoxicity observed in these cells in the presence of 
the AuNPs, free peptides and conjugates under the conditions used in this study.  
These results suggested low cytotoxicity of AuNPs and their nanoconjugates with 
peptides and are in agreement with the previous literature on poly (L-lysine)-
modified AuNPs (Shukla et al., 2005) 
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                        CHOH                  HeLa 
Figure 3-14.  Cytotoxicity assay of Pen peptide combinations in both CHO 
and HeLa cells. 
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
AuNP-peptide conjugates. Two-way ANOVA was used to analyse data and 
compare the effect of AuNP-peptide conjugates between CHO and HeLa cell 
line.  Analysis indicated a significant difference between treatments (P<0.001) 
but no significant difference between the cell lines (P0.4389). 
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Figure 3-15.  Cytotoxicity assay of TAT peptide combinations in both CHO 
and HeLa cells.  
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
AuNP-peptide conjugates.  Two-way ANOVA was used to analyse data and 
compare the effect of AuNP-peptide conjugates between CHO and HeLa cell 
line.  Analysis indicated a significant difference between treatments (P<0.001) 
but no significant difference in the row factor between the cell lines (P0.3965) 
CHO HeLa 
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3.5  Discussion 
This research has shown for the first time that it is possible to deliver 
nanoparticles specifically to the lysosomes of mammalian cell lines, by coating 
them with both cell-penetrating peptides and lysosome signal peptides.  The 
greater cell penetration and localisation slightly favors Pen over TAT.  L1 peptide 
was demonstrated to be more efficient than L2 in lysosomal localisation, as 
apparent from fluorescence spectrophotometry, fluorescence microscopy and 
TEM.  Although L2 peptide could target particles to lysosomes, they were fewer 
than with L1.  Both the sequences had a specific role in directing nanoparticles to 
the lysosomes.  There are distinct advantages of using nanoparticles for 
intracellular targeting, including the increased payload that can be attached to the 
particles, for subcellular imaging and for therapeutic applications including near-
infrared thermal ablation of tumours (Letfullin et al., 2006).  Adding nanoparticles 
in combination with CPPs and LSPs to this system offers the possibility of curing 
lysosomal diseases with the involvement of the central nervous system (CNS).  
This would be promising because the CPPs have the ability to cross the blood-
brain barrier (Weiss et al., 1999)and LSPs would than be able to direct the 
essential therapeutic molecules specifically to the lysosomes.  
3.5.1 AuNP synthesis and peptide conjugation  
In first part of this study, AuNPs were synthesised in the laboratory using the 
citrate reduction method (Turkevich, 1951). The resulting AuNPs were 
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monodispersed in nature and their average size was estimated to be 13 nm when 
examined by TEM.  This size of nanoparticles was small enough to cross the cell 
membrane upon attachment to a cell penetrating peptide and large enough to be 
visualised clearly using electron microscopy.  The size of nanoparticles affects 
their cellular uptake along with the targeting moieties attached (Chithrani et al., 
2006).  
After synthesising nanoparticles, the second task was to establish stabilised 
binding of FITC to the surface of the nanoparticles.  This type of arrangement 
was easily detected using fluorescence microscopy.  Binding of FITC was 
achieved through the interaction of the thiocyanate group of FITC with the gold 
surface (Shukla et al., 2005).  These FITC-AuNP conjugates were stable 
following conjugation, similar to citrate-stabilised AuNPs (Shukla et al., 2005).  
The potential quenching of FITC-associated fluorescence due to the interaction 
with the AuNPs (Mirabelli et al., 1985; Panyam et al., 2003) can be overcome by 
optimising the ratio between the concentration of FITC and AuNP as stated in 
previous studies of FITC-AuNP conjugates (Shukla et al., 2005).  
All of the peptides used in this study contained a terminal cysteine to facilitate 
directional attachment of peptides on the AuNP surface.  Following the 
attachment of FITC to the AuNP, the CPP and targeting peptides were then 
conjugated optimally with FITC-AuNP.  The aim of optimisation was to maximise 
peptide coating on the surface of the nanoparticles without inducing their 
aggregation.  During optimisation studies, aggregation of FITC 
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nanoparticles was monitored by monitoring change in the colour of the 
nanoparticles solution from red to blue due to plasmon resonance effects and 
associated shift in λmax to 600 nm (Burns et al., 2006).  A molar ratio of FITC-
AuNP: CPP: LSP of 1:2:4 at pH 7.4 was determined to be the optimal ratio that 
resulted in a uniform monolayer of peptides on the FITC-AuNP conjugates.  
These results suggest that the FITC-AuNP were coated with peptides with little 
aggregate formation, possibly due to localised charge interactions between the 
bound peptides similarl to that observed in previous studies using  peptide-
coated AuNP (Tullman, 2007; Kogan et al., 2006; Shukla et al., 2005).  
Fluorescent labelling of nanoparticles allowed in evaluating if nanoparticles were 
taken up particularly by a cell organelle, dispersed in cells or not taken up at all.  
This was required as the aim was to explore the targeting property of each of the 
peptides alone and in combinations for their efficacy.  In addition to the methods 
used above the physical characterisation (hydrodynamic diameter and zeta 
potential) data of AuNPs prior to and after FITC loading and peptide conjugation 
would be useful as a supporting data for understanding the physical 
characterisitics of the AuNP-FITC-peptide conjugates.  
3.5.2 Cell penetration as observed by quantitative and 
visualisation approaches.  
There was a significant difference between the cellular uptake of AuNP-Pen and 
AuNP-TAT test peptides and control peptides in both CHO and HeLa cell lines.   
The difference between the uptake of FITC-AuNP- CPP test nanoconjugates and 
their respective control conjugates may be due to the positive charges within the 
CPP sequences, which are required to penetrate the cells (Wender et al., 2000).  
There are electrostatic interactions between the positively charged Arg and Lys 
residues and the negatively charged plasma membrane that play an important 
role in  cell penetration (Rothbard et al., 2004).  Probably the environment or the 
cell membrane binding pocket is negatively charged (Zorko and Langel, 2005).  
Hence increasing the number of Arg and Lys would favour uptake as the peptide 
aggregates at the cell surface.  The increase in peptide concentration favours the 
interaction with phospholipids of the surface of the cell membrane and hence 
translocation (Rothbard et al., 2004).  Evidence that supports this was that when 
the basic amino acids Lys and Arg in the control peptides were replaced by Ala, 
there was no cell penetration of these control conjugates.   
The CPPs also interact with negatively charged surface glycosaminoglycans and 
it is possible that the differences in the observed uptakes of both Pen and TAT-
containing AuNP conjugates are due to the variable numbers and types of 
glycosaminoglycans present on the cell surfaces (Rothbard et al., 2004) and their 
interactions with the different peptides(Morris et al., 2008).  The presence of Arg 
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within the CPP sequences also influences the binding to cell surface heparan 
sulphates through bidentate interactions of the guanidinium groups (Mitchell et 
al., 2000). 
3.5.3 Lysosome Penetration – Pen vs TAT  
When the LSPs were added to Pen-AuNP test conjugates, there was an increase 
in the uptake of Pen-AuNP-L1 test and Pen-AuNP-L2 test compared to the 
AuNP-Pen test alone.  Although both CPPs helped in cell penetration Pen had 
greater cell penetration than TAT in both cell lines and both fluorescence 
microscopy and TEM suggested it had greater specificity inside the cells.  The 
difference between the targeting efficiency of lysosome signal peptides may be 
due to the different number of basic residues in Pen and TAT peptides both had 
the same, which led them to interact differently with the cell membrane and may 
influence the endosome structure and hence translocation and specificity  
(Hallbrink et al., 2001). 
3.5.4 Mechanism of increased penetration into the lysosomes  
The fate of the AuNPs and their intracellular localisation depended upon the 
combination of CPP and LSP bound to the AuNPs. The possible fates of AuNPs 
that have been internalised include: 
(1) they may undergo exocytosis after a period of time (Chithrani and Chan, 
2007).  Naked AuNPs can be taken up into cells via pinocytosis and endocytosis 
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but are subsequently removed from the cells by exocytosis within 30 min 
(Chithrani et al., 2006).  Similar mechanism may be involved here and explain the 
small uptake of into cells with AuNPs only.  
(2) they remain dispersed in the cytoplasm (Chithrani et al., 2006).  In the cells 
containing only AuNP-CPPs, the AuNPs were scattered throughout the cells as 
CPPs promoted the cell penetration of AuNPs. 
(3) they are localised into the lysosomes.  In this study AuNPs with CPPs and 
LSPs remained localised in the cells and lysosomes respectively for 12 h.  Hence 
they were not exocytosed by the cells.  When the LSPs were added to Pen-AuNP 
test conjugates there was an increase in the uptake of FITC-AuNP-Pen test-
LSPs test over the FITC-AuNP-Pen test in both the cell lines.  Pen may favour 
the lysosome localisation of AuNP.  First Pen interacts by helping the peptide 
conjugates to anchor on the cell membrane and penetrate into the cell.  During 
this, the LSPs would be available for recognition by the adaptor proteins, which 
are part of the clathrin complex present on the cell surface.  The adaptor proteins 
would bind tightly to the AuNP-LSPs, undergo endocytosis and finally target them 
to the lysosomes, unlike when FITC-AuNP-Pen test is used alone, when the 
particles are scattered throughout the cells.  This may be because the LSPs 
interact with the endosomal membrane more strongly than CPPs, preventing 
their escape.  The LSPs might interact strongly with the receptors and only 
detach when they have reached the lysosomes.  Degree of uptake also depends 
on the structure of the peptide, its interaction with the protein domain, 
  
143 
peptide exposure, the density loading of peptide signal on nanoparticles, the 
strength of the chemical linkage between the peptides and AuNPs and also the 
cell type (Hallbrink et al., 2001; Rajendran et al., 2010) 
3.5.5 Differences between the lysosome sorting signals. 
3.5.5.1 L1 signal interaction  
When two different LSPs were used namely (L1 and L2) in combination with the 
CPP test peptides on AuNPs, there was a difference in uptake of L1 as 
compared with L2.  Most of the experimental observations with fluorescence 
microscopy and especially TEM suggested that L1 was more efficient than L2 for 
targeted delivery to the lysomes.  The recognition of the L1 tyrosine signals by 
the adaptor protein was identified (Glickman et al., 1989) following their 
observation that Tyr residues in the cytosolic tail of the cation-independent 
mannose-6-phosphate receptor interacted with the AP-2 complex on the plasma 
membrane  and were sorted to the lysosomes through clathrin-mediated 
endocytosis.  AP-2 is a clathrin associated complex composed of two large 
subunits (α and β2), one medium subunit (µ2) and one small subunit (σ2)(Aguilar 
et al., 2001; Traub, 2009).  Accumulation of particles into the lysosomes through 
L1 peptide may be due to the fact that L1 peptide selectively binds to the µ2 
subunit in the AP-2 complexes (Kirchhausen et al., 1997). The peptide binds in 
an extended conformation with the Y and L residues fitting into two hydrophobic 
pockets of the (µ2) subunit of AP-2, as suggested by studies using the L1 
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sequence within fusion proteins.  The L2 signal cannot be accommodated in the 
YXXØ binding domain of the µ2 subunit of AP-2 (Bonifacino and Traub, 2003).  
The specificity of AP-2 recognition with the tyrosine signal sequences implies that 
it serves a quality control function and targets AuNPs or molecules to a 
lysosomal location.  Also, the interaction of AP-2 with lipids like 
phosphoinositides also aids the recognition of tyrosine sorting signals for 
specificity in sorting (Balla, 2005).  Thus in the YQRL (L1) signal recognition the 
clathrin, AP-2 complex, coat assembly and sorting are all coupled and linked 
(Bonifacino and Traub, 2003; Marks et al., 1997). 
3.5.5.2 L2 signal interaction 
The weaker targeting efficiency of L2 signal may be due to the following reasons.  
The Disabled – 2 (Dab2) proteins are involved in tyrosine kinase signalling 
proteins that bind in vitro to the FXNPXY sequence found in the cytosolic tails of 
members of the low-density lipoprotein receptor family (Stolt and Bock, 2006).  
Dab proteins contain an amino-terminal protein-interaction 
domain/phosphotyrosine binding domain (PID/PTB) (Morris and Cooper, 2001).  
These Dab proteins have important functions in signal transduction and 
endocytosis.  The Dab2 PTB domain has the ability to bind to signal peptides 
containing L2 sequences.  Dab2 binds to the adaptor protein AP-2 which is 
associated with clathrin-coated pits.  Dab2 can interact with the ear domain at the 
carboxy-terminus region of α adaptin of the AP-2 complex and mediate 
interaction and hence it is associated with AP-2 clathrin-coated pits(Pandey, 
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2009). Thus Dab2 may function as a linker molecule that links the NPXY (L2) 
signal to AP-2 and thus to clathrin (Mishra et al., 2002).   Dab 2 is capable of 
establishing a protein-protein interaction web at the clathrin bud site.  
L1 signal vs L2 signal  
The differences observed between the efficacy of L1 and L2 in accumulating 
particles into the lysosomes observed clearly by TEM may be because L1 
interacts directly with the AP2 complex whereas first L2 has to interact with Dab2, 
which than links it to AP2 and the clathrin coat.  Hence this may affect its final 
targeting to the lysosomes.  There is a clear mechanism for the interaction of L1 
with AP-2 and hence there is strong affinity as compared to the relatively weak 
affinity of binding of Dab2 with the L2 signal. 
These results clearly suggest that the LSPs peptides do have an important role in 
directing AuNPs into the lysosomes.  No intracellular delivery of AuNPs was seen 
alone and so this confirms that CPPs are needed for AuNP delivery in cells along 
with LSPs for localisation in lysosomes.  Previous studies have described the 
targeted delivery of fusion proteins containing the TAT sequence, such as the 
lysosomal enzyme, β-glucuronidase, which was delivered to lysosomes, relying 
on the intrinsic lysosomal targeting sequences within the enzyme sequence (Xia 
et al., 2001).  More recently,  the penetration and delivery of both 20 nm and 40 
nm AuNPs to lysosomes was described (Hosta et al., 2008) using two synthetic 
diasteromeric analogues of Kahalalide F, a marine cyclodepsipeptide found in 
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some molluscs that has also been shown to have anti-tumour properties.  Whilst 
this may be a useful approach for targeted therapy, Kahalalide F has been 
reported to induce damage to other cell compartments including mitochondria, 
endoplasmic reticulum and the plasma membrane(García-Rocha et al., 1996), 
which potentially restricts the use of this delivery peptide system in tumour cells.  
The use of short synthetic peptide analogues of L1 and L2 described in this study 
for the first time provides supporting evidence for a role of specific sequence-
dependent interactions of L1 and L2 with these adaptor proteins.  In the light of 
the differences in targeting efficiency observed with the L1 and L2 peptides, 
these differences may be due to the direct interaction of the L1 peptide with AP-2 
whereas the L2 peptide interaction is more indirect via an initial interaction with 
Dab2 which in turn interacts with AP-2.   
3.5.6 Cell toxicity 
There was no significant cytotoxicity observed with FITC- AuNPs, CPPs control, 
LSPs test and Lyso control suggesting that they were acceptable to the cells 
(Hosta et al., 2008).  The reasons for decrease in cell viability in the presence of 
CPPs test, FITC-AuNP-peptide conjugates on cell viability with two of the 
conjugates are unknown and so further studies are needed, but the treatment 
with greatest uptake and specificity (FITC-AuNP-Pen test-L1 test) had no cell 
toxicity in this assay and so cell toxicity does not seem to cause a significant 
barrier to their use for therapeutic purposes (Hosta et al., 2008). 
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3.6 Summary 
The findings in this research collectively confirm the role of CPPs in the peptide-
mediated translocation of nanoparticles into mammalian cells as described 
previously (Zorko and Langel, 2005).  Moreover, the role of LSP peptides has 
been shown in the efficient localisation of the AuNP-CPP-LSP conjugates to the 
lysosomes and lysosome-like structures.  The benefits of nanoparticles over 
proteins, lipsomes for intracellular targeting include the increased payload that 
can be attached to the particles and for subcellular imaging studies.  With these 
advantages, this novel delivery system could form the basis of new approaches 
for the treatment of lysosomal storage disorders including improved enzyme 
replacement therapy and/or targeted delivery of drugs after appropriate further 
tests in vitro and in vivo.  Most of the LSDs have central nervous system (CNS) 
involvement that leads to substrate accumulation in the brain, resulting in CNS 
cell death and neuropathologies (Begley et al., 2008; Montaño et al., 2008; 
Urayama et al., 2008).   
Using results of this research it would be possible to target therapeutic enzymes 
or drugs linked through AuNPs equipped with CPPs in combination with LSPs 
(L1/L2) specifically to the lysosomes.  These would even be able to cross the 
blood-brain barrier, offering a solution for the CNS-involved LSDs.  The 
effectiveness of this combination could be quantified by TEM and hence it could 
have enormous potential for therapy. 
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AuNPs are well suited for biomedical applications due to their straightforward 
synthesis and ability to incorporate multiple peptides on them, which can 
specifically guide the AuNPs to the desired intracellular location.  In this study 
AuNPs were used as transport vehicles to monitor the capacity of CPPs and 
LSPs to deliver AuNPs into the lysosomes.  This strategy would be interesting as 
it would eliminate the problems caused by inefficiency and degradation of 
enzymes/molecules at systemic level (Muro et al., 2006). 
The CPPs and LSPs were modified by introducing Cys, a free thiol on the peptide 
sequence to facilitate their stepwise attachment on the gold surface and this 
strategy should also allow the attachment of many different cargoes.  
Herein, CPPs were attached to enhance cell-penetrating activity along with LSPs 
to test their ability to deliver AuNPs to the lysosomes.  The cellular uptake of 
AuNP was examined by comparing the combinations of AuNP-CPP-LSP (test) 
and AuNP-CPP-LSP (control) in both CHO and HeLa cell lines.  The 
functionalisation of AuNP with CPP (TAT or Pen) introduces a positive charge, 
prompting its cell penetration by interaction with the negatively charged plasma-
membrane.  LSPs (L1 and L2), which are the tyrosine-based signals interact with 
adaptor proteins (AP), driving the clathrin coat formation and so leading to 
accumulation into the lysosomes. 
Of the CPPs, Pen was superior to TAT in allowing greater accumulation of AuNP 
conjugates inside the cells, and L1 was superior to L2 in allowing greater 
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accumulation inside the lysosomes of both CHO and HeLa cell lines.   The 
uptake of the nanoconjugates was greater in CHO cells than HeLa due to the 
difference in the membrane composition and presence of glycosaminoglycan 
residues.  This approach has to be further tested in endothelial cell lines having 
greater number of glyocosaminoglycans that compromise the monolayer of the 
BBB (Begley et al., 2008; Montaño et al., 2008; Urayama et al., 2008).  The 
targeting efficiency of nanoconjugates was therefore not limited to a single cell 
line.  However for assessing their full potential for targeting these nanoconjugates 
should be further tested in cell lines that are difficult to transfect such as primary 
cell lines, neuronal cell lines and the macrophages.   
Conjugation of novel LSPs in combination with other CPPs such as 
polyarginines, MPG and CADY could be explored to direct the delivery of drugs 
or non-lysosomal enzymes to the lysosomes of primary cell lines and neuronal 
cells for therapeutic purposes, thereby widening the pharmaceutical index for 
current lysosomal storage diseases. 
The synthesised peptides were conjugated with green fluorescent protein and 
tested for their ability to promote penetration of the cell membrane and 
subcellular localisation in mammalian cells in vitro in the following chapter.  
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Chapter 4  
Peptide-mediated delivery of 
green fluorescent protein 
into lysosomes 
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4.1 Introduction 
The intracellular lysosomal system plays a key role in the degradation and 
recycling of endogenous and exogenous components (Mellman, 1996).  As 
described previously, a deficiency or defect in one of the lysosomal enzymes can 
lead to a lysosomal storage disorder (LSD).  One possible way to palliate LSDs 
would be to deliver exogenous enzymes or proteins as a replacement of 
defective or absent proteins in the lysosomes.  Previous studies have shown that 
transfected fusion proteins containing di-leucine type LSPs signals were 
completely functional when directed to the lysosomes (Hou et al., 2006).  In this 
study, the aim was to study the ability of other type of LSP signals apart from di-
leucine type LSP signals for targeting a protein to the lysoomes.  In this chapter, 
both CPPs and LSPs were chemically conjugated to Green Fluorescent Protein 
(GFP) and ability of the cell-penetrating and delivery peptides to deliver these 
GFP-peptide conjugates into the lysosomes was assessed.  This study was 
conducted to demonstrate the potential use of the developed peptide delivery 
system for the targeted delivery of a native protein to the lysosomes in the cells, 
as an enhancement of the approach with the targeted delivery of GFPs described 
in Chapter 3.  GFP was chosen due to its intrinsic fluorescence properties that 
allows for easy quantification of intracellular delivery by fluorescence 
spectrophotometry and intracellular tracking by fluorescence microscopy.   
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GFP isolated from the jellyfish Aequorea Victoria is a stable protein that emits an 
intense fluorescence without the requirement of cofactors and is unaffected by 
high salt concentrations, pH and temperatures up to 78oC.  In addition, GFP is 
less susceptible to photobleaching in comparison to other widely used 
fluorophores such as fluorescein (Heim et al., 1994).  The discovery of GFP is a 
gift to biomedicine, cell biology and molecular biology (Tsien, 1998) with broad 
applications including its use as a reporter tag in bioengineering systems and cell 
biology(Suarez et al., 1997).  GFP has also been used in fluorescence resonance 
energy transfer (FRET) studies, as an energy transfer mechanism between 
two fluorescent molecules. A fluorescent donor is excited at its specific 
fluorescence excitation wavelength. By a long-range dipole-dipole coupling 
mechanism, this excited state is then nonradiatively transferred to a second 
molecule, the acceptor. The donor returns to the electronic ground state (Selvin, 
2000).  Moreover GFP has also been used to study protein/protein interactions 
through fluorescence cell sorting (FCS). More recently stem cells have been 
engineered to synthesise GFP, which have been used in stem cell research and 
also to monitor the cellular development of organisms from the zygotic level, 
thereby allowing a detailed analysis of embryonic development (Müller et al., 
2008). 
4.1.1 Aim of this chapter 
The primary aim of this chapter was to investigate the targeting efficacy of GFP 
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as model protein to lysosomes using LSPs in combination with CPPs.  This 
approach was one step ahead in attempt of targeting proteins to the lysosomes.  
GFP was purified, cross-linked with peptides and added to cells.   
4.2 Materials and Methods: 
4.2.1 Materials 
E. coli expressing His-tagged GFP was a gift of Dr Mike Ryan, Department of 
Biochemistry, La Trobe University, Melbourne, Australia.  Chelating Sepharose™ 
Fast Flow slurry was obtained from GE Healthcare, Piscataway, NJ, USA.  
Sodium dodecyl sulphate (SDS) was purchased from Bio-Rad, Hercules, CA, 
USA.  Both 0.20 µm pore size polypropylene membrane filters and Centricon 4.0 
ml 20 kDa MWCO concentrators were purchased from Millipore, MA 01821, USA. 
Vivaspin 3 kDa MWCO filters were purchased from Vivaproducts, MA01460, 
USA.  Sulphosuccinimidyl 4-N-maleimidomethyl cyclohexane-1-carboxylate 
(SMCC) was purchased from Pierce Biotechnology,, Rockford,IL,USA,  DNAse, 
glycerol, imidazole, lysozyme, ampicillin and MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 
5 diphenyltetrazolium bromide] reagent were procured from Sigma-Aldrich Ltd., 
St Louis, MO USA.  NuPAGE® Novex® Bis-Tris Mini Gels, NuPAGE® MES SDS 
Running Buffer, XCell SureLock™Mini-cell were purchased from Invitrogen Inc., 
Carlsbad, CA, USA.  Western Blue® stabilised AP Substrate was acquired from 
Promega, Madison, WI, USA.  Lysotracker ™ dye was obtained from Molecular 
Probes, Carlsbad, CA, USA.  Dulbecco’s modified Eagle medium (DMEM) 
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supplemented with 10% (v/v) new calf serum was purchased from Gibco BRL, 
Carlsbad, CA, USA. CHO (Chinese Hamster ovary) and HeLa (a human cervical 
cancer cell line) cells were obtained from ATCC, Manassas, VA, USA.  Tissue 
culture plates (6-well and 48-well) and 25 cm2 culture flasks were purchased from 
Greiner-Bio-one GmBH, Germany.  All other chemicals used were analytical 
grade laboratory reagents unless otherwise stated. 
4.2.2 Methods 
4.2.2.1 Growth conditions for expression of GFP 
A stock culture of the E. coli strain  BL21 obtained from Dr. Mike Ryan’s 
laboratory containing plasmid pEOTCGFP that expressed His-tagged GFP was 
inoculated into two 5 ml aliquots of autoclaved LB broth containing 100 µg/ml 
ampicillin overnight for 16h at 37OC with shaking at 225 rpm.  The next morning, 
2 ml of each overnight culture was inoculated into separate 250 ml conical flasks 
containing 100 ml of LB broth, and incubated at 37OC with shaking for a further 5 
h min until the optical density reached 0.5-0.7 at 600 nm.  No IPTG induction was 
carried out since less than 0.5 mg of GFP was required.   
4.2.2.2 Preparation of Whole Cell Lysates 
After incubation, the culture was centrifuged at 4000 x g for 10 min at 4OC, and 
the supernatant fluid was discarded.  The pelleted cells containing the His-tagged 
GFP protein were resuspended in 8 ml of lysis buffer containing 1 mM imidazole 
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pH 8.0 and 2 mg/ml lysozyme 40,000 units/mg protein.  The cell suspension was 
vortexed for 3 min, incubated for 30 min at RT with horizontal shaking, then 
exposed to three freeze/thaw cycles that involved initially freezing the cell 
suspension for 20min at -80OC, then thawed for 5 min at 37OC in a warm water 
bath.  After the second thaw, 10-25 units of DNase (1 mg/ml) per ml of the lysate 
was added followed by a further 15 min incubation at 37OC with horizontal 
shaking.  After the third freeze/thaw cycle, the lysed cell suspension was 
centrifuged at 5000 x g for 10 min at 4OC, and the supernatant fluid fraction 
containing soluble protein was collected and sterilised by filtration through a 
sterile 0.20 µm filter prior to loading on to the Chelating Sepharose column     A 
sample of this cell extract was retained for comparative SDS-PAGE and Western 
blot analysis. 
4.2.2.3 Purification of GFP using IMAC Chromatography  
Two 5 ml disposable columns (Biorad, Econo-Pac Chromatography Columns) 
were separately prepared for Immobilised metal affinity chromatography (IMAC) 
purification of the whole cell lysates containing the His-tagged GFP.  Ten 
milliliters of thoroughly mixed Chelating Sepharose™ Fast Flow resin slurry 
containing 20% (v/v) ethanol was added to each column, and the resin was 
allowed to settle to form 2 ml columns.  Both columns were washed with 7 
column volumes (CV) of Milli-Q water to remove the ethanol, charged with 0.5 CV 
of 0.2M nickel sulphate solution, then washed with 10 CV of Milli-Q water to 
remove unbound metal ions.  The columns were equilibrated with 7 CV 
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of equilibration wash buffer containing 1 mM imidazole, but no lysozyme. 
At this point, the soluble cell extracts containing the His-tagged GFP was loaded 
onto the column, and incubated for 1 h at RT ( with gentle horizontal shaking) to 
allow complete binding of the His-tagged GFP to the nickel-bound resin.  The 
column was returned to its vertical position, and the resin allowed to re-settle for 
15-30 min.  Each sample was run through the column, and 4 to 5 ml of crude 
eluate was collected.  The column was then washed with 10 CV of post-sample 
wash buffer containing 20 mM imidazole pH 8.0 and the flow through eluate 
containing unbound proteins was collected.  His-tagged GFP and other non-
specific poly-histidine-containing proteins were then eluted with 5 ml of elution 
buffer containing increasing concentrations of imidazole: 50, 100, 150, 200, 250 
and 250 mM imidazole respectively, all buffered at pH 8.0.  The eluted proteins 
were collected in 5 ml fractions and stored at -80°C as one ml aliquots.  The 
protein concentration of the fraction(s) containing His-tag GFP was measured by 
Bradford assay prior to storage.  
4.2.2.4 Regeneration of the IMAC column 
The IMAC columns were re-generated for further use by a procedure consisting 
of the following steps: 1) the addition of 5 x CV of 0.05 M EDTA containing 0.5 M 
NaCl at pH 7.0; 2) 5 x CV of 1.0 M NaOH; 3) 5 x CV of Milli-Q water; 4) 5 x CV of 
2.0 NaCl ; and  finally, 5) 5 x CV of Milli-Q water.  The column was then 
recharged with 0.5 CV of 0.2 M nickel sulphate prior to use for purification of 
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more His6 GFP. 
4.2.2.5 Concentration and Buffer exchange of IMAC-purified protein 
The eluted protein fractions were concentrated and the buffer was exchanged 
with sterile PBS using 20 kDa MWCO Centricon filter devices.  The Centricon 
filter devices were rinsed twice with milli-Q water. The IMAC-purified protein 
fractions were added to the Centricon filter devices and centrifuged at 4000 x g 
for 45 min.  After each centrifugation step, more eluted protein solution was 
added to the concentrated His-tagged GFP solution to the 4 ml mark, and re-
centrifuged until all of the purified His-tagged GFP was reduced to a final volume 
of approximately 0.5 ml.  The imidazole in the concentrated protein samples was 
replaced by sterile PBS by three buffer exchanges in the centrifugal filters to a 
final volume of 0.3 to 0.5 ml.  These purified and concentrated protein samples 
were stored at -80OC until analysed using SDS-PAGE, Western blot and 
Bradford protein assay 
4.2.3 SDS Polyacrylamide Gel Electrophoresis Analysis of 
purified GFP 
The purified GFP fractions were analysed by one-dimensional Sodium Dodecyl 
Sulphate -Polyacrylamide Gel Eleectrophoresis (SDS-PAGE) using NuPAGE® 
Novex® Bis-Tris Mini gels. 
A total volume of 1000 ml of 1X NuPAGE® MES SDS Running Buffer was 
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prepared from the 20X NuPAGE® MES SDS running buffer stock using Milli-Q 
water in accordance with the manufacturer’s instructions.  This running buffer 
was added to the lower (outer) buffer chamber of the XCell SureLock™Mini-cell.  
The comb in the precast gel was removed and the sample wells were rinsed with 
1X NuPAGE® MES SDS Running Buffer and placed in the electrophoresis 
apparatus prior to loading of samples. Samples were prepared for SDS-PAGE by 
adding 5 µl of 5 X SDS sample loading buffer to 20 µl of the GFP fractions 
followed by mixing and heating at 70o C for 3-5 min in a heating block.  Twenty 
microlitres of sample was loaded into each well in a pre-determined order.  One 
well was loaded with 5 µl of PageRuler™unstained Protein Ladder molecular 
weight markers, (Fermentas, Burlington, Ontario).  Electrophoresis was 
performed at 200 V in constant voltage mode for 35 minutes.  On completion of 
electrophoresis, the gel was stained with Coomassie dye stain (1.0 g of 
Coomassie Blue R-250 in 4:1:5 methanol: acetic acid: water) for 1 h at RT, and 
then destained overnight with Coomassie destaining solution in 1:1:4 of 
methanol:  acetic acid: water.  The western blot of the purified GFP protein was 
carried out in the presence anti-GFP antibody (1: 5000) and anti-rabbit-IgG 
Alkaline phophatase (AP) conjugate (1:5000) for reacting with AP western blue 
substrate. 
4.2.3.1 Estimation of Protein Content using the Bradford Assay 
The concentration of the purified and concentrated GFP fractions was 
determined by the Bradford method (Bradford, 1976) . Briefly, 10 
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microlitres of each test sample were added to Eppendorf tubes followed by the 
addition of 1 ml of Bradford reagent to all tubes, and after thorough mixing, the 
tubes were allowed to stand for 2 min at RT.  After colour development, 200 µl of 
each sample was transferred in duplicate to separate wells of a 96-well microtitre 
plate, and the absorbance was measured at 595 nm on a Bio-Rad Model 680 
plate reader (Bio-Rad Laboratories, Hercules, CA).  Protein concentrations were 
determined by reference to a linear protein standard curve containing 0 to 100 
µg/ml of bovine serum albumin included on the microtitre plate.   
4.2.3.2 Conjugation of peptides with GFP using SMCC 
The conjugation of the delivery peptides to GFP using the heterobifunctional 
crosslinker SMCC was carried out in two stages: (a) reaction of the amine-
reactive end of the crosslinker to the GFP followed by (b) reaction of the thiol-
reactive end of SMCC with the terminal cysteine residues of the delivery peptides  
Briefly, a 67µl sample of 0.5 mg/100 µl purified His-tagged GFP dissolved in 
PBS, pH 8.0 was mixed with 0.8mg of SMCC dissolved in 3 µl of 
dimethylformamide and reacted for 1 hr under dark conditions at RT. 
Approximately 1.2 mg of peptide was dissolved in 30 µl of PBS, pH 8.0 and 
added to the GFP/SMCC mixture and further reaction was allowed to proceed 
overnight at 4oC. 
A Vivaspin 500 3 kDa MWCO Centrifugal Concentrator column (Vivascience) 
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was filled with pre-swelled Sephadex G-10 gel (GE Healthcare, Uppsala, 
Sweden) in PBS; pH 8.0 and fitted into a 2 ml eppendorf tube and used to 
separate the crosslinked protein-peptide conjugates from low molecular weight 
components.  The tube containing the microspin column was spun at 1000 x g for 
2 min in order to remove excess buffer from the Sephadex G-10 gel and 
equilibrated with three changes to PBS buffer pH 7.4. 
The GFP-SMCC- peptide conjugate was loaded on to the Sephadex G-10 spin 
column spun at 4000 x g for 3 min to allow elution of the peptide-SMCC-GFP 
mixture from the column into the receiving bottom tube and retaining unreacted 
SMCC and peptide in the column.  The purified GFP-SMCC-peptide conjugate 
was stored at 4 °C until required and used for fluorimetry and fluorescence 
microscopy studies. 
4.2.3.3 Cell Culture 
Both CHO (Chinese Hamster Ovary) and HeLa cells (cervical cancer cell line) 
were used at a density of 1x105cells/ml in subsequent experiments to assess the 
targeted delivery of the GFP-peptide conjugates described in the previous 
section.  The cells were grown to ~75% confluency on glass cover slips which 
were placed in 6-well cell culture plates. CHO cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% (v/v) new calf serum 
and non-essential amino acids without the addition of antibiotics at 37 °C in a 
humidified atmosphere of 5% (v/v) CO2 and 95% air.   
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4.2.3.4 Fluorescence spectrophotometry studies 
The uptake of GFP-peptide conjugates containing cells were measured by a 
quantitative fluorescence method (Huang et al., 2002).  A 10 µl of 10 µg/ml of 
GFP-peptide conjugates was added to 1ml of CHO and HeLa cells containing 
total of  1x105cells  and incubated at 37 °C for 12 hours followed by removal of 
non-internalized surface bound GFP-conjugates with trypsin.  The cells were 
incubated with 200 µl of 0.1% (v/v) 1x trypsin (Invitrogen, Carlsbad, CA, USA) for 
10 min at 37 °C followed by centrifugation at 2000 x g for 5 minutes.  The cells 
were resuspended in 1 ml of cold PBS and transferred into 1.5 ml Eppendorf 
tubes.  After centrifugation of the resuspended cells at 1000 x g for 5 min at 4 °C, 
the supernatant fluid was discarded followed by addition of 300 µl of 0.1 M NaOH 
in 0.1% (v/v) Triton-X 100 to the pellet for 60 min at 4 °C to lyse the cells.  After 
the lysis step, 150 µl of cell lysate was collected to determine the total cell protein 
content and the relative fluorescence intensity.  Protein contents were estimated 
by reference to a standard curve containing 0 to 100 µg BSA using the Bradford 
assay (Bradford, 1976). Fluorescence intensity was measured in a black 96-well 
plate in a fluorescence microplate reader (Spectra Fluor, Tecan Group Ltd., 
Männedorf, Switzerland). The amount of internalised GFP-peptide conjugates 
was determined by measurement of relative fluorescence intensity at 494 nm 
excitation and 521 nm emission with reference to a standard curve containing 0.1 
µM to 20 µM GFP (Huang et al., 2002).  The specific uptake of GFP into cells 
was expressed in units of µM GFP/mg protein in the cell lysate.  
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4.2.3.5 Fluorescence microscopy 
The cells were seeded at a density of 1 x 105 cells per well in glass coverslips, 
and placed in 6 well cell culture plates and allowed to grow overnight.  A 10 µl of 
10 µg/ml of GFP-peptide conjugates containing different peptide combinations 
was added to 1ml of CHO and HeLa cells with a total of  1x105cells.  The GFP-
peptide conjugates containing cells were incubated for 12 h at 37°C in the dark at 
5% CO2.  Following the incubation, the cells were rinsed four times with cold PBS 
to remove un-reacted GFP-peptide conjugates.  Lysotracker red dye(Ex-Em 577 
nm-590 nm)  (Molecular Probes, Carlsbad, CA, USA) was then added at a 
concentration of 74nM to the cells, incubated for a further 30 min to stain the 
lysosomes in accordance with the manufacturer’s instructions following four 
washes with PBS, pH 7.4.  After four washes with ice-cold PBS, the cells were 
fixed in 3.7% (v/v) paraformaldehyde for 20 min, followed by four washes with 
PBS as described previously.  The treated cells were mounted with Dako 
mounting media and coverslipped .  The intracellular localisation of the different 
GFP-peptide conjugates to lysosomes was confirmed by co-localisation by 
merging the green and red fluorescence of the GFP (Ex-Em 395 nm-509 nm) 
with the LysoTracker Red™ dye by fluorescence microscopy.  The cells were 
visualised in an Olympus AX Fluorescence Microscope (Olympus, Tokyo, Japan) 
at 600 nm and the image analysis was performed using Spot Software version 
4.7(Sterling Heights, MI 48314,USA) 
  
163 
4.2.3.6 MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide] 
assay  
The MTT assay was used to assess the cytotoxicity of the peptides and GFP 
alone and in combination with CHO and HeLa cell lines following 12h of 
incubation.  The MTT was prepared at 5 mg/ml in PBS pH 7.4 and 10 µl of MTT 
reagent was added to about 1 x 105 cells/ml that were treated with AuNP-peptide 
conjugates for 4 h at room temperature in dark.  The rate of formazon production 
was measured spectrophotometrically at 570 nm (Mosmann, 1983) using UV-
visible absorption spectrophotometer. (Hitachi U-2000, Hitachi Ltd., Tokyo, 
Japan).  CHO and HeLa cells incubated with no added conjugate or particles and 
1 % (w/v) SDS were used as negative and positive controls respectively. 
4.2.3.7 Data and statistical analysis 
All plotting and statistical analysis of data was performed using GraphPad Prism 
software v. 5.00 (Graph Pad Software, San Diego, USA).  A one-way ANOVA 
with Bonferroni’s multiple comparison test were used to identify significant 
differences in the uptake of GFP-peptide conjugates and two-way ANOVA for 
cytotoxicity comparison among test groups in CHO and HeLa cell lines.  
4.3 Results 
4.3.1 IMAC purification of expressed GFP protein  
SDS-PAGE analysis revealed that the expressed His-tagged GFP was 
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successfully purified to homogeneity by IMAC chromatography (Fig. 4-1).  As   
seen in Figure 4-1, non-specific bound proteins in the cell lysate were eluted from 
the IMAC column in the fractions containing up to 100 mM Imadazole (lanes 2, 3, 
4 and 5).  This is likely to be due to the weak affinity of other His-containing 
proteins or non specific adsorption of proteins present in the cell lysate on the 
IMAC column.  The GFP was eluted as a single band when 250 mM Imadazole 
was used as the eluant (Lane 6, Fig. 4-1).  This fraction also contained the 
characteristic intense green fluorescence of GFP and from the SDS-PAGE 
analysis, had an estimated molecular weight of 28 kDa, confirming that it was 
His-tagged GFP that was purified by the procedures described above. 
4.3.1.1 Bradford protein assay 
The concentration of the 250mM imidazole purified His-tagged GFP eluate  was 
60 ug/ml as measured by the Bradford assay against a standard curve containing 
0 – 100 µg/ml. BSA.  The purified His-tagged GFP fraction was concentrated to 
0.5 ml containing 200ug/ml His-tagged GFP, stored at -20oC until required for the 
preparation of the GFP-peptide conjugates using the heterobifunctional 
crosslinker, SMCC.  
A set of GFP-peptide conjugates were prepared according to the method 
described previously using SMCC as a crosslinker.  These combinations included 
GFP-Pen test/control, GFP-TAT test/control, GFP-Pen test-L1/L2/Lyso control 
and GFP-TAT test-L1/L2/Lyso control.  A 10 µl of 10 µg/ml of GFP-peptide 
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conjugates containing different peptide combinations was added to 1ml of CHO 
and HeLa cells with a total of  1x105cells.  The uptake and localisation of GFP-
peptide conjugates was examined by fluorescence spectrophotometry and 
fluorescence microscopy.   
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                     1     2     3       4    5        6    7 
   
Figure 4-1.  SDS- PAGE electrophoresis of GFP containing eluants. 
Lane 1 -   Cell lysate    
Lane 2- Equilibration buffer eluate (20 mM Imidazole, 300mM NaCl and       
50mM Phosphate buffer (PB) (pH 8.0)  
Lane 3 - Wash buffer eluate (15mM Imidazole, 300mM NaCl and 50mM PB (pH 
8.0) 
Lane 4 -   50 mM Imidazole  
Lane 5 -  100 mM Imidazole  
Lane 6 - 250 mM Imidazole  
Lane 7 - Molecular weight markers 
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 Figure 4-2.  Western Blot of purified GFP protein with anti-GFP antibody. 
Lane 1 - Molecular weight markers 
Lane 2 - 250 mM Imidazole containing GFP   
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4.3.2 Fluorescence spectrophotometry studies 
 4.3.2.1 Uptake of GFP-peptide conjugates in CHO cells  
As seen in Fig. 4-3, the uptake of these GFP-peptide conjugates by CHO the 
[excitation (ex) 395 nm, emission (em) 509 nm] was initially assessed 
quantitatively by measuring GFP fluorescence intensity.  Using this technique, 
the cell uptake of different GFP-peptide conjugates was measured to be in the 
range of 0.2 µM to 1.0 µM per µg of total cell protein after 12 hours of incubation. 
The results obtained show that the uptake of GFP alone was significantly lower in 
uptake compared with GFP-CPP-LSP test conjugate combinations.  A similar 
trend was observed with the GFP-TAT control compared to the GFP-TAT test 
with a 7.9-fold increase uptake in the cells when the GFP-TAT test combination 
was used.  When the LSPs test peptides L1 and L2 were added along with GFP-
TAT test conjugates, there was no substantial enhancement in uptake efficiency 
of either GFP-TAT -L1 or GFP-TAT-L2 conjugates compared with GFP-TAT test 
only.  Conversely, very significant increases in the cellular uptake of both GFP-
TAT-L1 (13.6-fold) and GFP- TAT test-L2 test (11-fold) were observed relative to 
the GFP-Lyso control.  Nonetheless, the cellular uptake of GFP-L1 test (P< 
0.0001) and GFP-L2 test resulted in a significant increase (P< 0.0001) in uptake 
compared to GFP-TAT -LSP test. 
Furthermore, on addition of Pen peptide to form GFP-Pen-LSP combinations 
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resulted in a 7-fold increase the uptake of GFP-Pen test relative to the GFP-Pen 
control sample.  With Pen rather than TAT, a 1.25-fold increase in the uptake of 
the GFP-Pen-L1 (P<0.01) and 1.05-fold GFP-Pen-L2 (P>0.05) was observed 
when compared to GFP-Pen test only.  Similarly, an 18.5-fold increase in the 
uptake of GFP-Pen -L1 (P<0.001) and 14-fold increase in GFP-Pen -L2 uptake 
(P< 0.001) was observed compared to the uptake of the GFP control.  The GFP-
Pen test-L1 test uptake was 9 fold greater than GFP-L1 test (P<0.001) and 7.5 
fold greater than GFP-L2 test (P<0.001). 
The overall cellular uptake of both GFP-(CPP-LSP) test samples was notably 
greater than all of the GFP-(CPP-LSP) controls and GFP-(L1/L2) test alone. 
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Figure 4-3.  Quantitative analysis of GFP-peptide conjugates in CHO cells 
by fluorescence spectrophotometry. 
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
GFP-peptide conjugates.  One way ANOVA was used to analyse concentration 
by with GFP -peptide conjugates within CHO cell line, followed by Boneferroni 
post test  analysis to determine which means differ significantly (P<0.0001), as 
indicated by letters a-d 
GF
P
GF
P -
 
TA
T  
co
ntr
ol 
GF
P -
 
TA
T  
tes
t 
GF
P -
 
TA
T -
 
L1
GF
P -
TA
T -
 
L2
GF
P- 
Pe
n 
co
ntr
ol 
GF
P- 
Pe
n 
tes
t
GF
P -
 
Pe
n 
-
 
L 1
 
GF
P- 
Pe
n 
-
 
L2
GF
P- 
L1
GF
P- 
L2
GF
P -
Ly
so
 
co
ntr
ol 
0.0
0.2
0.4
0.6
0.8
1.0
a
a a
a a
a
b
b
b
bd
c
d
Sample
G
FP
 
c
o
n
c
e
n
tr
a
tio
n
 
( µµ µµ
M
/ µµ µµ
g) 
o
f t
o
ta
l c
e
ll 
pr
o
te
in
  
171 
4.3.2.2 Uptake of GFP-peptide conjugates in HeLa cells  
As seen in Fig. 4-4, there was also negligible uptake of GFP on its own into HeLa 
cells compared to the uptake of GFP-peptide test conjugates.  On addition of 
GFP-TAT test, a 4.8-fold increase in the uptake was observed relative to the level 
of uptake observed with the GFP-TAT control. When the LSPs, L1 and L2 were 
added in combination with GFP-TAT test conjugates, there was no improvement 
in the uptake of either GFP-TAT-L1 or GFP-TAT-L2 conjugates relative to GFP-
TAT test alone.  However, significant increases in the cellular uptake of both 
GFP-TAT-L1 (9.6-fold) and GFP- TAT-L2 test (4.8-fold) were observed compared 
with the GFP-Lyso control conjugate.  Nonetheless, the cellular uptake of GFP-
L1 test (P< 0.0001) and GFP-L2 test resulted in a significant increase (P< 
0.0001) in uptake compared to GFP-TAT -LSP test. 
For GFP-Pen-LSP combinations, fluorescence spectrophotometric analysis 
revealed a 4.75-fold increase in the uptake of GFP-Pen test relative to that of the 
GFP-Pen control indicating greater accumulation of Pen test in the cells.  With 
Pen rather than TAT, an increase in the uptake of GFP-Pen test-L1 test (P<0.01) 
and increase in GFP-Pen test-2 test (P>0.05) was observed relative to GFP-Pen 
test only.  Additionally, a 17-fold increase of GFP-Pen test-L1 test (P<0.001) and 
a 13-fold increase in GFP-Pen test-L2 test (P< 0.001) uptake was measured 
when compared with the GFP control.  The GFP-Pen test-L1 test uptake was 6.3 
fold greater than the GFP-L1 test (P<0.001) and 5.9 fold greater than GFP-L2 
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test (P<0.001). 
The observed trend of uptake in HeLa cells revealed that GFP-(CPP -LSP) test 
was significantly greater than all of the GFP-(CPP-LSP) controls and GFP-
(L1/L2) test conjugates alone. 
These results for both CHO and HeLa cells collectively demonstrate that L1 
peptide-containing GFP conjugates are more effectively taken up by the cells 
than conjugates containing L2 peptide irrespective whether the conjugates 
contained either TAT or Pen CPP.  The GFP Pen test-L1 test conjugate was 
observed to be the most effective combination for intracellular uptake amongst all 
of the combinations tested in both the cell lines.  
4.3.3 Fluorescence microscopy 
The fate of the GFP-peptide conjugates and their intracellular localisation was 
dependent upon the combination of CPP and LSP bound to the GFP molecules.  
To assess and compare the specificity of the LSPs in the targeting of GFPs to the 
lysosomes, studies using fluorescence microscopy were carried out using 
identical experimental conditions (Jones et al., 2004) 
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Figure 4-4.  Quantitative analysis of GFP-peptide conjugates uptake into 
HeLa cells by fluorescence spectrophotometry.  
Each bar represents the mean normalized expression (±SE; n = 4), X-axis labels: 
GFP-peptide conjugates.  One way ANOVA was used to analyse concentration  
by with GFP-peptide conjugates within HeLa cell line, followed by Boneferroni 
post test  analysis to determine which means differ significantly (P<0.0001), as 
indicated by letters a-d.  
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A set of GFP-peptide conjugates were crosslinked and purified as described in 
the methods section of this chapter.  Each of the GFP-peptide conjugates was 
added to a final concentration of 100ng/ml in either 1 x 105 cells/ml CHO cells or 
HeLa cells grown to 75% confluency and subsequently incubated for 12 h at 
37°C under 5% CO2. The intracellular localisation of the different GFP-peptide 
conjugates to lysosomes were confirmed by co-localisation of the conjugates with 
the specific lysosomal dye LysoTracker Red™ (Invitrogen, Carlsbad, CA, USA) 
and detected by fluorescence microscopy.   
4.3.3.1 Intracellular localisation of GFP-conjugates in CHO cells 
For both GFP-Pen and GFP-TAT test combinations, an increased uptake of 
Lysotracker Red dye (Figs 4-5.2a, 4-5.4a) was observed relative to the 
corresponding control treatments (Figs 4-5.1a, 4-5.3a).  Similarly, the test 
treatments increased the uptake of GFP resulting in an increase in the green 
fluorescence in the cells (Figs 4-5.2b, 4-5.4b) relative to the controls (Figs 4-5.1b, 
4-5.3b).  Lysosomal dye and GFP co-localisation explained that GFP was not 
localised into lysosomes inside the cells, but rather scattered and indistinct 
appearance throughout the cytoplasm (Figs 4-5.2c, 4-5.4c) indicating that the 
Pen/TAT peptide enhanced the uptake of GFP into the cells but not subcellular 
localisation into the lysosomes.  No co-localisation of both Lysotracker and GFP 
in control treatments (Figs 4-5.1c, 4-5.3c) was observed except for few green 
areas that indicated GFP may be attached due to inadequate washes with buffer 
prior to observing under the microscope.Cells were difficult to 
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resolve under bright-field and phase contrast was used in later experiments (Figs 
1-4d). 
For both GFP-CPPs-L1 test peptide combinations Lysotracker Red (Figs 4-6.2a, 
4-6.4a) uptake was greater than GFP-CPPs-Lyso control peptide (Figs 4-6.1a, 4-
6.3a).  The access of GFP-CPP test-L1 test (Figs 4-6.2b, 4-6.4b) was 
concentrated and as bright green spots of GFP relative to GFP-CPP test-Lyso 
control (Figs 4-6.1b, 4-6.3b) that was fuzzy throughout the cells.  In contrast, 
adding to GFP-Pen test -L1 test and GFP-TAT test- L1 test resulted again in 
significant cellular uptake but with significant accumulation of the conjugates into 
the lysosomes corresponding to the co-localisation of GFP and Lysotracker Red 
(Figs 4-6.2c, 4-6.4c) as observed by the orange and yellow coloured overlapping 
areas.  In GFP-CPP test-Lyso control treatment negligible co-localisation of GFP 
and Lysotracker was observed, with fuzzy distribution of GFP dispersed 
throughout the cytoplasm (Figs 4-6.1c, 4-6.3c).   
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              a                           b                              c                           
                 Red                  Green              Merged              
Figure 4-5. Intracellular localisation of GFP-CPP conjugates in CHO cells. 
 a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP conjugates 
and Lysotracker red.  
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               a                           b                              c                           
               Red                  Green              Merged              
 
Figure 4-6.  Intracellular localisation of GFP-CPP conjugates containing L1 
peptide in CHO cells.  
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP conjugates 
and Lysotracker red.  
GFP -Pen test –Lyso control  
GFP-Pen test – L1 test 
GFP-TAT test- Lyso control 
GFP-TAT test- L1 test 
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The treatments for both GFP-CPPs-L2 test peptides indicated the uptake of 
Lysotracker Red as observed as bright red spots (Figs 4-7.2a, 4-7.4a) that was 
also observed in GFP-CPPs-Lyso control peptide (Figs 4-7.1a, 4-7.3a).  In that 
order GFP-CPP test-L2 test (Figs 4-7.2b, 4-7.4b) combinations had a greater 
GFP uptake inside the cells relative to scattered GFP-CPP test-Lyso control (Figs 
4-7.1b, 4-7.3b).  The fluorescence micrographs of GFP-Pen test and GFP-TAT 
test with L2 peptide test revealed greater cell penetration again but this time 
localisation into lysosomes as observed by merging of GFP and Lysotracker Red 
fluorescence (Figs 4-7.2c, 4-7.4c) by contrast to GFP-CPP test-Lyso control that 
was distributed all over the cells (Figs 4-7.1c, 4-7.3c).  Furthermore GFP-Pen 
test-L2 test was more precise in lysosomal accumulation when compared to 
GFP-TAT test-L2 test (Figs 4-7.2c, 4-7.4c).   
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                   a                           b                              c                           
                     Red                  Green              Merged              
Figure 4-7.  Intracellular localisation of GFP-CPP conjugates containing L2 
peptide in CHO cells.   
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP conjugates 
and Lysotracker red.  
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4.3.3.2 Intracellular localisation of GFP-conjugates in HeLa cells 
In HeLa cells, both GFP-Pen and GFP-TAT, the test combinations uptake of 
Lysotracker Red dye (Figs 4-8.2a, 4-8.4a) was more localised relative to their 
corresponding control treatments (Figs 4-8.1a, 4-8.3a).  In addition, GFPs in test 
treatments was dispersed everywhere inside the cells (Figs 4-8.2b, 4-8.4b) in 
comparison to GFP-CPP-control (Figs 4-8.1b, 4-8.3b) that GFP adhered to the 
membrane as seen by green spots.  Co-localisation pattern of lysosomal dye and 
GFP explicated that GFP were not contained into lysosomes within the cells, but 
rather distributed throughout the cytoplasm (Figs 4-8.2c, 4-8.4c) indicating that 
the Pen/TAT peptide helped the uptake of GFPs into the cells but no subcellular 
localisation into the lysosomes.  No co-localisation of both Lysotracker and GFP 
in control treatments (Figs 4-8.1c, 4-8.3c) was observed except for only some 
green parts that indicated GFP possibly aggregated to the cell membrane.   
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Figure 4-8.  Intracellular localisation of GFP-CPP conjugates in  HeLa cells.  
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP conjugates 
and Lysotracker red.  
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For both GFP-CPPs-L1 test peptide resulted in increased uptake pattern of 
Lysotracker Red (Figs 4-9.2a, 4-9.4a) in the cells relative to the hazy uptake of 
GFP-Pen-Lyso control peptide but distint uptake for GFP-TAT-Lyso control (Figs 
4-9.1a, 4-9.3a).  Equally distinctive accumulation of GFP-CPPtest-L1 test (Figs 4-
9.2b, 4-9.4b) as green fluorescent dots was better and apparent than GFP-Pen 
test-Lyso control (Figs 4-9.1b, 4-9.3b) that was dispersed throughout the 
cells,however for GFP-TAT test-Lyso control there was concentrated 
accumulation of green areas that could be into the lysosomes.  However the 
green dotted fluorescence of GFP-Pen test-L1 test was clearer than GFP-TAT 
test – L1 test (Figs 4-9.2b, 4-9.4b).  In contrast, the addition of L1 peptide to 
GFP-Pen test and GFP-TAT test resulted again in greater cellular uptake but at 
this occasion principal accumulation into the lysosomes corresponding to the 
merging of GFP and Lysotracker Red (Figs 4-9.2c, 4-9.4c).  In GFP-TAT test-
Lyso control treatment co-localisation of GFP and Lysotracker was observed that 
indicates GFP accumulation into lysosomes compared with GFP-Pen test-Lyso 
control distributed everywhere inside the cells (Figs 4-9.1c, 4-9.3c).  In addition 
overlap of GFP -Pen test-L1 test was superior and concentrated as observed by 
orange and yellow overlapping areas relative to GFP-TAT test-L1 test (Figs 4-
9.1c, 4-9.3c).   
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            a                           b                              c                           
            Red                  Green              Merged              
 
Figure 4-9.  Intracellular localisation of GFP-CPP conjugates containing L1 
peptide in HeLa cells.  
a, Localization of lysosomes in cells by Lysotracker red. b, Localization of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP conjugates 
and Lysotracker red.  
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When GFP-CPPs-L2 test peptide was added uptake of Lysotracker Red (Figs 4-
10.2a, 4-10.4a) was elevated than GFP-CPPs-Lyso control peptide (Figs 4-
10.1a, 4-10.3a).  In that order, GFP-CPP test-L2 test (Figs 4-10.2b, 4-10.4b) 
combination promoted the uptake of GFPs inside the cells and accumulated as 
green dots relative to dispersed GFPs -CPP test-Lyso control (Figs 4-10.1b, 4-
10.3b).  The micrographs of GFP-Pen test and GFP-TAT with L2 peptide test 
show the cellular uptake but with less significant accumulation into the lysosomes 
as observed by merging of green and Lysotracker Red fluorescence (Figs 4-
10.2c, 4-10.4c) by contrast to GFP-Pen test-Lyso control that was scattered all 
over the cells (Figs 4-10.1c, 4-10.3c) with GFP-TAT test-Lyso control also 
accumulated into the lysosomes.  The GFP-TAT test -L2 test GFP-peptide 
conjugates were localised to lysosomes Fig. 4-10.4c, but was less in number 
than the GFP-Pen test -L2 combination Fig. 4-10.2c in HeLa cells.   
Overall, the analysis of the uptake trend using these various GFP-CPP and GFP-
CPP-LSP combinations revealed that GFP translocation across the cell 
membrane of CHO and HeLa cells was similar but GFP-Pen-LSP combinations 
resulted in efficient localisation than GFP-TAT-LSP combinations in targeting the 
protein to the lysosomes.  In terms of lysosomal accumulation of GFP L1 test 
sequence was better than L2 test sequence in both CPPs and cell lines. The 
cells were in healthy condition indicating their active metabolism and compatibility 
in presence of GFP-peptide conjugates within them.  Also, differences in the 
uptake of the GFP-peptide conjugates in CHO and HeLa cells explain the 
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preferential selectivity of these cell lines in allowing the entry of GFP-peptide 
conjugates inside the cells.  These data are consistent with the enhanced uptake 
of GFPs into the cells with LSPs and CPPs in combinations obtained in 
fluorescence spectrophotometry method.  
4.3.4 Cytotoxicity assay 
The cell viability of both CHO and HeLa cells in the presence of all of the different 
GFP-CPP-LSP conjugates was assessed using the MTT assay(Mosmann, 
1983)to check the biocompabitibility of the peptide conjugates.  
4.3.4.1 Cytotoxicity assay of Pen peptide combinations 
The cell viability of CHO and HeLa cells (Fig. 4-11) incubated with the Pen 
combinations   for 12h indicated more than 80% viability when added with GFP, 
Pen control, L1 test, L2 test, Lyso control, and GFP-Pen control.  However, in 
other combinations there was a slight decrease in cell viability down to 70% level 
in the case of Pen test, GFP-Pen test, GFP-Pen test-L1, and GFP-Pen test-L2 of 
the 13 treatments in both the cell lines (F= 32.74, P<0.0001 by two-way ANOVA).  
In GFP-Pen, test-Lyso control there was no significant decrease in cell viability (> 
80%).  In summary, the cell viability of both cell lines was well above 50% when 
the GFP- Pen peptide combinations were added to cells.  
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Figure 4-10.  Intracellular localisation of GFP-CPP conjugates containing L2 
conjugates in  HeLa cells.  
a, Localisation of lysosomes in cells by Lysotracker red. b, Localisation of GFP-
labelled GFP conjugates in cells (green). c, Co-localisation of GFP 
conjugatesand Lysotracker red.  
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Figure 4-11.  Cytotoxicity assay for Pen peptide combinations in CHO and 
HeLa cells 
Each bar represents the mean normalised expression (±SE; n = 4), X-axis labels: 
GFP-peptide conjugates. Two-way ANOVA was used to analyse data and 
compare the effect of GFP-peptide conjugates between CHO and HeLa cell line.  
Analysis indicated significant difference in the column factor (P<0.001) but no 
significant difference in the row factor between the cell line (P0.4127) 
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4.3.4.2 Cytotoxicity assay of TAT peptide combinations 
As shown in Figure 12, more than 90% of both CHO and HeLa cells were viable 
following 12 h of incubation in the presence of GFP TAT control, L1 test, L2 test, 
Lyso control and GFP-TAT control conjugates.  Cell viability was reduced 
significantly by treatment with GFP-TAT test-L1 test in both cell lines (F= 24.56, 
P<0.0001 by two-way ANOVA).  There was no significant decrease in the cell 
viability (68%) in the case of TAT test, GFP–TAT test and GFP-TAT test-L2 test.  
When GFP-TAT test- Lyso 1 was added to cells, there was no significant 
decrease in cell viability (greater than 80%). 
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Figure 4-12.  Cytotoxicity assay for TAT peptide combinations in CHO and HeLa 
cells. 
Each bar represents the mean normalised expression (±SE; n = 4), X-axis labels: 
GFP-peptide conjugates. Two-way ANOVA was used to analyse data and 
compare the effect of GFP-peptide conjugates between CHO and HeLa cell line.  
Analysis indicated significant difference in the column factor (P<0.001) but no 
significant difference in the row factor between the cell line (P0.3587) 
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4.4 Discussion 
4.4.1 IMAC purification of expressed GFP protein 
The His-tagged GFP was purified by immobilised metal ion affinity 
chromatography (IMAC) that exploits the ability of transition metal complexes of 
iminodiacetic and nitrilotriacetic acid (NTA) form a tetravalent chelate with Ni (II) 
and is subsequently coordinated by basic amino acids such as His (Gaberc-
Porekar and Menart, 2001).  GFP was purified as seen in the SDS-PAGE 
analysis of the eluted fractions (Fig. 1) obtained during the purification of the His-
tagged GFP.  A number of non-specific bound proteins low affinity for nickel and 
possibly containing exposed His residues were eluted from the column prior to 
the elution of the His-tagged GFP using 50-250 mM imidazole pH 8 as the eluant 
(Fig. 1).  A total of 60 µg of His-tagged GFP was purified to apparent 
homogeneity from 1 ml of bacterial culture using this purification scheme.  . 
NHS esters react with primary amines present in the GFP at pH 7-9 to form 
amide bonds, while maleimides react with sulphydryl groups of the peptides at 
pH 6.5-7.5 to form stable thioether bonds.  In aqueous solutions, NHS ester 
hydrolytic degradation is a competing reaction whose rate increases with pH.  
The maleimide group is stable compared to NHS-ester group but will gradually 
hydrolyse and lose its reaction specificity for sulphydryls at pH values > 7.5 
(Mattson et al., 1993).  For these reasons, the peptides were conjugated to GFP 
using this SMCC cross-linker at pH 7.4 in order to minimise NHS ester 
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hydrolysis. The purified GFP was soluble in aqueous buffer and was efficiently 
coupled to peptides using SMCC as cross-linker, and directly to the cell culture 
medium. The aim was to test the targeting efficiency of the peptides to deliver 
GFP across the cell membrane into to the lysosomes.  Samples containing GFP-
SMCC-peptide were used in the in vitro cell assays at 100 ng /ml to assess their 
intracellular transduction capacity after 12h using two different approaches, (a) 
quantitative fluorescence spectrophotometry and (b) fluorescence microscopy. 
4.4.2 Comparison of GFP-peptide conjugates uptake in CHO 
and HeLa cells 
The spectrophotometry results for both CHO and HeLA cell lines indicated   that 
there were noteworthy differences in the uptake of GFP-TAT test and GFP-TAT 
control and also in the uptake of GFP-Pen test and GFP-Pen control in both cell 
lines.  These differences in the uptake of GFP- CPP test conjugates in contrast to 
control conjugates is due to the positive charges within the CPP sequences 
which are required for efficient intake  into cells (Rothbard et al., 2004).  Previous 
studies have shown that there are electrostatic interactions between the 
positively charged Arg and Lys residues and the negatively charged plasma 
membrane which have been shown to have an important role in the cell 
penetration of GFP when used in conjunction with CPPs (Rothbard et al., 2004; 
Tréhin and Merkle, 2004).  As the peptide accumulates at the cell surface, there 
is an electrostatic interaction with the phospholipids resulting into translocation 
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through the cell membrane (Mueller et al., 2008a).  This requirement for positive 
charges at pH 7 was further supported by the data obtained by control CPPs 
containing Ala instead of the basic amino acids Lys and Arg, which resulted in no 
cell penetration of these conjugates.  Also studies have shown that the CPPs 
interact with negatively charged surface glycosaminoglycans and it is possible 
that the differences in the observed uptakes of both Pen and TAT-containing 
GFP conjugates are likely to be due to the differential binding to specific cell 
surface glycosaminoglycans prior to cell entry (Morris et al., 2008; Mueller et al., 
2008b).  It has been shown that the presence of Arg within the CPP sequences 
influences the binding to cell surface heparan sulphates through bidentate 
interactions of the guanidinium groups (Mitchell et al., 2000).  Observed 
differences in the efficiency of cell uptake mediated by TAT and Pen CPP in 
different cell lines can be due to the variable number and types of 
glycosaminoglycans present on the cell surface and negatively charged 
phospholipids (Morris et al., 2008), which is evident in this study with the 
observed differences in the uptake of GFP-peptide conjugates in CHO cells 
compared with HeLa cells.  The accumulation of GFP-TAT test-Lyso control into 
lysosomes or lysosome-like structures suggested that probably GFP when added 
with TATtest and Lyso control interacted in a different way with the HeLa cells 
compared with Pen test-Lyso control.  To confirm this altered observation GFP-
TAT test-Lyso control will have to be attached to AuNPs and targeted to HeLa 
cells as AuNPs can be observed by TEM and the exact localisation and 
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interaction of GFP-TAT test-Lyso could be determined with HeLa cells. 
4.4.3 Pen better than TAT  
In peptides containing Arg and Trp residues, the cation- delocalised π orbital 
interactions facilitates Arg entry into the hydrophobic environment inside a lipid 
layer.  Overall, the cationic nature and hydrogen bonding geometry of Arg and 
the complex properties of Trp complement each other (Jing et al., 2003).  Arg 
provides an effective means of attracting the CPP to the target membranes and 
hydrogen bonding facilitates its interaction with negatively charged surfaces such 
as the cell membrane and some of the phospholipids head groups(except e.g. 
phosphatidylcholine).  It has been suggested that Trp is the most important 
amino acid within a CPP sequence to prolong the association of the peptide with 
the membrane (Chan et al., 2006). 
The CPP-GFP conjugates were efficiently transducted in both CHO and HeLa 
cell lines.  However, similar to the findings of other studies, the degree of 
internalisation of the CPP- tagged GFP proteins was dependent upon both the 
cell type and variations within the amino acid sequences within the CPPs , 
(Schmidt et al., 2009). 
A recent study (Del Gaizo and Payne, 2003), successfully delivered a TAT-
containing mitochondrial malate dehydrogenase signal sequence (mMDH)–
enhanced GFP (eGFP) fusion protein into the mitochondria of both NIH 3T3 and 
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PC12 cell lines.  This study targeted GFP to mitochondria using mitochondria 
targeting sequence (MTS) and TAT as a CPP sequence. Targeting of a GFP 
fusion protein to the endoplasmic reticulum (ER) in MOLT-4 cells was also 
achieved by fusing GFP with TAT and the ER retention peptide sequence (KDEL)   
A similar concept has been employed in our study using synthetic peptide 
analogues of CPPs in combination with LSPs and conjugating them to GFP 
through chemical cross-linking to translocate the protein across the cell 
membrane and into lysosomes.  This concept of attaching LSP to the GFP would 
be an interesting approach for the delivery of non-lysosomal proteins to 
lysosomes.  
4.4.4 L1 peptide mechanism 
 The L1 test peptide used in this research study was designed following a 
sequence analysis of protein sequences from lysosome associated membrane 
proteins (LAMPs) that are targeted to the lysosomes due to the presence of 
(tyrosine-based signals)  –G-Y-X-X-Ǿ where Ǿ is a hydrophobic residue (Honing 
et al., 1996; Ohno et al., 1995) present at the C-terminal end of the sequence.  
Investigations into the function of the LAMP targeting signal revealed that the 
adaptor protein AP-2 interacts with the tyrosine-based signals and mediates the 
formation of clathrin-coated vesicles at the surface of the plasma membrane.  
Furthermore, the interaction between the µ2 subunit of AP-2 and the tyrosine 
based sorting signal, was confirmed by X-ray crystallographic analysis of the 
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complex (Yoshikawa et al., 2008).  It has been further demonstrated that the L1 
signal sequence (or LSP1) interacts with the AP-2 complex of the clathrin-
mediated pathway leading to localisation to the lysosomes (Robinson and 
Bonifacino, 2001).  The L1 peptide selectively binds to µ2 in the AP-2 complex.  
The peptide binds in an extended conformation with the Y and L residues fitting 
into two hydrophobic pockets of the (µ2) subunit of AP -2 (Bonifacino and Traub, 
2003).  The L2 signal cannot be accommodated in the YXXØ binding domain of 
the µ2 subunit of AP-2.  It is likely that the localisation of the GFP-CPP-L1 
conjugate to lysosomes in this study was mediated through specific interactions 
with AP-2 which form part of the clathrin complex.  The specificity of AP-2 
recognition with L1 sequences implies that it serves a quality control function to 
ensure targeting of the protein or other molecules to the correct intracellular 
location within the lysosomes.   
4.4.5 L2 peptide mechanism 
The Disabled – 2 (Dab-2) protein is involved in intracellular tyrosine kinase 
signaling.  The family of Dab proteins contains an amino-terminal protein-
interaction domain/phosphotyrosine binding domain (PID/PTB) (Morris and 
Cooper, 2001).  These Dab proteins have important functions in signal 
transduction and endocytosis.  Dab 2 PTB domains have the ability to bind to 
signal peptides containing the L2 sequence.  Dab2 binds to the adaptor protein 
AP-2 and also the ear domain at the carboxy-terminus region of α adaptin of the 
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AP-2 complex, both of which are associated with clathrin-coated pit formation 
(Morris, 2001) .Thus Dab2 may function as a linker molecule which links NPXY 
(L2) signal to AP-2 and thus to clathrin (Aguilar et al., 2001; Mishra et al., 2002).  
4.4.6 Difference between L1 and L2 
The difference in the lysosome localisation with L1 and L2 could be due to the 
fact that L1 interacts directly with the AP2 complex whereas L2 has to first 
interact with Dab2 which links it to AP2 and clathrin coat thereafter.  Hence this 
may affect its final targeting to the lysosomes.  There is a clear mechanism of 
interaction of L1 with AP2 hence there is strong affinity as compared to the 
affinity of binding of Dab2 with L2 signal. 
The importance of LSPs in intracellular targeting to lysosomes can be understood 
from the fluorescence microscopy data which indicates that when GFP-CPPs test 
are used alone they are scattered throughout the cell even if they have 
undergone endocytosis.  But when LSPs were incorporated into these GFP-
CPPs test conjugates, there was very significant accumulation of the conjugates 
in lysosomes.  This may be due to the fact that LSPs may interact with the 
endosomal membrane more strongly than CPPs thus preventing the CPPs from 
interacting with the endosomal membrane for their escape.    Moreover, the 
degree of uptake also depends on the structure of the LSP, its interaction with 
the AP-2 complex protein domain, density loading of peptide signal on the GFP 
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and the cell type being tested. 
4.4.7 Cytotoxicity assay 
The MTT assay data suggest overall that the GFP-peptide conjugates tested in 
this study exerted minimal cytotoxic effects, especially with GFP, CPPs control, 
LSPs test and Lyso control.  Slight decreases in cell viability occurred in the 
presence of CPPs test, GFP-CPP test–LSP test and GFP-CPP test-Lyso control.  
However, this toxicity was not significant enough to draw any conclusions but it 
does suggest that combination of these peptides may have some cytotoxic 
effects if exposed for longer time but this requires further investigation.  
4.5 Summary 
E.coli expressed His-tagged GFP was purified successfully and coupled to CPPs 
and LSPs to examine their intracellular localisation.  GFP was chosen because 
native GFP has a very tight barrel-shaped structure that has to be preserved for 
the molecule to emit its characteristic fluorescence.  Thus, the stability of the 
molecule in its native state could be monitored in these intracellular targeting 
studies. The fluorescence was detectable within the lysosomes indicating that the 
GFP-peptide conjugates do not unfold during the accumulation into the 
lysosomes (Katayama et al., 2008; Pooga et al., 2001). 
The quantitative uptake of GFP-peptide conjugates by cells was determined by 
fluorescence spectrophotometry analysis.  The uptake of GFP-peptides 
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test conjugates were greater than the GFP-peptide control conjugates in both cell 
lines studied.  The fluorescence spectrophotometry data were further supported 
by the fluorescence microscopy data which examined the specific intracellular 
localisation of the GFP-peptide conjugates.  The CPPs, Pen and TAT were 
selected based on their reported ability to efficiently deliver a range of cargo 
through the cell membrane, including proteins (Fonseca et al., 2009).   In this 
study, the dispersed fluorescence throughout the cytoplasm of treated cells 
confirmed that the synthetic peptide analogues of these two CPP sequences did 
effectively deliver GFP across the cell membrane.  A clear distinction between 
intracellular movement into the lysosomes and the cytoplasm could be observed 
using the Lysotracker stain.  Briefly, an analysis of the results obtained using 
these various GFP-CPP and GFP-CPP-LSP conjugate combinations revealed 
that the CPP-mediated uptake of GFP across the cell membrane of both CHO 
and HeLA cells was similar but GFP-Pen-LSP combinations were more efficient 
than GFP-TAT-LSP combinations for intracellular targeting into lysosomes.  The 
analysis of the data also showed that L1 was more effective than L2 for targeting 
of the GFP-peptide conjugates to the lysosomes Overall, the GFP-Pentest-L1 
test conjugate was the most effective CPP-LSP combination for intracellular 
targeting into lysosomes in this study.  
The potential cytotoxicity of the GFP-peptide conjugates when added to cells was 
also examined.  As expected, the cells generally remained viable following the 
addition of the conjugates to the cells and subsequent incubation for 12 h.   
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In summary, these findings demonstrate for the first time, that GFP, as a model 
protein, could be efficiently delivered across the cell membrane and specifically 
targeted to lysosomes through the incorporation of both LSP signal and CPP 
sequences.  This could prove as a promising approach to target exogenous 
enzyme molecules using CPPs and LSPs to replace defective enzymes in the 
lysosomes for the treatment of LSDs. The same strategy could be further 
explored by comparing the uptake studies of the peptides with GFP by chemical 
fusion versus genetic fusion and determine the efficiency of each system 
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The degradation of intracellular waste is mediated by enzymes in the lysosomes.  
Malfunctioning or deficiencies of the lysosomal enzymes can lead to lysosomal 
storage diseases such as Pompe’s disease, Niemann Pick A and B disease and 
many more (Heese, 2008). All these diseases share central nervous system 
(CNS) involvement, leading to severe neurological symptoms like mental 
retardation, dementia, blindness, motor and sensory disturbances. Current 
methods of treatment include enzyme replacement therapy, substrate reduction 
therapy, gene therapy and enzyme enhancement therapy (Caillaud and Poenaru, 
2000; Clarke, 2008).  All of these methods are used at the systemic level and 
cannot cross the blood-brain barrier.  Hence the development of a targeted 
delivery approach is more desirable than the approaches currently used. 
The primary aim of this research project was to devise a method to target model 
cargo (AuNPs and GFP) to the lysosomes of mammalian cells mediated through 
LSPs with CPPs in an effort to develop a therapeutic approach for targeted 
delivery to the lysosomes.  This would lay a foundation for the targeting of 
lysosomal enzymes or drugs, using CPPs and LSPs that have the ability to cross 
the cell membrane, accumulate specifically in the lysosomes and replace the 
missing enzyme(s) or deliver drugs.   
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Peptide synthesis 
In this study, three lysosomal peptide analogues were designed and manually 
synthesised using highly optimised t-Boc synthesis protocols developed by 
Schnölzer et al. (Schnolzer et al., 1992).  The sequences of the CPPs TAT and 
Pen were obtained from previous studies that targeted proteins into the mouse 
and across the cell membrane (Derossi et al., 1994; Schwarze et al., 1999) and 
were manually synthesised.  LSPs L1 and L2 were designed from the sequences 
present within nascent protein molecules that have specific signal sequences for 
lyososomal localisation.  All of the peptides were synthesised with an average 
coupling efficiency per residue above 99% and were analysed by RP-HPLC and 
MALDI-TOF MS.  The Pen control peptide had a deletion of one amino acid 
possibly due to multiple repeats of Ala leading to β- aggregation (Merrifield et al., 
1988) and incomplete assembly of peptide., As this was a control peptide 
sequence, the synthesis was not repeated.  These synthetic peptides needed to 
be directionally conjugated to AuNP and GFP through the incorporation of a 
functional group that would preferentially bind to the nanoparticle surface and to 
GFP protein.  Thus, all the peptides were modified with an extra functional group 
(Cys) at the C-terminal end or N-terminal end (in the case of L2).  The free N-
terminal end was required for all the peptides’ activity except for L2, which 
required a free C-terminal end for its lysosomal recognition activity.    
Similar approaches to this research could be tested in future, using different 
types of chimeric CPPs such as transportan (a chimera of the neuropeptide 
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galanin and the wasp venom toxin mastoparan) and totally synthetic CPPs such 
as the model amphipathic peptide (MAP), members of the PEP family that are 
primary amphipathic peptides and arginine oligomers (Mueller et al., 2008) 
instead of Pen and TAT peptide for cell penetration.  In addition, the LSPs could 
be designed and synthesised as single peptides having multiple repeats such as 
L1-L1, L2-L2, and L1-L2 peptide and tested for lysosome accumulation.  Another 
alternative would be to use dileucine-type sorting peptides for targeting to the 
lysosomes rather than the tyrosine-sorting peptides used in this study.  
Combining dileucine sorting peptides with CPPs and attaching them on a cargo 
could have equal or greater potential for lysosome targeting.  
Nanoparticle uptake and localisation 
The synthetic peptide CPPs and LSPs were attached to AuNPs that had a 
greater surface area and potential payload for intracellular and localisation 
studies.  Monodispersed AuNPs were synthesised with a diameter of 13 nm 
using the standard citrate reduction of chloroauric acid method (Turkevich J, 
1951).  FITC was added to the AuNPs for their intracellular detection and 
localisation.  FITC-labelled AuNPs were stable in the presence of FITC (Shukla 
et al., 2005) and on addition of CPPs and LSPs. Also, physical characterisation 
of AuNPs prior to and after FITC loading and peptide conjugation could be done 
in future studies that measure hydrodynamic diameter and zeta potential.  The 
molar ratio of 1:2:4 (FITC-AuNP: CPP: LSP) was found to be the most suitable 
ratio for the labelling of the FITC-AuNPs with peptides.  However, as the peptide 
concentration on the surface of the FITC-labelled nanoparticle increased, the 
monodispersity of AuNPs decreased, with maximal monodispersity observed at a 
molar ratio of 1:2:4 (FITC-AuNP: CPP: LSP) molar ratio.  These findings are 
in agreement with previous reports ( Tullman, 2007; Kang et al, 2010.) 
Covalent conjugation with FITC yielded fluorescent AuNPs that were further 
conjugated to form peptide-FITC-AuNPs which enabled the cellular uptake of 
AuNPs to be quantified by fluorescence spectrophotometry.  The potential FITC-
AuNP-peptide conjugate was evaluated as a delivery vehicle by examining its 
selective internalisation and specific localisation into the lysosomes.  This type of 
detection approach was used for the uptake of FITC-chitosan nanoparticles 
(Huang et al., 2002), in which Huang and colleagues measured the uptake of 
nanoparticles in A549 cells by fluorescence spectrophotometry. This approach 
was extended in this study by the addition of peptides on to the FITC-AuNPs and 
measuring their uptake into the cells by fluorescence microscopy.  Uptake and 
localisation were examined in two different cell lines so that the targeting 
efficiency could be compared to assess relative efficiency.  
The intracellular localisation and the competence of each CPP and LSP in the 
FITC-AuNP-peptide conjugates was compared by fluorescence microscopy.  
Although isolating different intracellular organelles and quantitatively analysing 
the levels of AuNPs in different cellular components would be useful for future 
studies.  Fluorescence microscopy supported the quantitative data generated 
from the fluorescence spectrophotometry uptake studies.  Although there was 
uptake for all of the nanoconjugates containing a CPP or a CPP with a LSP, 
uptake was greatest for FITC-AuNP-Pen-L1 for both the cell lines.  This 
combination was also optimal for intracellular lysosomal location, as shown by 
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fluorescence micrographs that showed co-localisation of Lysotracker red dye and 
FITC fluorescence, confirming the targeting into the lysosomes.  Pen had greater 
uptake into cells and greater lysosomal concentration than TAT in both CHO and 
HeLa cell lines.  The overall uptake of nanoconjugates was greater in CHO rather 
than HeLa cells due to the variable number and types of glycosaminoglycans 
present on the cell surface (Jones et al., 2005) TEM studies of Pen-L1 
conjugates in CHO cells demonstrated that the nanoparticles were localised to 
the lysosomes through LSP accompanied by Pen.   
Hosta et al (Hosta et al., 2008) have described the penetration and delivery of 
both 20 nm and 40 nm AuNPs to lysosomes using two synthetic diasteromeric 
analogues of Kahalalide F (KF), a marine cyclodepsipeptide found in some 
molluscs which has anti-tumour properties.  Whilst this may be a useful approach 
for targeted therapy, KF induces damage to other cell compartments, including 
mitochondria, endoplasmic reticulum and the plasma membrane, which 
potentially restricts the use of this delivery peptide system in tumour cells.  The 
pattern of localisation of AuNPs into the lysosomes with the combination of 
AuNP-Pen-L1/L2 was similar to that observed by Hosta et al. (Hosta et al., 2008), 
but negligible cytotoxicity was observed in these studies for both cell lines in the 
presence of AuNP-peptide conjugates.  Negligible toxicity was also observed in a 
similar type of study using synthetic SV40 large T antigen peptides (Ryan et al., 
2007). This type of approach using synthetic peptides therefore has significant 
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advantages over the use of natural products and should be pursued further. 
The overall uptake of AuNP-Pen conjugates was greater than that of AuNP-TAT 
conjugates, probably due to the π electrons of the aromatic indole moiety of Trp 
that contribute to the interaction of the Pen peptide with the lipid bilayer of cells 
and may explain why the Trp-containing Pen was more effective than the TAT 
(no Trp) peptide as a CPP in our system.  The localisation of L1 was more 
efficient than that of L2 to the lysosomes in this study.  These differences may be 
due to the direct interaction of the L1 peptide with AP-2, whereas the L2 peptide 
interaction is more indirect, via an initial interaction with Dab2, which in turn 
interacts with AP-2, which further interacts with clathrin and is targeted to the 
lysosomes.  The targeting efficiency of these nanoconjugates to the lyosomes 
could be tested in the presence of clathrin-mediated endocytosis inhibitors in 
order to confirm the pathway of uptake into the cells.  Moreover L1 and L2 
peptides could be attached to the cargo using different CPPs as mentioned 
above and tested for their lysosomal accumulation using di-leucine sorting 
peptides and tested for their efficacy in targeting of cargo to the lysosomes.  
The study of uptake and localisation of test LSPs was further extended by the 
addition of the model protein cargo GFP instead of FITC-AuNPs to study the 
localisation of protein cargo into the cells and lysosomes.  Previous studies have 
used fusion GFP containing CPP sequences and mitochondria-targeting 
sequences to target to the mitochondria of PC12 cells (Del Gaizo and Mark 
Payne, 2003).  Instead of producing a fusion protein, in this study a novel 
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aspect is that GFP was chemically cross-linked with CPP and LSP peptides to 
form GFP-peptide conjugates that were targeted to the cells to determine their 
intracellular uptake and localisation using florescence spectrophotometry and 
microscopy as before as an alternative strategy to genetic fusion.  Similar uptake 
patterns of GFP-peptide conjugates were observed to those seen with FITC-
AuNP peptide conjugates and the GFP-Pen-L1 conjugate again gave the 
greatest uptake and localisation within the lysosomes. 
A difference in the study conducted here from previous literature is that the GFP 
was transported to the lysosomes in a non-invasive manner.  This approach was 
very different from that of Xia et al. (2001), of using genetic engineering of 
proteins with improved cell membrane permeability but the GFP localisation into 
the lysosomes was in agreement with this previous study.  That study described 
the targeted delivery of fusion proteins containing the TAT sequence, such as the 
lysosomal enzyme β-glucuronidase, which was delivered to lysosomes, relying 
on the intrinsic lysosomal targeting sequences within the enzyme sequence.  In 
this study again there was minimal cytotoxicity in both cell lines on addition of 
GFP-peptide conjugates, indicating their biocompatibility.   
A similar pattern of uptake to that observed with AuNP-peptide conjugates was 
shown with GFP-peptide conjugates.  Pen was again better than TAT at 
transporting GFP conjugates into the cell, probably likely due to the presence of 
the Trp residue within the Pen sequence that would favour hydrophobic 
interactions with the cell membrane and thus aid in greater uptake 
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compared with TAT peptide.  The L1 peptide was better at accumulating GFP 
into lysosomes than the L2 peptide, probably because L1 , for reasons discussed 
previously that  the L2 sequence would first have to interact with Dab2 and hence 
the L2 peptide would be less efficient than the L1 peptide.  The pattern of 
lysosomal accumulation for both cargos, which was similar in spite of using 
different cargo this time, indicated that lysosomal targeting was not cargo-
specific.  Hence different molecules such as active lysosomal enzymes could 
potentially replace GFP attached to CPPs and LSPs to test their lysosomal 
targeting capability.   
Overview 
The studies described here have demonstrated for the first time that synthetic 
LSPs in combination with CPPs can be used to specifically target AuNPs and a 
protein (GFP) to lysosomes in cultured mammalian cells.  As the LSPs are 
recognised by specific receptors, they can be effectively targeted to the 
lysosomes.  Thus AuNPs/GFP on their own cannot enter the cells but when 
conjugated in combination with CPPs they can cross the plasma membrane into 
the cells.  Upon addition of LSPs to AuNP/GFP+CPP conjugates, the conjugates 
can not only penetrate into the cells but also accumulate into the lysosomes.  
These LSP-CPP conjugates are therefore a new and promising development due 
to their flexibility in delivering a variety of cargo with negligible cytotoxicity.  
Recent studies have explored the possibility of delivery of silica nanoparticle-
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protein conjugates in a human breast cancer cell line (MCF-7) and rat neural 
stem cells (NSCs) and elucidated the mechanism of cytosolic transport (Bale et 
al., 2010).  That study could be extended further by the addition of GFP to 
AuNPs and then attaching delivery peptides to assess their intracellular 
localisation.  This could be further tested in several cell lines with different 
functions and sensitive cell lines such as hepatic cell line, human skin cell line 
and cancerous cell lines.  The GFP could be further replaced by lysosome-active 
enzymes that can be targeted to an LSD cell line derived from patients suffering 
from LSDs in order to establish an effective therapeutic strategy for lysosomal 
targeting; these cell lines should be examined using the strategies developed 
here.   
Recently this type of approach was tested by delivering lipoamide 
dehydrogenase (LAD) fused to TAT peptide into mitochondria in fibroblasts from 
patients suffering from mitochondrial disease due to LAD deficiency (Vyas and 
Payne, 2008).  The TAT peptide transduced the LAD protein across both the cell 
and both mitochondrial membrane.  For LSDs, this idea can be further explored 
by preparing an artificial protein or inserting LSP sequences between the 
proteins for lysosomal targeting.  In order to achieve sustained delivery of 
lysosomal enzymes in LSDs through CPPs and LSPs, biodegradable 
nanoparticles like chitosan and poly (DL-lactide- co- glycolide) (PLGA) that have 
been previously explored to deliver drugs, plasmids, peptides intracellularly 
(Panyam and Labhasetwar, 2003) could be used.  These bio-nanoconjugates 
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containing lysosomal enzymes and peptides have been delivered into LSD 
mouse models (Cardone et al., 2006; Muro et al., 2006) and this system could be 
extended for further in vivo studies using the system described here before tests 
on human LSD lines.   
The Blood-Brain Barrier poses a difficult obstacle for delivery of drug therapy into 
the central nervous system. It is made up of a monolayer of polarized endothelial 
cells that are connected by complex tight junctions separating the blood 
compartment from the extracellular fluid compartment of the brain parenchyma.  
The most important factors determining the extent of crossing of a drug from 
blood vessels into the CNS are lipid solubility, molecular mass, and charge.   
These limitations could be overcome with the use of CPPs to deliver the 
molecules.  CPPs such as TAT, Penetratin, polyarginine, MPG, PEP and CADY 
would represent a novel and promising approach as they are versatile and have 
been able to deliver molecules across the cell membrane.  All these various 
types of CPPs could be tested for their efficiency to deliver a lysosomal enzyme 
in primary neuronal and macrophage cell lines especially in the presence of 
serum and eventually in vivo studies in rat brain cells. In this research study the 
uptake of peptide-conjugates was not assessed in the presence of serum and 
hence it is one major factor that needs to be considered in future studies.  All the 
various types of CPPs mentioned above could be tested for their efficiency to 
deliver a lysosomal enzyme in primary, neuronal and macrophage cell lines 
especially in the presence of serum that could be carried out further.  
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The research described here has developed a novel, non-toxic delivery system 
with the potential to deliver therapeutic cargo to defective lysosomes for patients 
suffering from lysosomal storage diseases and as such opens a new window in 
attempts to devise an improved therapy to cure these diseases.  
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Appendix A 
Peptide synthesis data 
Average coupling percentage, HPLC chromatogram and mass spectrum of each 
peptide of CPPs and LSPs except for TAT control. 
A) Penetratin control sequence 
 
Figure A.1 Coupling percentage of Pen (control) sequence 
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Figure A.2 HPLC chromatogram of Pen (control) sequence 
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Figure A.3 Mass spectrum of Pen (control) sequence. 
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B) Penetratin (test) sequence 
 
Figure B.1 Coupling percentage of Pen (test) sequence 
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Figure B.2.  HPLC chromatogram of Pen (test) sequence. 
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                                                           m/z  
Figure B.3. Mass spectrum of Pen (test) sequence. 
C) TAT (test) sequence 
 
Figure C.1. Coupling percentage of TAT (test) sequence. 
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          Figure C.2. HPLC chromatogram of Tat (test) sequence 
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        Figure C.3 Mass spectrum of TAT test sequence 
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D) Lyso control sequence 
 
Figure D.1. Coupling percentage of Lyso control sequence 
0
50
100
150
200
250
300
350
400
450
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
 
                          Retention time 
    Figure D.2. HPLC chromatogram of Lyso control sequence 
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     Figure D.3 Mass spectrum of Lyso control sequence 
E) L1 test sequence 
 
 
                                   
 
 
    Figure E.1. Coupling percentage of L1 test sequence 
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    Figure E.2. HPLC chromatogram of L1 test sequence 
 
 
 
 
 
 
 
 
Figure E.3 Mass spectrum of L1 test sequence 
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F) L2 test sequence 
 
 
 
 
     
Figure F.1. Coupling percentage of L2 test sequence 
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Figure F.2. HPLC chromatogram of L2 test sequence  
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Figure F.3 Mass spectrum of L2 test sequence 
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Figure G.Optimisation of FITC on AuNPs, showing that excitation-emission 
was optimal at 0.5 µm FITC. 
